>pdb|7MHT|C Chain C, Cytosine-Specific Methyltransferase HhaiDNA COMPLEX
NTCAGCGCATGG
>pdb|436D|B Chain B, The Dickerson-Drew B-Dna Dodecamer Revisited-At Atomic Resolution
CGCGAANTCGCG
>pdb|436D|A Chain A, The Dickerson-Drew B-Dna Dodecamer Revisited-At Atomic Resolution
CGCGAANTCGCG
>pdb|428D|B Chain B, STRUCTURE OF THE POTASSIUM FORM OF CGCGAATTCGCG: DNA DEFORMATION BY ELECTROSTATIC COLLAPSE AROUND SMALL CATIONS
CGCGAATTCGCG
>pdb|428D|A Chain A, STRUCTURE OF THE POTASSIUM FORM OF CGCGAATTCGCG: DNA DEFORMATION BY ELECTROSTATIC COLLAPSE AROUND SMALL CATIONS
CGCGAATTCGCG
>pdb|397D|B Chain B, A 1.3 A Resolution Crystal Structure Of The Hiv-1 Trans- Activation Response Region Rna Stem Reveals A Metal Ion- Dependent Bulge Conformation
GCTCTCTGGCCC
>pdb|389D|B Chain B, Crystal Structure Of B-Dna With Incorporated 2'-Deoxy-2'- Fluoro-Arabino-Furanosyl Thymines: Implications Of Conformational Preorganization For Duplex Stability
CGCGAANTCGCG
>pdb|389D|A Chain A, Crystal Structure Of B-Dna With Incorporated 2'-Deoxy-2'- Fluoro-Arabino-Furanosyl Thymines: Implications Of Conformational Preorganization For Duplex Stability
CGCGAANTCGCG
>pdb|388D|B Chain B, Crystal Structure Of B-Dna With Incorporated 2'-Deoxy-2'- Fluoro-Arabino-Furanosyl Thymines: Implications Of Conformational Preorganization For Duplex Stability
CGCGAANNCGCG
>pdb|388D|A Chain A, Crystal Structure Of B-Dna With Incorporated 2'-Deoxy-2'- Fluoro-Arabino-Furanosyl Thymines: Implications Of Conformational Preorganization For Duplex Stability
CGCGAANNCGCG
>pdb|360D|B Chain B, STRUCTURE OF 2,5-BIS{[4-(N-ETHYLAMIDINO)PHENYL]}FURAN COMPLEXED TO 5'-D(CPGPCPGPAPAPTPTPCPGPCPG)-3'. A MINOR GROOVE DRUG COMPLEX, SHOWING PATTERNS OF GROOVE HYDRATION
CGCGAATTCGCG
>pdb|360D|A Chain A, STRUCTURE OF 2,5-BIS{[4-(N-ETHYLAMIDINO)PHENYL]}FURAN COMPLEXED TO 5'-D(CPGPCPGPAPAPTPTPCPGPCPG)-3'. A MINOR GROOVE DRUG COMPLEX, SHOWING PATTERNS OF GROOVE HYDRATION
CGCGAATTCGCG
>pdb|353D|B Chain B, CRYSTAL STRUCTURE OF DOMAIN A OF THERMUS FLAVUS 5S RRNA AND THE CONTRIBUTION OF WATER MOLECULES TO ITS STRUCTURE
GGTGCGGGGGAT
>pdb|353D|A Chain A, CRYSTAL STRUCTURE OF DOMAIN A OF THERMUS FLAVUS 5S RRNA AND THE CONTRIBUTION OF WATER MOLECULES TO ITS STRUCTURE
ATCCCCCGTGCC
>pdb|1SJL|B Chain B, A Duplex Dna With An Abasic Site In A Da Tract, Beta Form, Nmr, Minimized Average Structure
CGCATTNTTGCG
>pdb|1SJL|A Chain A, A Duplex Dna With An Abasic Site In A Da Tract, Beta Form, Nmr, Minimized Average Structure
CGCAAAAATGCG
>pdb|355D|B Chain B, The B-dna Dodecamer At High Resolution
CGCGAATTCGCG
>pdb|355D|A Chain A, The B-dna Dodecamer At High Resolution
CGCGAATTCGCG
>pdb|5MHT|D Chain D, TERNARY STRUCTURE OF HHAI METHYLTRANSFERASE WITH HEMIMETHYLATED DNA AND ADOHCY
NTCAGCGCATGG
>pdb|5MHT|C Chain C, TERNARY STRUCTURE OF HHAI METHYLTRANSFERASE WITH HEMIMETHYLATED DNA AND ADOHCY
NCATGNGCTGAC
>pdb|287D|B Chain B, X-Ray And Solution Studies Of Dna Oligomers And Implications For The Structural Basis Of A-Tract-Dependent Curvature
CGCGATATCGCG
>pdb|287D|A Chain A, X-Ray And Solution Studies Of Dna Oligomers And Implications For The Structural Basis Of A-Tract-Dependent Curvature
CGCGATATCGCG
>pdb|285D|B Chain B, X-Ray And Solution Studies Of Dna Oligomers And Implications For The Structural Basis Of A-Tract-Dependent Curvature
CGCANATNTGCG
>pdb|285D|A Chain A, X-Ray And Solution Studies Of Dna Oligomers And Implications For The Structural Basis Of A-Tract-Dependent Curvature
CGCANATNTGCG
>pdb|1AC3|A Chain A, SOLUTION STRUCTURE OF AN RNA-DNA HYBRID DUPLEX CONTAINING A 3'-THIOFORMACETAL LINKER AND AN RNA A-TRACT, NMR, 8 STRUCTURES
CGCGTNNTGCGC
>pdb|1AIO|D Chain D, Crystal Structure Of A Double-Stranded Dna Containing The Major Adduct Of The Anticancer Drug Cisplatin
GGAGACCAGAGG
>pdb|1AIO|B Chain B, Crystal Structure Of A Double-Stranded Dna Containing The Major Adduct Of The Anticancer Drug Cisplatin
GGAGACCAGAGG
>pdb|328D|B Chain B, Structure Of A D(Cgcgaattcgcg)2-Sn7167 Complex
CGCGAATTCGCG
>pdb|328D|A Chain A, Structure Of A D(Cgcgaattcgcg)2-Sn7167 Complex
CGCGAATTCGCG
>pdb|329D|B Chain B, Effect Of Cytosine Methylation On Dna-Dna Recognition At Cpg Steps
GGCGCNGGCGGT
>pdb|329D|A Chain A, Effect Of Cytosine Methylation On Dna-Dna Recognition At Cpg Steps
ACCGCNGGCGCC
>pdb|330D|B Chain B, BASE-PAIRING SHIFT IN THE MAJOR GROOVE OF (CA)N TRACTS BY B-DNA CRYSTAL STRUCTURES
GGCGCCGGCGGT
>pdb|330D|A Chain A, BASE-PAIRING SHIFT IN THE MAJOR GROOVE OF (CA)N TRACTS BY B-DNA CRYSTAL STRUCTURES
ACCGCCGGCGCC
>pdb|297D|B Chain B, X-Ray And Solution Studies Of Dna Oligomers And Implications For The Structural Basis Of A-Tract-Dependent Curvature
CGCANATNTGCG
>pdb|297D|A Chain A, X-Ray And Solution Studies Of Dna Oligomers And Implications For The Structural Basis Of A-Tract-Dependent Curvature
CGCANATNTGCG
>pdb|280D|D Chain D, THE STRUCTURE OF AN RNA DODECAMER SHOWS HOW TANDEM U-U BASE PAIRS INCREASE THE RANGE OF STABLE RNA STRUCTURES AND THE DIVERSITY OF RECOGNITION SITES
GGCGCTTGCGTC
>pdb|280D|C Chain C, THE STRUCTURE OF AN RNA DODECAMER SHOWS HOW TANDEM U-U BASE PAIRS INCREASE THE RANGE OF STABLE RNA STRUCTURES AND THE DIVERSITY OF RECOGNITION SITES
GGCGCTTGCGTC
>pdb|280D|B Chain B, THE STRUCTURE OF AN RNA DODECAMER SHOWS HOW TANDEM U-U BASE PAIRS INCREASE THE RANGE OF STABLE RNA STRUCTURES AND THE DIVERSITY OF RECOGNITION SITES
GGCGCTTGCGTC
>pdb|280D|A Chain A, THE STRUCTURE OF AN RNA DODECAMER SHOWS HOW TANDEM U-U BASE PAIRS INCREASE THE RANGE OF STABLE RNA STRUCTURES AND THE DIVERSITY OF RECOGNITION SITES
GGCGCTTGCGTC
>pdb|263D|B Chain B, Isohelicity And Phasing In Drug-Dna Sequence Recognition: Crystal Structure Of A Tris(Benzimidazole)-Oligonucleotide Complex
CGCAAATTTGCG
>pdb|263D|A Chain A, Isohelicity And Phasing In Drug-Dna Sequence Recognition: Crystal Structure Of A Tris(Benzimidazole)-Oligonucleotide Complex
CGCAAATTTGCG
>pdb|291D|B Chain B, Crystal Structures Of Oligodeoxyribonucleotides Containing 6'-Alpha-Methyl And 6'-Alpha-Hydroxy Carbocyclic Thymidines
CGCGAANNCGCG
>pdb|291D|A Chain A, Crystal Structures Of Oligodeoxyribonucleotides Containing 6'-Alpha-Methyl And 6'-Alpha-Hydroxy Carbocyclic Thymidines
CGCGAANNCGCG
>pdb|290D|B Chain B, Crystal Structures Of Oligodeoxyribonucleotides Containing 6'-Alpha-Methyl And 6'-Alpha-Hydroxy Carbocyclic Thymidines
CGCGAANNCGCG
>pdb|290D|A Chain A, Crystal Structures Of Oligodeoxyribonucleotides Containing 6'-Alpha-Methyl And 6'-Alpha-Hydroxy Carbocyclic Thymidines
CGCGAANNCGCG
>pdb|298D|B Chain B, Targeting The Minor Groove Of Dna: Crystal Structures Of Two Complexes Between Furan Derivatives Of Berenil And The Dna Dodecamer D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|298D|A Chain A, Targeting The Minor Groove Of Dna: Crystal Structures Of Two Complexes Between Furan Derivatives Of Berenil And The Dna Dodecamer D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|296D|B Chain B, Sequence-Dependent Effects In Drug-Dna Interaction: The Crystal Structure Of Hoechst 33258 Bound To The D(Cgcaaatttgcg)2 Duplex
NGCAAATTTGCG
>pdb|296D|A Chain A, Sequence-Dependent Effects In Drug-Dna Interaction: The Crystal Structure Of Hoechst 33258 Bound To The D(Cgcaaatttgcg)2 Duplex
NGCAAATTTGCG
>pdb|289D|B Chain B, Targeting The Minor Groove Of Dna: Crystal Structures Of Two Complexes Between Furan Derivatives Of Berenil And The Dna Dodecamer D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|289D|A Chain A, Targeting The Minor Groove Of Dna: Crystal Structures Of Two Complexes Between Furan Derivatives Of Berenil And The Dna Dodecamer D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|4MHT|C Chain C, Ternary Structure Of Hhai Methyltransferase With Native Dna And Adohcy
NATAGNGCTATC
>pdb|3MHT|C Chain C, Ternary Structure Of Hhai Methyltransferase With Unmodified Dna And Adohcy
NATAGCGCTATC
>pdb|303D|B Chain B, Meta-Hydroxy Analogue Of Hoechst 33258 ('hydroxyl Out' Conformation) Bound To D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|303D|A Chain A, Meta-Hydroxy Analogue Of Hoechst 33258 ('hydroxyl Out' Conformation) Bound To D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|302D|B Chain B, Meta-Hydroxy Analogue Of Hoechst 33258 ('hydroxyl In' Conformation) Bound To D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|302D|A Chain A, Meta-Hydroxy Analogue Of Hoechst 33258 ('hydroxyl In' Conformation) Bound To D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|311D|B Chain B, The Role Of Hydrogen Bonding In Minor-Groove Drug-Dna Recognition. Structure Of A Bis-Amidinium Derivative Of Hoechst 33258 Complexed To The Dodecanucleotide D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|311D|A Chain A, The Role Of Hydrogen Bonding In Minor-Groove Drug-Dna Recognition. Structure Of A Bis-Amidinium Derivative Of Hoechst 33258 Complexed To The Dodecanucleotide D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|1TGH|C Chain C, TATA BINDING PROTEIN (TBP)/DNA COMPLEX
CGTATATATACG
>pdb|1TGH|B Chain B, TATA BINDING PROTEIN (TBP)/DNA COMPLEX
CGTATATATACG
>pdb|265D|B Chain B, Structural Studies On Nucleic Acids
CGNGAATTNGCG
>pdb|265D|A Chain A, Structural Studies On Nucleic Acids
CGNGAATTNGCG
>pdb|266D|B Chain B, Structural Studies On Nucleic Acids
CGCGAATTNGCG
>pdb|266D|A Chain A, Structural Studies On Nucleic Acids
CGCGAATTNGCG
>pdb|268D|B Chain B, Structural Studies On Nucleic Acids
CGCGAATTNGCG
>pdb|268D|A Chain A, Structural Studies On Nucleic Acids
CGCGAATTNGCG
>pdb|267D|B Chain B, Structural Studies On Nucleic Acids
CGCGAATTNGCG
>pdb|267D|A Chain A, Structural Studies On Nucleic Acids
CGCGAATTNGCG
>pdb|269D|B Chain B, Structural Studies On Nucleic Acids
CGCGAATTNGCG
>pdb|269D|A Chain A, Structural Studies On Nucleic Acids
CGCGAATTNGCG
>pdb|270D|B Chain B, Structural Studies On Nucleic Acids
CGCGAATTNGCG
>pdb|270D|A Chain A, Structural Studies On Nucleic Acids
CGCGAATTNGCG
>pdb|249D|D Chain D, STRUCTURAL COMPARISON BETWEEN THE D(CTAG) SEQUENCE IN OLIGONUCLEOTIDES AND TRP AND MET REPRESSOR-OPERATOR COMPLEXES
CGCTCTAGAGCG
>pdb|249D|C Chain C, STRUCTURAL COMPARISON BETWEEN THE D(CTAG) SEQUENCE IN OLIGONUCLEOTIDES AND TRP AND MET REPRESSOR-OPERATOR COMPLEXES
CGCTCTAGAGCG
>pdb|249D|B Chain B, STRUCTURAL COMPARISON BETWEEN THE D(CTAG) SEQUENCE IN OLIGONUCLEOTIDES AND TRP AND MET REPRESSOR-OPERATOR COMPLEXES
CGCTCTAGAGCG
>pdb|249D|A Chain A, STRUCTURAL COMPARISON BETWEEN THE D(CTAG) SEQUENCE IN OLIGONUCLEOTIDES AND TRP AND MET REPRESSOR-OPERATOR COMPLEXES
CGCTCTAGAGCG
>pdb|233D|B Chain B, The Crystal Structure Analysis Of D(Cgcgaasscgcg)2: A Synthetic Dna Dodecamer Duplex Containing Four 4'-Thio-2'- Deoxythymidine Nucleotides
CGCGAANNCGCG
>pdb|233D|A Chain A, The Crystal Structure Analysis Of D(Cgcgaasscgcg)2: A Synthetic Dna Dodecamer Duplex Containing Four 4'-Thio-2'- Deoxythymidine Nucleotides
CGCGAANNCGCG
>pdb|1MHT|B Chain B, COVALENT TERNARY STRUCTURE OF HHAI METHYLTRANSFERASE, DNA AND S-ADENOSYL-L-HOMOCYSTEINE
NATAGNGCTATC
>pdb|1LEY|B Chain B, Structure Of A Dicationic Monoimidazole Lexitropsin Bound To Dna (orientation 2)
CGCGAATTCGCG
>pdb|1LEY|A Chain A, Structure Of A Dicationic Monoimidazole Lexitropsin Bound To Dna (orientation 2)
CGCGAATTCGCG
>pdb|1LEX|B Chain B, Structure Of A Dicationic Monoimidazole Lexitropsin Bound To Dna (Orientation 1)
CGCGAATTCGCG
>pdb|1LEX|A Chain A, Structure Of A Dicationic Monoimidazole Lexitropsin Bound To Dna (Orientation 1)
CGCGAATTCGCG
>pdb|104D|B Chain B, Dna Duplexes Flanked By Hybrid Duplexes: The Solution Structure Of Chimeric Junctions In
NNNNTATACGCG
>pdb|104D|A Chain A, Dna Duplexes Flanked By Hybrid Duplexes: The Solution Structure Of Chimeric Junctions In
NNNNTATACGCG
>pdb|218D|B Chain B, THE STRUCTURE OF A NEW CRYSTAL FORM OF A DNA DODECAMER CONTAINING T.(O6ME)G BASE PAIRS
CGTGAATTCNCG
>pdb|218D|A Chain A, THE STRUCTURE OF A NEW CRYSTAL FORM OF A DNA DODECAMER CONTAINING T.(O6ME)G BASE PAIRS
CGTGAATTCNCG
>pdb|227D|B Chain B, A Crystallographic And Spectroscopic Study Of The Complex Between D(Cgcgaattcgcg)2 And 2,5-Bis(4-Guanylphenyl)furan, An Analogue Of Berenil. Structural Origins Of Enhanced Dna- Binding Affinity
CGCGAATTCGCG
>pdb|227D|A Chain A, A Crystallographic And Spectroscopic Study Of The Complex Between D(Cgcgaattcgcg)2 And 2,5-Bis(4-Guanylphenyl)furan, An Analogue Of Berenil. Structural Origins Of Enhanced Dna- Binding Affinity
CGCGAATTCGCG
>pdb|205D|B Chain B, Structure Of An Rna Double Helix Including Uracil-Uracil Base Pairs In An Internal Loop
GGACTTTGGTCC
>pdb|205D|A Chain A, Structure Of An Rna Double Helix Including Uracil-Uracil Base Pairs In An Internal Loop
GGACTTTGGTCC
>pdb|144D|B Chain B, Minor Groove Binding Of Sn6999 To An Alkylated Dna: Molecular Structure Of D(Cgc[e6g]aattcgcg)-Sn6999 Complex
CGCNAATTCGCG
>pdb|144D|A Chain A, Minor Groove Binding Of Sn6999 To An Alkylated Dna: Molecular Structure Of D(Cgc[e6g]aattcgcg)-Sn6999 Complex
CGCNAATTCGCG
>pdb|109D|B Chain B, Variability In Dna Minor Groove Width Recognised By Ligand Binding: The Crystal Structure Of A Bis-Benzimidazole Compound Bound To The Dna Duplex D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|109D|A Chain A, Variability In Dna Minor Groove Width Recognised By Ligand Binding: The Crystal Structure Of A Bis-Benzimidazole Compound Bound To The Dna Duplex D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|195D|B Chain B, X-Ray Structures Of The B-Dna Dodecamer D(Cgcgttaacgcg) With An Inverted Central Tetranucleotide And Its Netropsin Complex
CGCGTTAACGCG
>pdb|195D|A Chain A, X-Ray Structures Of The B-Dna Dodecamer D(Cgcgttaacgcg) With An Inverted Central Tetranucleotide And Its Netropsin Complex
CGCGTTAACGCG
>pdb|194D|B Chain B, X-Ray Structures Of The B-Dna Dodecamer D(Cgcgttaacgcg) With An Inverted Central Tetranucleotide And Its Netropsin Complex
CGCGTTAACGCG
>pdb|194D|A Chain A, X-Ray Structures Of The B-Dna Dodecamer D(Cgcgttaacgcg) With An Inverted Central Tetranucleotide And Its Netropsin Complex
CGCGTTAACGCG
>pdb|264D|B Chain B, Three-dimensional Crystal Structure Of The A-tract Dna Dodecamer D(cgcaaatttgcg) Complexed With The Minor-groove-binding Drug Hoechst 33258
CGCAAATTTGCG
>pdb|264D|A Chain A, Three-dimensional Crystal Structure Of The A-tract Dna Dodecamer D(cgcaaatttgcg) Complexed With The Minor-groove-binding Drug Hoechst 33258
CGCAAATTTGCG
>pdb|1SDR|D Chain D, Crystal Structure Of An Rna Dodecamer Containing The Escherichia Coli Shine-Dalgarno Sequence
ATCACCTCCTTA
>pdb|1SDR|C Chain C, Crystal Structure Of An Rna Dodecamer Containing The Escherichia Coli Shine-Dalgarno Sequence
TAAGGAGGTGAT
>pdb|1SDR|B Chain B, Crystal Structure Of An Rna Dodecamer Containing The Escherichia Coli Shine-Dalgarno Sequence
ATCACCTCCTTA
>pdb|1SDR|A Chain A, Crystal Structure Of An Rna Dodecamer Containing The Escherichia Coli Shine-Dalgarno Sequence
TAAGGAGGTGAT
>pdb|102D|B Chain B, Sequence-Dependent Drug Binding To The Minor Groove Of Dna: The Crystal Structure Of The Dna Dodecamer D(Cgcaaatttgcg) 2 Complexed With Propamidine
CGCAAATTTGCG
>pdb|102D|A Chain A, Sequence-Dependent Drug Binding To The Minor Groove Of Dna: The Crystal Structure Of The Dna Dodecamer D(Cgcaaatttgcg) 2 Complexed With Propamidine
CGCAAATTTGCG
>pdb|101D|B Chain B, Refinement Of Netropsin Bound To Dna: Bias And Feedback In Electron Density Map Interpretation
CGCGAATTNGCG
>pdb|101D|A Chain A, Refinement Of Netropsin Bound To Dna: Bias And Feedback In Electron Density Map Interpretation
CGCGAATTNGCG
>pdb|5BNA|B Chain B, The Primary Mode Of Binding Of Cisplatin To A B-Dna Dodecamer: C-G-C-G-A-A-T-T-C-G-C-G
CGCGAANTCGCG
>pdb|1D99|B Chain B, Structural Features And Hydration Of A Dodecamer Duplex Containing Two C.A Mispairs
CGCAAATTCGNG
>pdb|1D98|B Chain B, The Structure Of An Oligo(Da).Oligo(Dt) Tract And Its Biological Implications
CGNTTTTTTGCG
>pdb|178D|B Chain B, Crystal Structure Of A Dna Duplex Containing 8- Hydroxydeoxyguanine.Adenine Base-Pairs
CGCAAATTNGCG
>pdb|178D|A Chain A, Crystal Structure Of A Dna Duplex Containing 8- Hydroxydeoxyguanine.Adenine Base-Pairs
CGCAAATTNGCG
>pdb|166D|B Chain B, Drug-Dna Minor Groove Recognition: Crystal Structure Of Gamma-Oxapentamidine Complexed With D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|166D|A Chain A, Drug-Dna Minor Groove Recognition: Crystal Structure Of Gamma-Oxapentamidine Complexed With D(Cgcgaattcgcg)2
CGCGAATTCGCG
>pdb|157D|B Chain B, Crystal And Molecular Structure Of R(Cgcgaauuagcg): An Rna Duplex Containing Two G(Anti).A(Anti) Base-Pairs
CGCGAATTAGCG
>pdb|157D|A Chain A, Crystal And Molecular Structure Of R(Cgcgaauuagcg): An Rna Duplex Containing Two G(Anti).A(Anti) Base-Pairs
CGCGAATTAGCG
>pdb|150D|B Chain B, Guanine.1,N6-Ethenoadenine Base-Pairs In The Crystal Structure Of D(Cgcgaatt(Eda)gcg)
CGCGAATTNGCG
>pdb|150D|A Chain A, Guanine.1,N6-Ethenoadenine Base-Pairs In The Crystal Structure Of D(Cgcgaatt(Eda)gcg)
CGCGAATTNGCG
>pdb|1PRP|B Chain B, Crystal Structure Of D(Cgcgaattcgcg) Complexed With Propamidine, A Short-Chain Homologue Of The Drug Pentamidin
CGCGAATTCGCG
>pdb|1PRP|A Chain A, Crystal Structure Of D(Cgcgaattcgcg) Complexed With Propamidine, A Short-Chain Homologue Of The Drug Pentamidin
CGCGAATTCGCG
>pdb|153D|B Chain B, CRYSTAL STRUCTURE OF A MISPAIRED DODECAMER, D(CGAGAATTC(O6ME)GCG)2, CONTAINING A CARCINOGENIC O6-METHYLGUANINE
CGAGAATTCNCG
>pdb|153D|A Chain A, CRYSTAL STRUCTURE OF A MISPAIRED DODECAMER, D(CGAGAATTC(O6ME)GCG)2, CONTAINING A CARCINOGENIC O6-METHYLGUANINE
CGAGAATTCNCG
>pdb|130D|B Chain B, Molecular Structure Of D(Cgc[e6g]aattcgcg) Complexed With Hoechst 33342
CGCNAATTCGCG
>pdb|130D|A Chain A, Molecular Structure Of D(Cgc[e6g]aattcgcg) Complexed With Hoechst 33342
CGCNAATTCGCG
>pdb|129D|B Chain B, Dna (5'-D(CpGpCpGpApApTpTpCpGpCpG)-3') Complexed With Hoechst 33342
CGCGAATTCGCG
>pdb|129D|A Chain A, Dna (5'-D(CpGpCpGpApApTpTpCpGpCpG)-3') Complexed With Hoechst 33342
CGCGAATTCGCG
>pdb|128D|B Chain B, Molecular Structure Of D(Cgc[e6g]aattcgcg) Complexed With Hoechst 33258
CGCNAATTCGCG
>pdb|128D|A Chain A, Molecular Structure Of D(Cgc[e6g]aattcgcg) Complexed With Hoechst 33258
CGCNAATTCGCG
>pdb|127D|B Chain B, Dna (5'-D(CpGpCpGpApApTpTpCpGpCpG)-3') Complexed With Hoechst 33258
CGCGAATTCGCG
>pdb|127D|A Chain A, Dna (5'-D(CpGpCpGpApApTpTpCpGpCpG)-3') Complexed With Hoechst 33258
CGCGAATTCGCG
>pdb|121D|B Chain B, MOLECULAR STRUCTURE OF THE A-TRACT DNA DODECAMER D(CGCAAATTTGCG) COMPLEXED WITH THE MINOR GROOVE BINDING DRUG NETROPSIN
CGCAAATTTGCG
>pdb|121D|A Chain A, MOLECULAR STRUCTURE OF THE A-TRACT DNA DODECAMER D(CGCAAATTTGCG) COMPLEXED WITH THE MINOR GROOVE BINDING DRUG NETROPSIN
CGCAAATTTGCG
>pdb|1D99|A Chain A, Structural Features And Hydration Of A Dodecamer Duplex Containing Two C.A Mispairs
CGCAAATTCGCG
>pdb|1D98|A Chain A, The Structure Of An Oligo(Da).Oligo(Dt) Tract And Its Biological Implications
CGCAAAAAAGCG
>pdb|1D89|F Chain F, A Dna Dodecamer Containing An Adenine Tract Crystallizes In A Unique Lattice And Exhibits A New Bend
CGTTTTTTCGCG
>pdb|1D89|E Chain E, A Dna Dodecamer Containing An Adenine Tract Crystallizes In A Unique Lattice And Exhibits A New Bend
CGCGAAAAAACG
>pdb|1D89|D Chain D, A Dna Dodecamer Containing An Adenine Tract Crystallizes In A Unique Lattice And Exhibits A New Bend
CGTTTTTTCGCG
>pdb|1D89|C Chain C, A Dna Dodecamer Containing An Adenine Tract Crystallizes In A Unique Lattice And Exhibits A New Bend
CGCGAAAAAACG
>pdb|1D89|B Chain B, A Dna Dodecamer Containing An Adenine Tract Crystallizes In A Unique Lattice And Exhibits A New Bend
CGTTTTTTCGCG
>pdb|1D89|A Chain A, A Dna Dodecamer Containing An Adenine Tract Crystallizes In A Unique Lattice And Exhibits A New Bend
CGCGAAAAAACG
>pdb|1D86|B Chain B, Structural Consequences Of A Carcinogenic Alkylation Lesion On Dna: Effect Of O6-Ethyl-Guanine On The Molecular Structure Of D(Cgc[e6g]aattcgcg)-Netropsin Complex
CGCGAATTCGCG
>pdb|1D86|A Chain A, Structural Consequences Of A Carcinogenic Alkylation Lesion On Dna: Effect Of O6-Ethyl-Guanine On The Molecular Structure Of D(Cgc[e6g]aattcgcg)-Netropsin Complex
CGCGAATTCGCG
>pdb|1D85|B Chain B, Structural Consequences Of A Carcinogenic Alkylation Lesion On Dna: Effect Of O6-Ethyl-Guanine On The Molecular Structure Of D(Cgc[e6g]aattcgcg)-Netropsin Complex
CGCNAATTCGCG
>pdb|1D85|A Chain A, Structural Consequences Of A Carcinogenic Alkylation Lesion On Dna: Effect Of O6-Ethyl-Guanine On The Molecular Structure Of D(Cgc[e6g]aattcgcg)-Netropsin Complex
CGCNAATTCGCG
>pdb|1D80|B Chain B, Crystal Structure Of An Oligonucleotide Duplex Containing G.G Base-Pairs: The Influence Of Mispairing On Dna Backbone Conformation
CGCGAATTGGCG
>pdb|1D80|A Chain A, Crystal Structure Of An Oligonucleotide Duplex Containing G.G Base-Pairs: The Influence Of Mispairing On Dna Backbone Conformation
CGCGAATTGGCG
>pdb|1D77|B Chain B, Crystal Structure Of A B-Dna Dodecamer Containing Inosine, D(Cgciaattcgcg), At 2.4 Angstroms Resolution And Its Comparison With Other B-Dna Dodecamers
CGCNAATTCGCG
>pdb|1D77|A Chain A, Crystal Structure Of A B-Dna Dodecamer Containing Inosine, D(Cgciaattcgcg), At 2.4 Angstroms Resolution And Its Comparison With Other B-Dna Dodecamers
CGCNAATTCGCG
>pdb|119D|B Chain B, Crystal And Molecular Structure Of D(Cgtagatctacg) At 2.25 Angstroms Resolution
CGTAGATCTACG
>pdb|119D|A Chain A, Crystal And Molecular Structure Of D(Cgtagatctacg) At 2.25 Angstroms Resolution
CGTAGATCTACG
>pdb|114D|B Chain B, Inosine-Adenine Base Pairs In A B-Dna Duplex
CGCNAATTAGCG
>pdb|114D|A Chain A, Inosine-Adenine Base Pairs In A B-Dna Duplex
CGCNAATTAGCG
>pdb|113D|B Chain B, The Structure Of Guanosine-Thymidine Mismatches In B-Dna At 2.5 Angstroms Resolution
CGCGAATTTGCG
>pdb|113D|A Chain A, The Structure Of Guanosine-Thymidine Mismatches In B-Dna At 2.5 Angstroms Resolution
CGCGAATTTGCG
>pdb|112D|B Chain B, Molecular Structure Of The G.A Base Pair In Dna And Its Implications For The Mechanism Of Transversion Mutations
CGCGAATTAGCG
>pdb|112D|A Chain A, Molecular Structure Of The G.A Base Pair In Dna And Its Implications For The Mechanism Of Transversion Mutations
CGCGAATTAGCG
>pdb|111D|B Chain B, Crystal Structure And Stability Of A Dna Duplex Containing A(Anti).G(Syn) Base-Pairs
CGCAAATTGGCG
>pdb|111D|A Chain A, Crystal Structure And Stability Of A Dna Duplex Containing A(Anti).G(Syn) Base-Pairs
CGCAAATTGGCG
>pdb|4DNB|B Chain B, Methylation Of The Ecori Recognition Site Does Not Alter Dna Conformation. The Crystal Structure Of D(Cgcgam6attcgcg) At 2.0 Angstroms Resolution
CGCGANTTCGCG
>pdb|4DNB|A Chain A, Methylation Of The Ecori Recognition Site Does Not Alter Dna Conformation. The Crystal Structure Of D(Cgcgam6attcgcg) At 2.0 Angstroms Resolution
CGCGANTTCGCG
>pdb|1D59|D Chain D, Crystal Structure Of 4-Stranded Oxytricha Telomeric Dna
GGGGTTTTGGGG
>pdb|1D59|C Chain C, Crystal Structure Of 4-Stranded Oxytricha Telomeric Dna
GGGGTTTTGGGG
>pdb|1D59|B Chain B, Crystal Structure Of 4-Stranded Oxytricha Telomeric Dna
GGGGTTTTGGGG
>pdb|1D59|A Chain A, Crystal Structure Of 4-Stranded Oxytricha Telomeric Dna
GGGGTTTTGGGG
>pdb|1D27|B Chain B, High-Resolution Structure Of A Mutagenic Lesion In Dna
CGCNAATTTGCG
>pdb|1D27|A Chain A, High-Resolution Structure Of A Mutagenic Lesion In Dna
CGCNAATTTGCG
>pdb|116D|A Chain A, Crystal And Molecular Structure Of The A-Dna Dodecamer D(Ccgtacgtacgg): Choice Of Fragment Helical Axis
CCGTACGTACGG
>pdb|8BNA|B Chain B, Binding Of Hoechst 33258 To The Minor Groove Of B-dna
CGCGAATTCGCG
>pdb|8BNA|A Chain A, Binding Of Hoechst 33258 To The Minor Groove Of B-dna
CGCGAATTCGCG
>pdb|7BNA|B Chain B, Anisotropic Thermal-Parameter Refinement Of The Dna Dodecamer Cgcgaattcgcg By The Segmented Rigid-Body Method
CGCGAATTCGCG
>pdb|7BNA|A Chain A, Anisotropic Thermal-Parameter Refinement Of The Dna Dodecamer Cgcgaattcgcg By The Segmented Rigid-Body Method
CGCGAATTCGCG
>pdb|5BNA|A Chain A, The Primary Mode Of Binding Of Cisplatin To A B-Dna Dodecamer: C-G-C-G-A-A-T-T-C-G-C-G
CGCGAATTCGCG
>pdb|2DND|B Chain B, A Bifurcated Hydrogen-Bonded Conformation In The D(A.T) Base Pairs Of The Dna Dodecamer D(Cgcaaatttgcg) And Its Complex With Distamycin
CGCAAATTTGCG
>pdb|2DND|A Chain A, A Bifurcated Hydrogen-Bonded Conformation In The D(A.T) Base Pairs Of The Dna Dodecamer D(Cgcaaatttgcg) And Its Complex With Distamycin
CGCAAATTTGCG
>pdb|2DBE|B Chain B, Crystal Structure Of A Berenil-Dodecanucleotide Complex: The Role Of Water In Sequence-Specific Ligand Binding
CGCGAATTCGCG
>pdb|2DBE|A Chain A, Crystal Structure Of A Berenil-Dodecanucleotide Complex: The Role Of Water In Sequence-Specific Ligand Binding
CGCGAATTCGCG
>pdb|2D47|B Chain B, MOLECULAR STRUCTURE OF A COMPLETE TURN OF A-DNA
CCCCCGCGGGGG
>pdb|2D47|A Chain A, MOLECULAR STRUCTURE OF A COMPLETE TURN OF A-DNA
CCCCCGCGGGGG
>pdb|2BNA|B Chain B, Structure Of A B-Dna Dodecamer At 16 Kelvin
CGCGAATTCGCG
>pdb|2BNA|A Chain A, Structure Of A B-Dna Dodecamer At 16 Kelvin
CGCGAATTCGCG
>pdb|1NDN|A Chain A, Molecular Structure Of Nicked Dna. Model T4
CGCGAAAACGCG
>pdb|1DNM|B Chain B, CRYSTAL STRUCTURE AND SEQUENCE-DEPENDENT CONFORMATION OF THE A.G MIS-PAIRED OLIGONUCLEOTIDE D(CGCAAGCTGGCG)
CGCAAGCTGGCG
>pdb|1DNM|A Chain A, CRYSTAL STRUCTURE AND SEQUENCE-DEPENDENT CONFORMATION OF THE A.G MIS-PAIRED OLIGONUCLEOTIDE D(CGCAAGCTGGCG)
CGCAAGCTGGCG
>pdb|1DNH|B Chain B, The Molecular Structure Of The Complex Of Hoechst 33258 And The Dna Dodecamer D(Cgcgaattcgcg)
CGCGAATTCGCG
>pdb|1DNH|A Chain A, The Molecular Structure Of The Complex Of Hoechst 33258 And The Dna Dodecamer D(Cgcgaattcgcg)
CGCGAATTCGCG
>pdb|1DNE|B Chain B, Molecular Structure Of The Netropsin-D(Cgcgatatcgcg) Complex: Dna Conformation In An Alternating At Segment; Conformation 2
CGCGATATCGCG
>pdb|1DNE|A Chain A, Molecular Structure Of The Netropsin-D(Cgcgatatcgcg) Complex: Dna Conformation In An Alternating At Segment; Conformation 2
CGCGATATCGCG
>pdb|1DN9|B Chain B, Structure Of An Alternating-B Dna Helix And Its Relationship To A-Tract Dna
CGCATATATGCG
>pdb|1DN9|A Chain A, Structure Of An Alternating-B Dna Helix And Its Relationship To A-Tract Dna
CGCATATATGCG
>pdb|1D81|B Chain B, The Conformational Variability Of An Adenosine. Inosine Base-Pair In A Synthetic Dna Dodecamer
CGCAAATTNGCG
>pdb|1D81|A Chain A, The Conformational Variability Of An Adenosine. Inosine Base-Pair In A Synthetic Dna Dodecamer
CGCAAATTNGCG
>pdb|1D75|B Chain B, Conformation Of The Guanine.8-Oxoadenine Base Pairs In The Crystal Structure Of D(Cgcgaatt(O8a)gcg)
CGCGAATTNGCG
>pdb|1D75|A Chain A, Conformation Of The Guanine.8-Oxoadenine Base Pairs In The Crystal Structure Of D(Cgcgaatt(O8a)gcg)
CGCGAATTNGCG
>pdb|1D65|B Chain B, Molecular Structure Of The B-Dna Dodecamer D(Cgcaaatttgcg) 2; An Examination Of Propeller Twist And Minor-Groove Water Structure At 2.2 Angstroms Resolution
CGCAAATTTGCG
>pdb|1D65|A Chain A, Molecular Structure Of The B-Dna Dodecamer D(Cgcaaatttgcg) 2; An Examination Of Propeller Twist And Minor-Groove Water Structure At 2.2 Angstroms Resolution
CGCAAATTTGCG
>pdb|1D64|B Chain B, Crystal Structure Of A Pentamidine-Oligonucleotide Complex: Implications For Dna-Binding Properties
CGCGAATTCGCG
>pdb|1D64|A Chain A, Crystal Structure Of A Pentamidine-Oligonucleotide Complex: Implications For Dna-Binding Properties
CGCGAATTCGCG
>pdb|1D63|B Chain B, Crystal Structure Of A Berenil-D(Cgcaaatttgcg) Complex; An Example Of Drug-Dna Recognition Based On Sequence- Dependent Structural Features
CGCAAATTTGCG
>pdb|1D63|A Chain A, Crystal Structure Of A Berenil-D(Cgcaaatttgcg) Complex; An Example Of Drug-Dna Recognition Based On Sequence- Dependent Structural Features
CGCAAATTTGCG
>pdb|1D46|B Chain B, Dna Dodecamer C-G-C-G-A-A-T-T-C-G-C-GHOECHST 33258 COMPLEX:-100 Degrees C, Piperazine Down
CGCGAATTCGCG
>pdb|1D46|A Chain A, Dna Dodecamer C-G-C-G-A-A-T-T-C-G-C-GHOECHST 33258 COMPLEX:-100 Degrees C, Piperazine Down
CGCGAATTCGCG
>pdb|1D45|B Chain B, Dna Dodecamer C-G-C-G-A-A-T-T-C-G-C-GHOECHST 33258 COMPLEX:-25 Degrees C, Piperazine Down
CGCGAATTCGCG
>pdb|1D45|A Chain A, Dna Dodecamer C-G-C-G-A-A-T-T-C-G-C-GHOECHST 33258 COMPLEX:-25 Degrees C, Piperazine Down
CGCGAATTCGCG
>pdb|1D44|B Chain B, Dna Dodecamer C-G-C-G-A-A-T-T-C-G-C-GHOECHST 33258 COMPLEX: 0 DEGREES C, Piperazine Down
CGCGAATTCGCG
>pdb|1D44|A Chain A, Dna Dodecamer C-G-C-G-A-A-T-T-C-G-C-GHOECHST 33258 COMPLEX: 0 DEGREES C, Piperazine Down
CGCGAATTCGCG
>pdb|1D43|B Chain B, Dna Dodecamer C-G-C-G-A-A-T-T-C-G-C-GHOECHST 33258 COMPLEX: 0 DEGREES C, Piperazine Up
CGCGAATTCGCG
>pdb|1D43|A Chain A, Dna Dodecamer C-G-C-G-A-A-T-T-C-G-C-GHOECHST 33258 COMPLEX: 0 DEGREES C, Piperazine Up
CGCGAATTCGCG
>pdb|1D30|B Chain B, The Structure Of Dapi Bound To Dna
CGCGAATTCGCG
>pdb|1D30|A Chain A, The Structure Of Dapi Bound To Dna
CGCGAATTCGCG
>pdb|1D29|B Chain B, Crystal Structure Analysis Of The B-Dna Dodecamer Cgtgaattcacg
CGTGAATTCACG
>pdb|1D29|A Chain A, Crystal Structure Analysis Of The B-Dna Dodecamer Cgtgaattcacg
CGTGAATTCACG
>pdb|1D28|B Chain B, Crystal And Molecular Structure Of A Dna Fragment: D(Cgtgaattcacg)
CGTGAATTCACG
>pdb|1D28|A Chain A, Crystal And Molecular Structure Of A Dna Fragment: D(Cgtgaattcacg)
CGTGAATTCACG
>pdb|1BNA|B Chain B, Structure Of A B-Dna Dodecamer. Conformation And Dynamics
CGCGAATTCGCG
>pdb|1BNA|A Chain A, Structure Of A B-Dna Dodecamer. Conformation And Dynamics
CGCGAATTCGCG
>pdb|1BDN|D Chain D, Crystal Lattice Packing Is Important In Determining The Bend Of A Dna Dodecamer Containing An Adenine Tract
CGCATTTTTGCG
>pdb|1BDN|C Chain C, Crystal Lattice Packing Is Important In Determining The Bend Of A Dna Dodecamer Containing An Adenine Tract
CGCAAAAATGCG
>pdb|1BDN|B Chain B, Crystal Lattice Packing Is Important In Determining The Bend Of A Dna Dodecamer Containing An Adenine Tract
CGCATTTTTGCG
>pdb|1BDN|A Chain A, Crystal Lattice Packing Is Important In Determining The Bend Of A Dna Dodecamer Containing An Adenine Tract
CGCAAAAATGCG
>pdb|6DT8|D Chain D, Bacteriophage N4 RNA polymerase II elongation complex 1
AAAATTTGGTGG
>pdb|5WTI|H Chain H, Crystal structure of the CRISPR-associated protein in complex with crRNA and DNA
NTGTGGATTCCG
>pdb|5VAJ|D Chain D, BhRNase H - amide-RNA/DNA complex
GAATCAGGTGTC
>pdb|5NPP|C Chain C, 2.22a Structure Of Thiophene2 And Gsk945237 With S.aureus Dna Gyrase And Dna
NTACCTACGGCT
>pdb|5NPP|A Chain A, 2.22a Structure Of Thiophene2 And Gsk945237 With S.aureus Dna Gyrase And Dna
NTACCTACGGCT
>pdb|5IWI|G Chain G, 1.98A structure of GSK945237 with S.aureus DNA gyrase and singly nicked DNA
GTACCTACGGCN
>pdb|5G2X|B Chain B, Structure a of Group II Intron Complexed with its Reverse Transcriptase
NACATCCATAAC
>pdb|4XQN|K Chain K, Crystal structure of AgrA LytTR domain in complex with promoters
ACAGTTAAGAAT
>pdb|4XQN|H Chain H, Crystal structure of AgrA LytTR domain in complex with promoters
NCAGTTAAGAAT
>pdb|4XQN|E Chain E, Crystal structure of AgrA LytTR domain in complex with promoters
NCAGTTAAGAAT
>pdb|4XQN|B Chain B, Crystal structure of AgrA LytTR domain in complex with promoters
NCAGTTAAGAAT
>pdb|4XQJ|E Chain E, Crystal structure of AgrA LytTR domain in complex with promoters
ACAGTTAAGAAT
>pdb|4XQJ|B Chain B, Crystal structure of AgrA LytTR domain in complex with promoters
NCAGTTAAGAAT
>pdb|5CDN|P Chain P, 2.8A structure of etoposide with S.aureus DNA gyrase and DNA
GGCCGTACGCTC
>pdb|5CDN|N Chain N, 2.8A structure of etoposide with S.aureus DNA gyrase and DNA
GGCCGTACGCTC
>pdb|5CDN|O Chain O, 2.8A structure of etoposide with S.aureus DNA gyrase and DNA
GGCCGTACGCTC
>pdb|5CDN|G Chain G, 2.8A structure of etoposide with S.aureus DNA gyrase and DNA
GGCCGTACGCTC
>pdb|4HUG|F Chain F, Structure of 5-chlorouracil modified A:U base pairs
CGCGAANNCGCG
>pdb|4HUG|E Chain E, Structure of 5-chlorouracil modified A:U base pairs
CGCGAANNCGCG
>pdb|4HUG|D Chain D, Structure of 5-chlorouracil modified A:U base pairs
CGCGAANNCGCG
>pdb|4HUG|C Chain C, Structure of 5-chlorouracil modified A:U base pairs
CGCGAANNCGCG
>pdb|4HUF|F Chain F, Structure of 5-chlorouracil modified A:U base pair
CGCGAANTCGCG
>pdb|4HUF|E Chain E, Structure of 5-chlorouracil modified A:U base pair
CGCGAANTCGCG
>pdb|4HUF|D Chain D, Structure of 5-chlorouracil modified A:U base pair
CGCGAANTCGCG
>pdb|4HUF|C Chain C, Structure of 5-chlorouracil modified A:U base pair
CGCGAANTCGCG
>pdb|4HUE|F Chain F, Structure of 5-chlorouracil modified G:U base pair
CGCGAATTNGCG
>pdb|4HUE|E Chain E, Structure of 5-chlorouracil modified G:U base pair
CGCGAATTNGCG
>pdb|4HUE|D Chain D, Structure of 5-chlorouracil modified G:U base pair
CGCGAATTNGCG
>pdb|4HUE|C Chain C, Structure of 5-chlorouracil modified G:U base pair
CGCGAATTNGCG
>pdb|4HTU|F Chain F, Structure of 5-chlorouracil modified A:U base pair
CGCGAATNCGCG
>pdb|4HTU|E Chain E, Structure of 5-chlorouracil modified A:U base pair
CGCGAATNCGCG
>pdb|4HTU|D Chain D, Structure of 5-chlorouracil modified A:U base pair
CGCGAATNCGCG
>pdb|4HTU|C Chain C, Structure of 5-chlorouracil modified A:U base pair
CGCGAATNCGCG
>pdb|2XCT|Y Chain Y, The twinned 3.35A structure of S. aureus Gyrase complex with Ciprofloxacin and DNA
GTACACCGCACA
>pdb|2XCT|X Chain X, The twinned 3.35A structure of S. aureus Gyrase complex with Ciprofloxacin and DNA
GTACCCACGGCT
>pdb|2XCT|H Chain H, The twinned 3.35A structure of S. aureus Gyrase complex with Ciprofloxacin and DNA
GTACACCGCACA
>pdb|2XCT|G Chain G, The twinned 3.35A structure of S. aureus Gyrase complex with Ciprofloxacin and DNA
GTACCCACGGCT
>pdb|2WCN|B Chain B, Solution structure of an LNA-modified quadruplex
GNGNTTTTGNGN
>pdb|2WCN|A Chain A, Solution structure of an LNA-modified quadruplex
GNGNTTTTGNGN
>pdb|2ATW|D Chain D, Structure of a Mycobacterium tuberculosis NusA-RNA complex
AGAACTCAATAG
>pdb|2ATW|B Chain B, Structure of a Mycobacterium tuberculosis NusA-RNA complex
AGAACTCAATAG
>pdb|1PHJ|D Chain D, Crystal Structure Of The Oxytricha Nova Telomere End- Binding Protein Complexed With Noncognate Ssdna Gg(3dr) Gttttgggg
GGNGTTTTGGGG
>pdb|1PH9|D Chain D, Crystal Structure Of The Oxytricha Nova Telomere End-Binding Protein Complexed With Noncognate Ssdna Ggggttttgagg
GGGGTTTTGAGG
>pdb|1PH8|D Chain D, Crystal Structure Of The Oxytricha Nova Telomere End- Binding Protein Complexed With Noncognate Ssdna Ggggttttgcgg
GGGGTTTTGCGG
>pdb|1PH4|D Chain D, Crystal Structure Of The Oxytricha Nova Telomere End-Binding Protein Complexed With Noncognate Ssdna Ggggttttggcg
GGGGTTTTGGCG
>pdb|1PH3|D Chain D, Crystal Structure Of The Oxytricha Nova Telomere End-Binding Protein Complexed With Noncognate Ssdna Ggggttttggtg
GGGGTTTTGGTG
>pdb|1PA6|H Chain H, Crystal structure of the OXYTRICHA nova telomere end-binding protein complexed with noncognate ssDNA GGGGTTTTGAGG
GGGGTTTTGGGG
>pdb|1PA6|G Chain G, Crystal structure of the OXYTRICHA nova telomere end-binding protein complexed with noncognate ssDNA GGGGTTTTGAGG
GGGGTTTTGGGG
>pdb|1PA6|D Chain D, Crystal structure of the OXYTRICHA nova telomere end-binding protein complexed with noncognate ssDNA GGGGTTTTGAGG
GGGGTTTTGAGG
>pdb|1JB7|H Chain H, DNA G-Quartets in a 1.86 A Resolution Structure of an Oxytricha nova Telomeric Protein-DNA Complex
GGGGTTTTGGGG
>pdb|1JB7|G Chain G, DNA G-Quartets in a 1.86 A Resolution Structure of an Oxytricha nova Telomeric Protein-DNA Complex
GGGGTTTTGGGG
>pdb|1JB7|D Chain D, DNA G-Quartets in a 1.86 A Resolution Structure of an Oxytricha nova Telomeric Protein-DNA Complex
GGGGTTTTGGGG
>pdb|1OTC|D Chain D, THE O. NOVA TELOMERE END BINDING PROTEIN COMPLEXED WITH SINGLE STRAND DNA
GGGGTTTTGGGG
>MD388233.1 WO 2020090211-A/94: Stabilization of double-stranded RNA by cationic artificial oligosaccharide
CAGTCAGTCAGT
>MD388232.1 WO 2020090211-A/93: Stabilization of double-stranded RNA by cationic artificial oligosaccharide
ACTGACTGACTG
>MD388231.1 WO 2020090211-A/92: Stabilization of double-stranded RNA by cationic artificial oligosaccharide
CAGTCAGTCAGT
>MD388230.1 WO 2020090211-A/91: Stabilization of double-stranded RNA by cationic artificial oligosaccharide
ACTGACTGACTG
>MD394419.1 JP 2020519306-A/1: Pharmaceutical composition for prevention or treatment of Alzheimer's disease, comprising stem cell secreting sRAGE
GTTTTAGAGCTA
>MD390315.1 WO 2020100826-A/8: Bridged Artificial Nucleric Acid ALNA
AGCAAANAACGC
>MD390314.1 WO 2020100826-A/7: Bridged Artificial Nucleric Acid ALNA
AGCAAAAAACGC
>MD390313.1 WO 2020100826-A/6: Bridged Artificial Nucleric Acid ALNA
AGCAAAAAACGC
>MD390308.1 WO 2020100826-A/1: Bridged Artificial Nucleric Acid ALNA
GCGTTNTTTGCT
>LY976687.1 KR 1020200024905-A/76568: NOVEL NUCLEIC ACID MOLECULES
GCCGCTGCAGCC
>LY976674.1 KR 1020200024905-A/76555: NOVEL NUCLEIC ACID MOLECULES
GGCCCCAGCCTG
>LY976612.1 KR 1020200024905-A/76493: NOVEL NUCLEIC ACID MOLECULES
GCCGCCGCGGCC
>LY976599.1 KR 1020200024905-A/76480: NOVEL NUCLEIC ACID MOLECULES
GGCCCCAGCCTG
>LY803301.1 KR 1020200025249-A/14: Aptamer for DEHP detection and DEHP detecting device using the same
GGTGCCGCGCTT
>LY801769.1 KR 1020200005050-A/5: Melamine-mediated synthesis of bright and stable DNA-silver nanoclusters and its use for the development of a biosensor and an antimicrobial agent
AGGTCGCCGCCC
>LY801768.1 KR 1020200005050-A/4: Melamine-mediated synthesis of bright and stable DNA-silver nanoclusters and its use for the development of a biosensor and an antimicrobial agent
CCTCCTTCCTCC
>LY801767.1 KR 1020200005050-A/3: Melamine-mediated synthesis of bright and stable DNA-silver nanoclusters and its use for the development of a biosensor and an antimicrobial agent
CCCCCCCCCCCC
>LY801766.1 KR 1020200005050-A/2: Melamine-mediated synthesis of bright and stable DNA-silver nanoclusters and its use for the development of a biosensor and an antimicrobial agent
CCCTAACTCCCC
>LY801765.1 KR 1020200005050-A/1: Melamine-mediated synthesis of bright and stable DNA-silver nanoclusters and its use for the development of a biosensor and an antimicrobial agent
CCCTTAATCCCC
>LY837439.1 KR 1020200015606-A/108: A HIGH-THROUGHPUT (HTP) GENOMIC ENGINEERING PLATFORM FOR IMPROVING SACCHAROPOLYSPORA SPINOSA
AAAGAGGAGAAA
>LY837428.1 KR 1020200015606-A/97: A HIGH-THROUGHPUT (HTP) GENOMIC ENGINEERING PLATFORM FOR IMPROVING SACCHAROPOLYSPORA SPINOSA
AGGAGGTCCCAT
>LY836372.1 KR 1020200010379-A/1: ANGIOPOIETIN-1- OR VEGF-SECRETING STEM CELL AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASE, COMPRISING SAME
GTTTTAGAGCTA
>LY835878.1 KR 1020200005660-A/2079: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGGG
>LY835877.1 KR 1020200005660-A/2078: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGGC
>LY835876.1 KR 1020200005660-A/2077: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGGT
>LY835875.1 KR 1020200005660-A/2076: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGGA
>LY835874.1 KR 1020200005660-A/2075: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGCG
>LY835873.1 KR 1020200005660-A/2074: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGCC
>LY835872.1 KR 1020200005660-A/2073: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGCT
>LY835871.1 KR 1020200005660-A/2072: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGCA
>LY835870.1 KR 1020200005660-A/2071: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGTC
>LY835869.1 KR 1020200005660-A/2070: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGTT
>LY835868.1 KR 1020200005660-A/2069: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGTA
>LY835867.1 KR 1020200005660-A/2068: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGAG
>LY835866.1 KR 1020200005660-A/2067: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGAC
>LY835865.1 KR 1020200005660-A/2066: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGAT
>LY835864.1 KR 1020200005660-A/2065: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGAA
>LY835862.1 KR 1020200005660-A/2063: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGTG
>LY835859.1 KR 1020200005660-A/2060: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGNN
>LY835858.1 KR 1020200005660-A/2059: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGGG
>LY835857.1 KR 1020200005660-A/2058: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGGC
>LY835856.1 KR 1020200005660-A/2057: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGGT
>LY835855.1 KR 1020200005660-A/2056: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGGA
>LY835854.1 KR 1020200005660-A/2055: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGCG
>LY835853.1 KR 1020200005660-A/2054: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGCC
>LY835852.1 KR 1020200005660-A/2053: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGCT
>LY835851.1 KR 1020200005660-A/2052: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGCA
>LY835850.1 KR 1020200005660-A/2051: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGTG
>LY835849.1 KR 1020200005660-A/2050: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGTC
>LY835848.1 KR 1020200005660-A/2049: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGTT
>LY835847.1 KR 1020200005660-A/2048: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGTA
>LY835846.1 KR 1020200005660-A/2047: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGAG
>LY835845.1 KR 1020200005660-A/2046: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGAC
>LY835844.1 KR 1020200005660-A/2045: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGAT
>LY835843.1 KR 1020200005660-A/2044: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGAGACAGAA
>LY798372.1 KR 1020200001159-A/24: DNA marker for discrimination of spicy taste degree in pepper pericarp and uses thereof
TGATGACGTGGC
>LY798370.1 KR 1020200001159-A/22: DNA marker for discrimination of spicy taste degree in pepper pericarp and uses thereof
TGATGACGTGGC
>LY834711.1 KR 1020200005660-A/912: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGGCATCCGTTG
>LY834759.1 KR 1020200005660-A/960: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GGTGTTCCACTG
>LY834758.1 KR 1020200005660-A/959: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GGCCATCATCAG
>LY834757.1 KR 1020200005660-A/958: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GATAGATCGCAT
>LY834756.1 KR 1020200005660-A/957: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAGACTGCACTC
>LY834755.1 KR 1020200005660-A/956: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CGTCGATCATCA
>LY834754.1 KR 1020200005660-A/955: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GCGCGCTTATGA
>LY834753.1 KR 1020200005660-A/954: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GGTTGGATCAAC
>LY834752.1 KR 1020200005660-A/953: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AAGAGCTGTGCC
>LY834751.1 KR 1020200005660-A/952: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTTCGATGATGG
>LY834750.1 KR 1020200005660-A/951: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACGATACGTGGA
>LY834749.1 KR 1020200005660-A/950: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACGATCATAGCC
>LY834748.1 KR 1020200005660-A/949: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGCTCAGTAACA
>LY834747.1 KR 1020200005660-A/948: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGCTCATTACGG
>LY834746.1 KR 1020200005660-A/947: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CGCTAGGATCAC
>LY834745.1 KR 1020200005660-A/946: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTGGTACCACGT
>LY834744.1 KR 1020200005660-A/945: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CAAGTGTGATGA
>LY834743.1 KR 1020200005660-A/944: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGTTAAGTTGGA
>LY834742.1 KR 1020200005660-A/943: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CGCATGTTGTGC
>LY834741.1 KR 1020200005660-A/942: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTCGCAGTTCCT
>LY834740.1 KR 1020200005660-A/941: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AACATGGATACG
>LY834739.1 KR 1020200005660-A/940: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTCGATATATGG
>LY834738.1 KR 1020200005660-A/939: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTGGTCACACGC
>LY834737.1 KR 1020200005660-A/938: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGACGGTCTAGT
>LY834736.1 KR 1020200005660-A/937: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCTATGTAGACG
>LY834735.1 KR 1020200005660-A/936: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AAGGCTAATGTC
>LY834734.1 KR 1020200005660-A/935: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGAGCGTACACG
>LY834733.1 KR 1020200005660-A/934: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GAATCTTCCGCG
>LY834732.1 KR 1020200005660-A/933: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTTGCTCACGTG
>LY834731.1 KR 1020200005660-A/932: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AACCGGCTGTCT
>LY834730.1 KR 1020200005660-A/931: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CGCAGGACGATT
>LY834729.1 KR 1020200005660-A/930: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGCTTAGGTATG
>LY834728.1 KR 1020200005660-A/929: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTCAACGCTAAG
>LY834727.1 KR 1020200005660-A/928: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACGCTGTTAGCA
>LY834726.1 KR 1020200005660-A/927: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CAGTTGTGCTAT
>LY834725.1 KR 1020200005660-A/926: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACTAACGCGACT
>LY834724.1 KR 1020200005660-A/925: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GGTGGAACCATG
>LY834723.1 KR 1020200005660-A/924: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATTAAGCCTAAG
>LY834722.1 KR 1020200005660-A/923: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CACCTGCACGAT
>LY834721.1 KR 1020200005660-A/922: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTCTCGTGTGCG
>LY834720.1 KR 1020200005660-A/921: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTAAGACTTAAG
>LY834719.1 KR 1020200005660-A/920: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGCCGAGACTTC
>LY834718.1 KR 1020200005660-A/919: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTTGGCATGTAC
>LY834717.1 KR 1020200005660-A/918: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGAGTAGGTCAG
>LY834716.1 KR 1020200005660-A/917: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAGTCAACGTAG
>LY834715.1 KR 1020200005660-A/916: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CGTCAACGTGGT
>LY834714.1 KR 1020200005660-A/915: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTCGATATAGTT
>LY834713.1 KR 1020200005660-A/914: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TACCGTCAAGTG
>LY834712.1 KR 1020200005660-A/913: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACCGTCGCTTGA
>LY834710.1 KR 1020200005660-A/911: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACGTCGGAAGGT
>LY834709.1 KR 1020200005660-A/910: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AATTGGCTATAG
>LY834708.1 KR 1020200005660-A/909: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGTCTGTATCAT
>LY834707.1 KR 1020200005660-A/908: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCCATCAGATAA
>LY834706.1 KR 1020200005660-A/907: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GGAAGTGATTAA
>LY834705.1 KR 1020200005660-A/906: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACACACTTCTAG
>LY834704.1 KR 1020200005660-A/905: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GGTTACCGAGGA
>LY834703.1 KR 1020200005660-A/904: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TACCTGGTCGGT
>LY834702.1 KR 1020200005660-A/903: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTCGCGTTATTG
>LY834701.1 KR 1020200005660-A/902: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGAAGTCGCCTC
>LY834700.1 KR 1020200005660-A/901: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GGTTATGAAGAA
>LY834699.1 KR 1020200005660-A/900: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GCAGAATTGCGA
>LY834698.1 KR 1020200005660-A/899: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGTTCGCATACA
>LY834697.1 KR 1020200005660-A/898: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGGCTGACAT
>LY834696.1 KR 1020200005660-A/897: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ACTGAGGCGTTC
>LY834695.1 KR 1020200005660-A/896: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGTCAAGAGATT
>LY834694.1 KR 1020200005660-A/895: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GCCTCTGGTAAC
>LY834693.1 KR 1020200005660-A/894: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CATCCACTAATC
>LY834692.1 KR 1020200005660-A/893: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATGTCGATCTAG
>LY834691.1 KR 1020200005660-A/892: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTCCTCGTGGTT
>LY834690.1 KR 1020200005660-A/891: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATATATCTCAGC
>LY834689.1 KR 1020200005660-A/890: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAAGATGCTTGA
>LY834688.1 KR 1020200005660-A/889: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CCTGTTCTGATT
>LY834687.1 KR 1020200005660-A/888: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CGCATGTATGCC
>LY834686.1 KR 1020200005660-A/887: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTGTTGCTACCA
>LY834685.1 KR 1020200005660-A/886: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTACGTCCGCAA
>LY834684.1 KR 1020200005660-A/885: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCTCTAGTTCGG
>LY834683.1 KR 1020200005660-A/884: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGCTAACTCTCC
>LY834682.1 KR 1020200005660-A/883: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTGTCACAACTC
>LY834681.1 KR 1020200005660-A/882: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTGCATGCATAA
>LY834680.1 KR 1020200005660-A/881: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AATACTGGCTAA
>LY834679.1 KR 1020200005660-A/880: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
AGAGCCAGTCGT
>LY834678.1 KR 1020200005660-A/879: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTACTGGCACAA
>LY834677.1 KR 1020200005660-A/878: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TCGCTAATGTAG
>LY834676.1 KR 1020200005660-A/877: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATTGAGAGCTAT
>LY834675.1 KR 1020200005660-A/876: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TTGTGCTGGACT
>LY834674.1 KR 1020200005660-A/875: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TGGATCCTTCAT
>LY834673.1 KR 1020200005660-A/874: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTGCATTCACGA
>LY834672.1 KR 1020200005660-A/873: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GCGGTCACATAT
>LY834671.1 KR 1020200005660-A/872: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CCTACCTGTGGA
>LY834670.1 KR 1020200005660-A/871: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GACGCATACCTC
>LY834669.1 KR 1020200005660-A/870: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GTGCTTCAGGAG
>LY834668.1 KR 1020200005660-A/869: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TAGTGGTCGTCA
>LY834667.1 KR 1020200005660-A/868: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
TATACTACAAGC
>LY834666.1 KR 1020200005660-A/867: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
CTTAAGGAGCGC
>LY834665.1 KR 1020200005660-A/866: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
ATACTCCGAGAT
>LY834664.1 KR 1020200005660-A/865: SET OF RANDOM PRIMERS AND METHOD FOR PREPARING DNA LIBRARY USING THE SAME
GCTGTTGAACCG
>LY832682.1 KR 1020200006111-A/288: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
TGGCGTGTGGCT
>LY832681.1 KR 1020200006111-A/287: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
CCCCACAGCAGT
>LY832673.1 KR 1020200006111-A/279: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
GGGCGTCGTGGC
>LY832672.1 KR 1020200006111-A/278: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
TAGGTTGGAAAG
>LY832671.1 KR 1020200006111-A/277: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
GCGTATGGCGTG
>LY832670.1 KR 1020200006111-A/276: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
AGCGACGTTGCG
>LY832666.1 KR 1020200006111-A/272: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
KRDNWGGTGGCH
>LY832664.1 KR 1020200006111-A/270: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
RNNRRWGCGGGG
>LY832661.1 KR 1020200006111-A/267: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
GNRWGCGGKGGC
>LY832660.1 KR 1020200006111-A/266: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
AGTTGGAANGCG
>LY832659.1 KR 1020200006111-A/265: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
ARABMDAGGYGC
>LY832657.1 KR 1020200006111-A/263: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
TASGTTGGRAMG
>LY832656.1 KR 1020200006111-A/262: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
GCGTADKKBGBG
>LY832655.1 KR 1020200006111-A/261: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
AGMGRYGGTCGT
>LY832653.1 KR 1020200006111-A/259: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
AGCGAYGKTGYG
>LY832652.1 KR 1020200006111-A/258: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
GSGCGKHGTGGY
>LY832650.1 KR 1020200006111-A/256: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
RNRDGTGGCRTG
>LY832649.1 KR 1020200006111-A/255: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
CMYCACAKCMGY
>LY832648.1 KR 1020200006111-A/254: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
WGCGASGTSGYG
>LY832647.1 KR 1020200006111-A/253: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
VGTGKGKTGTGC
>LY832646.1 KR 1020200006111-A/252: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
DDGTGGNYGTGC
>LY832644.1 KR 1020200006111-A/250: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
TGGCKTGTGGCT
>LY832627.1 KR 1020200006111-A/233: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
CYGSRYTKRGRG
>LY832625.1 KR 1020200006111-A/231: COMPOSITIONS AND METHODS FOR LOADING EXTRACELLULAR VESICLES WITH CHEMICAL AND BIOLOGICAL AGENTS/MOLECULES
WWMGYGCWYMYW
>LY997670.1 KR 1020200043542-A/103: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CATGTCAGAGTC
>LY997667.1 KR 1020200043542-A/100: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTGAGACTGTAC
>LY997648.1 KR 1020200043542-A/81: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
TTTGCTTGCTCT
>LY997647.1 KR 1020200043542-A/80: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GATGCCTGCTCT
>LY997646.1 KR 1020200043542-A/79: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
ATTCGGTGCTCT
>LY997645.1 KR 1020200043542-A/78: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTTCAATGCTCT
>LY997644.1 KR 1020200043542-A/77: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
TCCTGTCGGTTC
>LY997643.1 KR 1020200043542-A/76: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATCGTCCT
>LY997642.1 KR 1020200043542-A/75: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATTTGCAC
>LY997641.1 KR 1020200043542-A/74: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATACCTAC
>LY997640.1 KR 1020200043542-A/73: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATTTCTAC
>LY997639.1 KR 1020200043542-A/72: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATTGCTCT
>LY997638.1 KR 1020200043542-A/71: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATTGTGCT
>LY997637.1 KR 1020200043542-A/70: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
AGGCATGCGATG
>LY997636.1 KR 1020200043542-A/69: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCTGACCT
>LY997635.1 KR 1020200043542-A/68: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCCGTCCT
>LY997634.1 KR 1020200043542-A/67: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCGTACCT
>LY997633.1 KR 1020200043542-A/66: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCGTTCCT
>LY997632.1 KR 1020200043542-A/65: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCACTCCT
>LY997631.1 KR 1020200043542-A/64: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCTGTCCT
>LY997630.1 KR 1020200043542-A/63: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCTGTGCT
>LY997629.1 KR 1020200043542-A/62: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCTGTACT
>LY997628.1 KR 1020200043542-A/61: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCTGCTCT
>LY997627.1 KR 1020200043542-A/60: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCGACTCT
>LY997626.1 KR 1020200043542-A/59: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCCTCTCT
>LY997625.1 KR 1020200043542-A/58: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CTTTTCACCTCT
>LY997624.1 KR 1020200043542-A/57: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCCGTCCT
>LY997623.1 KR 1020200043542-A/56: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCTTGCCT
>LY997622.1 KR 1020200043542-A/55: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCTTGCAC
>LY997621.1 KR 1020200043542-A/54: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCACAAAC
>LY997620.1 KR 1020200043542-A/53: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCCGAAAC
>LY997619.1 KR 1020200043542-A/52: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCCGTAAC
>LY997618.1 KR 1020200043542-A/51: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCAACTAC
>LY997617.1 KR 1020200043542-A/50: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCTTCGAC
>LY997616.1 KR 1020200043542-A/49: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCACTCAC
>LY997615.1 KR 1020200043542-A/48: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCACCTAC
>LY997614.1 KR 1020200043542-A/47: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCTTCTAC
>LY997613.1 KR 1020200043542-A/46: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCGACTAC
>LY997612.1 KR 1020200043542-A/45: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCCGCTAC
>LY997611.1 KR 1020200043542-A/44: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
GTCATCTCCTAC
>LY997610.1 KR 1020200043542-A/43: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CATCGCATGCCT
>LY997609.1 KR 1020200043542-A/42: ENZYME- AND AMPLIFICATION-FREE SEQUENCING
CACGAACGTCAG
>LY996746.1 KR 1020200044145-A/14: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
CATGACGTTCCT
>LY996732.1 KR 1020200044982-A/94: COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
GGAGGAGGAGGA
>LY996731.1 KR 1020200044982-A/93: COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
GGTGGAGGAGGA
>LY996730.1 KR 1020200044982-A/92: COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
GGAGGTGGAGGA
>LY996729.1 KR 1020200044982-A/91: COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
GGAGGAGGTGGA
>LY996728.1 KR 1020200044982-A/90: COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
GGAGGAGGAGGT
>LY996727.1 KR 1020200044982-A/89: COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
GGAGGTGGAGGT
>LY996726.1 KR 1020200044982-A/88: COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
GGAGGAGGTGGT
>LY996725.1 KR 1020200044982-A/87: COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
GGAGGTGGTGGA
>LY996724.1 KR 1020200044982-A/86: COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
GGTGGAGGAGGT
>LY996723.1 KR 1020200044982-A/85: COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
GGTGGAGGTGGA
>LY996722.1 KR 1020200044982-A/84: COMPOSITIONS AND METHODS FOR LYOPHILIZATION OF BACTERIA OR LISTERIA STRAINS
GGTGGTGGAGGA
>LY996517.1 KR 1020200075830-A/8: GENE EXPRESSION SYSTEM FOR PROBIOTIC MICROORGANISMS
GCACAAGGACGT
>LY996513.1 KR 1020200075830-A/2: GENE EXPRESSION SYSTEM FOR PROBIOTIC MICROORGANISMS
GCACAAGAACGT
>LY828022.1 KR 1020200010285-A/308: GENOMIC ENGINEERING OF BIOSYNTHETIC PATHWAYS LEADING TO INCREASED NADPH
TGACACCTATTG
>LY827456.1 KR 1020200003390-A/150: ALPHAVIRUS NEOANTIGEN VECTORS
GTGAGCTGGCGG
>LY928129.1 KR 1020200024905-A/3708: NOVEL NUCLEIC ACID MOLECULES
GGCGTGGCCGAG
>LY927917.1 KR 1020200024905-A/3496: NOVEL NUCLEIC ACID MOLECULES
GGCGTGGCCGAG
>LY992080.1 KR 1020200036041-A/54: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CAGGCAGGCAGG
>LY992074.1 KR 1020200036041-A/48: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
GCAGCAGCAGCA
>LY992070.1 KR 1020200036041-A/44: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
AGCAGCAGCAGC
>LY992066.1 KR 1020200036041-A/40: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CAGCAGCAGCAG
>LY927685.1 KR 1020200024905-A/3052: NOVEL NUCLEIC ACID MOLECULES
CRRRRRRRRRRR
>LY927669.1 KR 1020200024905-A/3036: NOVEL NUCLEIC ACID MOLECULES
CRRRRRRRRRRC
>LY988327.1 KR 1020200039765-A/16: T CELL MODIFICATION
GCCGCCACCATG
>LY815311.1 KR 1020200061688-A/5: GLUCAGON-LIKE PEPTIDE-1 DERIVATIVE CONJUGATED WITH ALBUMIN
ATCGAAGGTAGG
>LY815083.1 KR 1020200060644-A/4: Recombinant Expression Vectors for Producing Norovirus Vaccine
ATGTCCGCAGTA
>LY915575.1 KR 1020200015939-A/232: EXPRESSION OF NOVEL CELL TAGS
CGTGCAAAGCGT
>LY915574.1 KR 1020200015939-A/231: EXPRESSION OF NOVEL CELL TAGS
AGAGCTAAGAGG
>LY915496.1 KR 1020200015939-A/17: EXPRESSION OF NOVEL CELL TAGS
AGTGGCAGCGGC
>LY981339.1 KR 1020200062184-A/6: COMPOSITIONS AND METHODS FOR MODIFYING GENOMES
TTTTTTTGTTTT
>LY978438.1 KR 1020200018726-A/28: COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS
TTTTTTTTTTTT
>LY978076.1 KR 1020200028415-A/696: A TWO-COMPONENT VECTOR LIBRARY SYSTEM FOR RAPID ASSEMBLY AND DIVERSIFICATION OF FULL-LENGTH T-CELL RECEPTOR OPEN READING FRAMES
TCGAGGGTCTCA
>LY927640.1 KR 1020200024905-A/3007: NOVEL NUCLEIC ACID MOLECULES
GGGTTTTTTGGG
>LY927629.1 KR 1020200024905-A/2996: NOVEL NUCLEIC ACID MOLECULES
GGTTTTTTTTGG
>LY824044.1 KR 1020200005549-A/101: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
TTCTTCTTCGTT
>LY824043.1 KR 1020200005549-A/99: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
TTCTTCTTCATC
>LY824042.1 KR 1020200005549-A/97: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
TTCATCTTCGTT
>LY824041.1 KR 1020200005549-A/95: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
TTCCTTTTCGTT
>LY824040.1 KR 1020200005549-A/93: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
TTCGTTTTCGTT
>LY824039.1 KR 1020200005549-A/91: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
TTCGTTTTCATC
>LY824038.1 KR 1020200005549-A/89: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
TTCATCTTCATC
>LY824037.1 KR 1020200005549-A/87: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
TTCATCTTCCTT
>LY824036.1 KR 1020200005549-A/85: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
TTCTTCTTCCTT
>LY824035.1 KR 1020200005549-A/83: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
TTCCTTTTCCTT
>LY824034.1 KR 1020200005549-A/81: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
ATGAAAAAAAGA
>LY824033.1 KR 1020200005549-A/79: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
ATGAGAAGAAAA
>LY824032.1 KR 1020200005549-A/77: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
ATGAGAAAAAGA
>LY824031.1 KR 1020200005549-A/75: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
ATGAAAAGAAGA
>LY824030.1 KR 1020200005549-A/73: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
ATGAAAAAAAAA
>LY824027.1 KR 1020200005549-A/67: GENETIC CONSTRUCT FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDER OR STROKE
ATGAGAAGAAGA
>LY823988.1 KR 1020200021449-A/1: PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS OR CARDIOVASCULAR DISEASES, COMPRISING SRAGE-SECRETING STEM CELL
GTTTTAGAGCTA
>LY823950.1 KR 1020200021446-A/1: PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE, COMPRISING STEM CELL SECRETING SRAGE
GTTTTAGAGCTA
>LY823777.1 KR 1020200003370-A/518: METHODS AND COMPOSITIONS FOR TRANSDUCING AND EXPANDING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
GCCGCCACCANN
>LY821916.1 KR 1020200062063-A/9: Novel Probe for Specific Staphylococcus aureus and Uses Thereof
TCACAATTCCGT
>LY821915.1 KR 1020200062063-A/8: Novel Probe for Specific Staphylococcus aureus and Uses Thereof
TCACCTCCGCTT
>LY821914.1 KR 1020200062063-A/7: Novel Probe for Specific Staphylococcus aureus and Uses Thereof
TCACCGTTCCGT
>LY821913.1 KR 1020200062063-A/6: Novel Probe for Specific Staphylococcus aureus and Uses Thereof
TTCACCCTCCGT
>LY821912.1 KR 1020200062063-A/5: Novel Probe for Specific Staphylococcus aureus and Uses Thereof
ATCACCCTCCGT
>LY821862.1 KR 1020200056948-A/16: Recombinant vector to increase the expression of capsid protein in plant expression system and virus-like particles preparation method using the same
CATGATGAGCTC
>LY821556.1 KR 1020200049594-A/245: Manipulated immune cell
AAAAAGATGCCT
>LY821555.1 KR 1020200049594-A/244: Manipulated immune cell
AAAGATGAATTA
>LY821231.1 KR 1020200044709-A/3: Nucleic acid variant with improved therapeutic efficacy and anticancer pharmaceutical composition comprising the same
TGGTGGTTGTGG
>LY821230.1 KR 1020200044709-A/2: Nucleic acid variant with improved therapeutic efficacy and anticancer pharmaceutical composition comprising the same
TGGTTGTGGTGG
>LY821171.1 KR 1020200056913-A/12: Recombinant vector expressing virus-like particles in plants and methods of preparing vaccine compositions comprising circovirus-like particles using the same
CATGATGAGCTC
>LY988715.1 KR 1020200038303-A/137: MODULAR BINDING PROTEINS
GACATCAACAAC
>LY988714.1 KR 1020200038303-A/136: MODULAR BINDING PROTEINS
GACATCAACAAC
>LY988713.1 KR 1020200038303-A/134: MODULAR BINDING PROTEINS
AGAAGAAGAGGC
>LY988712.1 KR 1020200038303-A/133: MODULAR BINDING PROTEINS
CGTCGTCGTGGT
>LY988689.1 KR 1020200038303-A/101: MODULAR BINDING PROTEINS
CAGAGAGTTCTG
>LY988688.1 KR 1020200038303-A/100: MODULAR BINDING PROTEINS
CAGCGTGTTCTG
>LY819423.1 KR 1020200012786-A/9: A gene editing of anticoagulant factors
AAGGCTAGTCCG
>LY819415.1 KR 1020200012786-A/1: A gene editing of anticoagulant factors
GTTTTAGAGCTA
>LY923026.1 KR 1020200022467-A/343: ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
ATCCCGTACACT
>LY798018.1 KR 1020200000928-A/4: Composition for Diagnosing Antibacterial Susceptibility Comprising an Agent for Detecting Nuclease in Microorganism and Uses Thereof
ATCACCCTCCGT
>LY818581.1 KR 1020200011899-A/9: Genome editing for treating autoimmune disease
AAGGCTAGTCCG
>LY818573.1 KR 1020200011899-A/1: Genome editing for treating autoimmune disease
GTTTTAGAGCTA
>LY816475.1 KR 1020200069603-A/3: PNA probe for detecting Porcine reproductive and respiratory syndrome virus genetic type and a method for detecting Porcine reproductive and respiratory syndrome virus genetic type using the same
ATACGCTGTGAG
>LY815979.1 KR 1020200064233-A/545: Double-stranded oligo nucleotide structure comprising androgen receptor specific sequences and composition comprising the same for preventing hair loss and hair growth
AAAAAAAAAAAA
>LY919992.1 KR 1020200017476-A/3897: METHODS FOR MODIFYING RNA SPLICING
GATATCTAGAGA
>MD245298.1 JP 2020110070-A/5: A composition for immunostimulation
ATATATAAATAT
>MD245297.1 JP 2020110070-A/4: A composition for immunostimulation
GCGGTACCTGGA
>MD245296.1 JP 2020110070-A/3: A composition for immunostimulation
TCCAGGTACCGC
>MD245219.1 JP 2020103258-A/101: Method for identifying positions of post transcription modification of uridine or citidine in RNA
TANTCTCAAACT
>MD245151.1 JP 2020103258-A/33: Method for identifying positions of post transcription modification of uridine or citidine in RNA
CTAAACCANTCG
>MD245139.1 JP 2020103258-A/21: Method for identifying positions of post transcription modification of uridine or citidine in RNA
TACCCATATCCG
>LC589450.1 Homo sapiens RNA for doRNA
GACTCTTAGCGG
>LY729832.1 KR 1020190088512-A/59: SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION
CCAGGAACTGCG
>LY729829.1 KR 1020190088512-A/56: SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION
CCAGGAACTGCG
>LY729826.1 KR 1020190088512-A/53: SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION
CCAGGAACTGCG
>LY766139.1 KR 1020190129082-A/96: HIGH AFFINITY MAGE-A1-SPECIFIC TCRS AND USES THEREOF
CACATCAGCAGA
>LY765650.1 KR 1020190118688-A/94: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765649.1 KR 1020190118688-A/93: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765648.1 KR 1020190118688-A/92: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765647.1 KR 1020190118688-A/91: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765646.1 KR 1020190118688-A/90: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765645.1 KR 1020190118688-A/89: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765644.1 KR 1020190118688-A/88: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765643.1 KR 1020190118688-A/87: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765642.1 KR 1020190118688-A/86: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765641.1 KR 1020190118688-A/85: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765640.1 KR 1020190118688-A/84: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765639.1 KR 1020190118688-A/83: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765638.1 KR 1020190118688-A/82: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765637.1 KR 1020190118688-A/81: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765636.1 KR 1020190118688-A/80: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765635.1 KR 1020190118688-A/79: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765634.1 KR 1020190118688-A/78: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765633.1 KR 1020190118688-A/77: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765611.1 KR 1020190118688-A/55: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765579.1 KR 1020190118688-A/23: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY765578.1 KR 1020190118688-A/22: miR-155 Inhibitors for Treating Cutaneous T Cell Lymphoma (CTCL)
CGATTAGCATTA
>LY729021.1 KR 1020190086001-A/58: MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT
ACATAGACTGTA
>LY729020.1 KR 1020190086001-A/57: MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT
TACAGTCTATGT
>LY728620.1 KR 1020190080952-A/42: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GAGGGTTTTAAG
>LY728619.1 KR 1020190080952-A/41: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
ATGTTGTGGGTA
>LY728618.1 KR 1020190080952-A/40: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GAGTTGGATGAG
>LY728617.1 KR 1020190080952-A/39: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
ATGGGAAAAAGT
>LY728616.1 KR 1020190080952-A/38: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GTTAGTGGGAAA
>LY728615.1 KR 1020190080952-A/37: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
TTTGGGTTTAGG
>LY728614.1 KR 1020190080952-A/36: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GTTGTTATTGTG
>LY728613.1 KR 1020190080952-A/35: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
TGAGAAGGGTAG
>LY728612.1 KR 1020190080952-A/34: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGCGTGGAAAAG
>LY728611.1 KR 1020190080952-A/33: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GAGGGCGAAAAG
>LY728610.1 KR 1020190080952-A/32: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
CGAGAGGAAAAG
>LY728609.1 KR 1020190080952-A/31: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGCCGAGAAAAG
>LY728608.1 KR 1020190080952-A/30: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GTGAGGGAAAAG
>LY728607.1 KR 1020190080952-A/29: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GGGGATGAAAAG
>LY728606.1 KR 1020190080952-A/28: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GAAGGAGAAAAG
>LY728605.1 KR 1020190080952-A/27: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
TGGATGGAAAAG
>LY728604.1 KR 1020190080952-A/26: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGGGTGGATGAC
>LY728603.1 KR 1020190080952-A/25: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGCCGAGATGAC
>LY728602.1 KR 1020190080952-A/24: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGTGGGGAGGAG
>LY728601.1 KR 1020190080952-A/23: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGAGGGGATGAC
>LY728600.1 KR 1020190080952-A/22: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGGGGTGAGGAG
>LY728599.1 KR 1020190080952-A/21: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGGAGTGATGAC
>LY728598.1 KR 1020190080952-A/20: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GTATCGGATGAC
>LY728597.1 KR 1020190080952-A/19: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGGACAGATGAC
>LY728308.1 KR 1020190085980-A/4: COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 MUTATIONS
TATGTCATGGCT
>LY728307.1 KR 1020190085980-A/2: COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING EGFR OR HER2 EXON 20 MUTATIONS
TCCAGGAAGCCT
>LY725707.1 KR 1020190082850-A/582: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGAGGAGGA
>LY725706.1 KR 1020190082850-A/581: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGTGGAGGAGGA
>LY725705.1 KR 1020190082850-A/580: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGTGGAGGA
>LY725704.1 KR 1020190082850-A/579: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGAGGTGGA
>LY725703.1 KR 1020190082850-A/578: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGAGGAGGT
>LY725702.1 KR 1020190082850-A/577: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGTGGAGGT
>LY725701.1 KR 1020190082850-A/576: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGAGGTGGT
>LY725700.1 KR 1020190082850-A/575: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGTGGTGGA
>LY725699.1 KR 1020190082850-A/574: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGTGGAGGAGGT
>LY725698.1 KR 1020190082850-A/573: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGTGGAGGTGGA
>LY725697.1 KR 1020190082850-A/572: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGTGGTGGAGGA
>LY724936.1 KR 1020190099397-A/169: COMPOSITIONS AND METHODS FOR THE PRODUCTION OF COMPOUNDS
CTAGGGGGTTGC
>LY724885.1 KR 1020190099396-A/39: COMPOSITIONS AND METHODS FOR THE PRODUCTION OF COMPOUNDS
CTAGGGGGTTGC
>LY724858.1 KR 1020190086473-A/20: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GCANNNNNACCG
>LY724857.1 KR 1020190086473-A/19: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGATGNNCTCGA
>LY724856.1 KR 1020190086473-A/18: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGANGTTCNCGA
>LY724855.1 KR 1020190086473-A/17: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGANGTTCTCGA
>LY724854.1 KR 1020190086473-A/16: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGATGTTCNCGA
>LY724853.1 KR 1020190086473-A/11: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GCANNNNNACCG
>LY724852.1 KR 1020190086473-A/10: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGATGTTNTNGA
>LY724851.1 KR 1020190086473-A/9: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGATGTTCTNGA
>LY724850.1 KR 1020190086473-A/8: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGATGTTNTCGA
>LY724849.1 KR 1020190086473-A/7: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGATNTTCTCGA
>LY724848.1 KR 1020190086473-A/6: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGNTGTTCTCGA
>LY724847.1 KR 1020190086473-A/5: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGATGTTCTNGA
>LY724846.1 KR 1020190086473-A/4: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGATGTTNTCGA
>LY724845.1 KR 1020190086473-A/3: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGATGNNCTCGA
>LY724844.1 KR 1020190086473-A/2: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGANGTTCTCGA
>LY724843.1 KR 1020190086473-A/1: NOVEL BICYCLIC NUCLEOSIDES AND OLIGOMERS PREPARED THEREFROM
GGATGTTCNCGA
>LY721022.1 KR 1020190078555-A/25: Genetic Marker for Discrimination and Detection of Vibriosis in fish and Method for Discrimination and Detection of Vibriosis in fish Using the Same
AGCGCATGCAGG
>LY721017.1 KR 1020190078555-A/20: Genetic Marker for Discrimination and Detection of Vibriosis in fish and Method for Discrimination and Detection of Vibriosis in fish Using the Same
GGCGGCCTGTTA
>LY721009.1 KR 1020190078555-A/12: Genetic Marker for Discrimination and Detection of Vibriosis in fish and Method for Discrimination and Detection of Vibriosis in fish Using the Same
GGCGGCCTGTTA
>LY721006.1 KR 1020190078555-A/9: Genetic Marker for Discrimination and Detection of Vibriosis in fish and Method for Discrimination and Detection of Vibriosis in fish Using the Same
AGCGCATGCAGG
>LY720996.1 KR 1020190076944-A/25: Genetic Marker for Discrimination and Detection of Vibriosis in fish and Method for Discrimination and Detection of Vibriosis in fish Using the Same
AGCGCATGCAGG
>LY720991.1 KR 1020190076944-A/20: Genetic Marker for Discrimination and Detection of Vibriosis in fish and Method for Discrimination and Detection of Vibriosis in fish Using the Same
GGCGGCCTGTTA
>LY720983.1 KR 1020190076944-A/12: Genetic Marker for Discrimination and Detection of Vibriosis in fish and Method for Discrimination and Detection of Vibriosis in fish Using the Same
GGCGGCCTGTTA
>LY720980.1 KR 1020190076944-A/9: Genetic Marker for Discrimination and Detection of Vibriosis in fish and Method for Discrimination and Detection of Vibriosis in fish Using the Same
AGCGCATGCAGG
>LY792275.1 KR 1020190122893-A/428: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTTGGTGTGGGC
>LY792274.1 KR 1020190122893-A/427: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCCACACCAAC
>LY792273.1 KR 1020190122893-A/426: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTGGTGTGGGCC
>LY792272.1 KR 1020190122893-A/425: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGCCCACACCAA
>LY792271.1 KR 1020190122893-A/424: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGTGTGGGCCT
>LY792270.1 KR 1020190122893-A/423: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGCCCACACCA
>LY792269.1 KR 1020190122893-A/422: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGTGTGGGCCTC
>LY792268.1 KR 1020190122893-A/421: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAGGCCCACACC
>LY792267.1 KR 1020190122893-A/420: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGTGGGCCTCC
>LY792266.1 KR 1020190122893-A/419: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGAGGCCCACAC
>LY792265.1 KR 1020190122893-A/418: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGTGGGCCTCCA
>LY792264.1 KR 1020190122893-A/417: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGAGGCCCACA
>LY792263.1 KR 1020190122893-A/416: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGGGCCTCCAC
>LY792262.1 KR 1020190122893-A/415: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGGAGGCCCAC
>LY792261.1 KR 1020190122893-A/414: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGGCCTCCACC
>LY792260.1 KR 1020190122893-A/413: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGTGGAGGCCCA
>LY792259.1 KR 1020190122893-A/412: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGGCCTCCACCA
>LY792258.1 KR 1020190122893-A/411: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGTGGAGGCCC
>LY792257.1 KR 1020190122893-A/410: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGCCTCCACCAG
>LY792256.1 KR 1020190122893-A/409: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTGGTGGAGGCC
>LY792255.1 KR 1020190122893-A/408: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCTCCACCAGC
>LY792254.1 KR 1020190122893-A/407: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCTGGTGGAGGC
>LY792253.1 KR 1020190122893-A/406: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCTCCACCAGCT
>LY792252.1 KR 1020190122893-A/405: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGCTGGTGGAGG
>LY792251.1 KR 1020190122893-A/404: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCATCCAGAAGC
>LY792250.1 KR 1020190122893-A/403: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCTTCTGGATGG
>LY792249.1 KR 1020190122893-A/402: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CATCCAGAAGCC
>LY792248.1 KR 1020190122893-A/401: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGCTTCTGGATG
>LY792247.1 KR 1020190122893-A/400: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATCCAGAAGCCA
>LY792246.1 KR 1020190122893-A/399: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGCTTCTGGAT
>LY792245.1 KR 1020190122893-A/398: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCCAGAAGCCAA
>LY792244.1 KR 1020190122893-A/397: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTGGCTTCTGGA
>LY792243.1 KR 1020190122893-A/396: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCAGAAGCCAAA
>LY792242.1 KR 1020190122893-A/395: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTTGGCTTCTGG
>LY792241.1 KR 1020190122893-A/394: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGAAGCCAAAC
>LY792240.1 KR 1020190122893-A/393: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTTTGGCTTCTG
>LY757180.1 KR 1020190119107-A/20: NUCLEIC ACID BASED DATA STORAGE
GACNNNNNNGTC
>LY757176.1 KR 1020190119107-A/16: NUCLEIC ACID BASED DATA STORAGE
CGANNNNNNTGC
>LY757172.1 KR 1020190119107-A/12: NUCLEIC ACID BASED DATA STORAGE
CCANNNNNNTGG
>LY757168.1 KR 1020190119107-A/8: NUCLEIC ACID BASED DATA STORAGE
CAANNNNNGTGG
>LY720622.1 KR 1020190140868-A/81: Composition For Preventing Or Treating Hepatitis B
GGGGGGAATTGA
>LY792239.1 KR 1020190122893-A/392: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGAAGCCAAACT
>LY792238.1 KR 1020190122893-A/391: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGTTTGGCTTCT
>LY792237.1 KR 1020190122893-A/390: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAAGCCAAACTG
>LY792236.1 KR 1020190122893-A/389: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGTTTGGCTTC
>LY792235.1 KR 1020190122893-A/388: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAGCCAAACTGG
>LY792234.1 KR 1020190122893-A/387: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCAGTTTGGCTT
>LY792233.1 KR 1020190122893-A/386: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGCCAAACTGGC
>LY792232.1 KR 1020190122893-A/385: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCAGTTTGGCT
>LY792231.1 KR 1020190122893-A/384: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCAAACTGGCC
>LY792230.1 KR 1020190122893-A/383: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGCCAGTTTGGC
>LY792229.1 KR 1020190122893-A/382: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCAAACTGGCCA
>LY792228.1 KR 1020190122893-A/381: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGCCAGTTTGG
>LY792227.1 KR 1020190122893-A/380: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAAACTGGCCAC
>LY792226.1 KR 1020190122893-A/379: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGGCCAGTTTG
>LY792225.1 KR 1020190122893-A/378: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAACTGGCCACC
>LY792224.1 KR 1020190122893-A/377: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGTGGCCAGTTT
>LY792223.1 KR 1020190122893-A/376: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AACTGGCCACCC
>LY792222.1 KR 1020190122893-A/375: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGGTGGCCAGTT
>LY792221.1 KR 1020190122893-A/374: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACTGGCCACCCA
>LY792220.1 KR 1020190122893-A/373: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGGTGGCCAGT
>LY792219.1 KR 1020190122893-A/372: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCTTCCTGCTCA
>LY792218.1 KR 1020190122893-A/371: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGAGCAGGAAGG
>LY792217.1 KR 1020190122893-A/370: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTTCCTGCTCAG
>LY792216.1 KR 1020190122893-A/369: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTGAGCAGGAAG
>LY792215.1 KR 1020190122893-A/368: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTCCTGCTCAGG
>LY792214.1 KR 1020190122893-A/367: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCTGAGCAGGAA
>LY792213.1 KR 1020190122893-A/366: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCCTGCTCAGGG
>LY792212.1 KR 1020190122893-A/365: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCCTGAGCAGGA
>LY792211.1 KR 1020190122893-A/364: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCTGCTCAGGGT
>LY792210.1 KR 1020190122893-A/363: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACCCTGAGCAGG
>LY792209.1 KR 1020190122893-A/362: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTGCTCAGGGTG
>LY792208.1 KR 1020190122893-A/361: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CACCCTGAGCAG
>LY792207.1 KR 1020190122893-A/360: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGCTCAGGGTGA
>LY792206.1 KR 1020190122893-A/359: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCACCCTGAGCA
>LY792205.1 KR 1020190122893-A/358: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCTCAGGGTGAT
>LY792204.1 KR 1020190122893-A/357: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATCACCCTGAGC
>LY792203.1 KR 1020190122893-A/356: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTCAGGGTGATA
>LY792202.1 KR 1020190122893-A/355: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TATCACCCTGAG
>LY792201.1 KR 1020190122893-A/354: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCAGGGTGATAT
>LY792200.1 KR 1020190122893-A/353: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATATCACCCTGA
>LY792199.1 KR 1020190122893-A/352: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCAGTCAGCCA
>LY792198.1 KR 1020190122893-A/351: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGCTGACTGGC
>LY792197.1 KR 1020190122893-A/350: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCAGTCAGCCAT
>LY792196.1 KR 1020190122893-A/349: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATGGCTGACTGG
>LY792195.1 KR 1020190122893-A/348: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGTCAGCCATG
>LY792194.1 KR 1020190122893-A/347: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CATGGCTGACTG
>LY792193.1 KR 1020190122893-A/346: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGTCAGCCATGG
>LY792192.1 KR 1020190122893-A/345: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCATGGCTGACT
>LY792191.1 KR 1020190122893-A/344: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTCAGCCATGGA
>LY792190.1 KR 1020190122893-A/343: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCCATGGCTGAC
>LY792189.1 KR 1020190122893-A/342: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCAGCCATGGAG
>LY792188.1 KR 1020190122893-A/341: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTCCATGGCTGA
>LY792187.1 KR 1020190122893-A/340: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGCCATGGAGA
>LY792186.1 KR 1020190122893-A/339: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCTCCATGGCTG
>LY792185.1 KR 1020190122893-A/338: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTGTTGCAGTAT
>LY792184.1 KR 1020190122893-A/337: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATACTGCAACAA
>LY792183.1 KR 1020190122893-A/336: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGTTGCAGTATT
>LY792182.1 KR 1020190122893-A/335: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AATACTGCAACA
>LY792181.1 KR 1020190122893-A/334: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTTGCAGTATTT
>LY792180.1 KR 1020190122893-A/333: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAATACTGCAAC
>LY792179.1 KR 1020190122893-A/332: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTGCAGTATTTC
>LY792178.1 KR 1020190122893-A/331: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAAATACTGCAA
>LY792177.1 KR 1020190122893-A/330: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGCAGTATTTCT
>LY792176.1 KR 1020190122893-A/329: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGAAATACTGCA
>LY792175.1 KR 1020190122893-A/328: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCAGTATTTCTC
>LY792174.1 KR 1020190122893-A/327: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAGAAATACTGC
>LY792173.1 KR 1020190122893-A/326: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGTATTTCTCC
>LY792172.1 KR 1020190122893-A/325: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGAGAAATACTG
>LY792171.1 KR 1020190122893-A/324: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGTCGTGTTGT
>LY792170.1 KR 1020190122893-A/323: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACAACACGACCT
>LY792169.1 KR 1020190122893-A/322: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGTCGTGTTGTA
>LY792168.1 KR 1020190122893-A/321: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TACAACACGACC
>LY792167.1 KR 1020190122893-A/320: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTCGTGTTGTAG
>LY792166.1 KR 1020190122893-A/319: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTACAACACGAC
>LY792165.1 KR 1020190122893-A/318: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCGTGTTGTAGT
>LY792164.1 KR 1020190122893-A/317: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACTACAACACGA
>LY792163.1 KR 1020190122893-A/316: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CGTGTTGTAGTC
>LY792162.1 KR 1020190122893-A/315: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GACTACAACACG
>LY792161.1 KR 1020190122893-A/314: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGTTGTAGTCA
>LY792160.1 KR 1020190122893-A/313: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGACTACAACAC
>LY792159.1 KR 1020190122893-A/312: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGTTGTAGTCAC
>LY792158.1 KR 1020190122893-A/311: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGACTACAACA
>LY792157.1 KR 1020190122893-A/310: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTTGTAGTCACT
>LY792156.1 KR 1020190122893-A/309: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGTGACTACAAC
>LY792155.1 KR 1020190122893-A/308: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTGTAGTCACTG
>LY792154.1 KR 1020190122893-A/307: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGTGACTACAA
>LY792153.1 KR 1020190122893-A/306: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGTAGTCACTGT
>LY792152.1 KR 1020190122893-A/305: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACAGTGACTACA
>LY792151.1 KR 1020190122893-A/304: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTAGTCACTGTA
>LY792150.1 KR 1020190122893-A/303: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TACAGTGACTAC
>LY792149.1 KR 1020190122893-A/302: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TAGTCACTGTAG
>LY792148.1 KR 1020190122893-A/301: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTACAGTGACTA
>LY792147.1 KR 1020190122893-A/300: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAGGAAGTGCCT
>LY792146.1 KR 1020190122893-A/299: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGCACTTCCTT
>LY792145.1 KR 1020190122893-A/298: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGAAGTGCCTT
>LY792144.1 KR 1020190122893-A/297: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAGGCACTTCCT
>LY792143.1 KR 1020190122893-A/296: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGAAGTGCCTTC
>LY792142.1 KR 1020190122893-A/295: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAAGGCACTTCC
>LY792141.1 KR 1020190122893-A/294: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAAGTGCCTTCT
>LY792140.1 KR 1020190122893-A/293: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGAAGGCACTTC
>LY792139.1 KR 1020190122893-A/292: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAGTGCCTTCTC
>LY792138.1 KR 1020190122893-A/291: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAGAAGGCACTT
>LY792137.1 KR 1020190122893-A/290: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGTGCCTTCTCT
>LY792136.1 KR 1020190122893-A/289: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGAGAAGGCACT
>LY792135.1 KR 1020190122893-A/288: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTGCCTTCTCTG
>LY792134.1 KR 1020190122893-A/287: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGAGAAGGCAC
>LY792133.1 KR 1020190122893-A/286: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGCCTTCTCTGT
>LY792132.1 KR 1020190122893-A/285: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACAGAGAAGGCA
>LY792131.1 KR 1020190122893-A/284: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCTTCTCTGTC
>LY792130.1 KR 1020190122893-A/283: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GACAGAGAAGGC
>LY792129.1 KR 1020190122893-A/282: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCTTCTCTGTCA
>LY792128.1 KR 1020190122893-A/281: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGACAGAGAAGG
>LY792127.1 KR 1020190122893-A/280: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTTCTCTGTCAT
>LY792126.1 KR 1020190122893-A/279: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATGACAGAGAAG
>LY792125.1 KR 1020190122893-A/278: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTCTCTGTCATG
>LY792124.1 KR 1020190122893-A/277: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CATGACAGAGAA
>LY792123.1 KR 1020190122893-A/276: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCTCTGTCATGC
>LY792122.1 KR 1020190122893-A/275: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCATGACAGAGA
>LY792121.1 KR 1020190122893-A/274: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTCTGTCATGCC
>LY792120.1 KR 1020190122893-A/273: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGCATGACAGAG
>LY792119.1 KR 1020190122893-A/272: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGATGTTGGTGG
>LY792118.1 KR 1020190122893-A/271: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CCACCAACATCT
>LY792117.1 KR 1020190122893-A/270: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GATGTTGGTGGC
>LY792116.1 KR 1020190122893-A/269: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCCACCAACATC
>LY792115.1 KR 1020190122893-A/268: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ATGTTGGTGGCC
>LY792114.1 KR 1020190122893-A/267: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGCCACCAACAT
>LY792113.1 KR 1020190122893-A/266: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGTTGGTGGCCT
>LY792112.1 KR 1020190122893-A/265: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGCCACCAACA
>LY792111.1 KR 1020190122893-A/264: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTTGGTGGCCTG
>LY792110.1 KR 1020190122893-A/263: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGGCCACCAAC
>LY792109.1 KR 1020190122893-A/262: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTGGTGGCCTGC
>LY792108.1 KR 1020190122893-A/261: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCAGGCCACCAA
>LY792107.1 KR 1020190122893-A/260: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGTGGCCTGCA
>LY792106.1 KR 1020190122893-A/259: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGCAGGCCACCA
>LY792105.1 KR 1020190122893-A/258: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGTGGCCTGCAG
>LY792104.1 KR 1020190122893-A/257: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTGCAGGCCACC
>LY792103.1 KR 1020190122893-A/256: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGACGCTGACCT
>LY792102.1 KR 1020190122893-A/255: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGTCAGCGTCT
>LY792101.1 KR 1020190122893-A/254: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GACGCTGACCTC
>LY792100.1 KR 1020190122893-A/253: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAGGTCAGCGTC
>LY792099.1 KR 1020190122893-A/252: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACGCTGACCTCC
>LY792098.1 KR 1020190122893-A/251: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGAGGTCAGCGT
>LY792097.1 KR 1020190122893-A/250: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CGCTGACCTCCC
>LY792096.1 KR 1020190122893-A/249: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGGAGGTCAGCG
>LY792095.1 KR 1020190122893-A/248: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCTGACCTCCCA
>LY792094.1 KR 1020190122893-A/247: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGGGAGGTCAGC
>LY792093.1 KR 1020190122893-A/246: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTGACCTCCCAG
>LY792092.1 KR 1020190122893-A/245: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CTGGGAGGTCAG
>LY792091.1 KR 1020190122893-A/244: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGACCTCCCAGC
>LY792090.1 KR 1020190122893-A/243: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCTGGGAGGTCA
>LY792089.1 KR 1020190122893-A/242: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GACCTCCCAGCT
>LY792088.1 KR 1020190122893-A/241: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGCTGGGAGGTC
>LY792087.1 KR 1020190122893-A/240: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
ACCTCCCAGCTC
>LY792086.1 KR 1020190122893-A/239: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAGCTGGGAGGT
>LY792085.1 KR 1020190122893-A/238: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TTCAGCAGGTAC
>LY792084.1 KR 1020190122893-A/237: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GTACCTGCTGAA
>LY792083.1 KR 1020190122893-A/236: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TCAGCAGGTACT
>LY792082.1 KR 1020190122893-A/235: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGTACCTGCTGA
>LY792081.1 KR 1020190122893-A/234: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGCAGGTACTT
>LY792080.1 KR 1020190122893-A/233: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAGTACCTGCTG
>LY792079.1 KR 1020190122893-A/232: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGCAGGTACTTC
>LY792078.1 KR 1020190122893-A/231: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAAGTACCTGCT
>LY792077.1 KR 1020190122893-A/230: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GCAGGTACTTCT
>LY792076.1 KR 1020190122893-A/229: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGAAGTACCTGC
>LY792075.1 KR 1020190122893-A/228: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
CAGGTACTTCTT
>LY792074.1 KR 1020190122893-A/227: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AAGAAGTACCTG
>LY792073.1 KR 1020190122893-A/226: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
AGGTACTTCTTC
>LY792072.1 KR 1020190122893-A/225: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GAAGAAGTACCT
>LY792071.1 KR 1020190122893-A/224: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
GGTACTTCTTCA
>LY792070.1 KR 1020190122893-A/223: ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES
TGAAGAAGTACC
>LY756959.1 KR 1020190109587-A/8759: Abtibody libraries
NNGGTACTTCGA
>LY756958.1 KR 1020190109587-A/8758: Abtibody libraries
CTGGTACTTCGA
>LY756955.1 KR 1020190109587-A/8755: Abtibody libraries
NNATACTTCCAG
>LY756954.1 KR 1020190109587-A/8754: Abtibody libraries
GAATACTTCCAG
>LY756747.1 KR 1020190109587-A/8408: Abtibody libraries
GGABHCACACAA
>LY756746.1 KR 1020190109587-A/8407: Abtibody libraries
GGABHCACAGCT
>LY756745.1 KR 1020190109587-A/8406: Abtibody libraries
GGABHCGGACTA
>LY756744.1 KR 1020190109587-A/8405: Abtibody libraries
GGABHCGGATGG
>LY756743.1 KR 1020190109587-A/8404: Abtibody libraries
AGGAGAVHGTAC
>LY756742.1 KR 1020190109587-A/8403: Abtibody libraries
GGTAGAVHGTAC
>LY756741.1 KR 1020190109587-A/8402: Abtibody libraries
CCABHCGGATAC
>LY756740.1 KR 1020190109587-A/8401: Abtibody libraries
AGCBHCGGATAC
>LY756739.1 KR 1020190109587-A/8400: Abtibody libraries
AGABHCGGATAC
>LY756738.1 KR 1020190109587-A/8399: Abtibody libraries
GGABHCGGATAC
>LY756667.1 KR 1020190109587-A/5568: Abtibody libraries
VHABTCGGAGGT
>LY756666.1 KR 1020190109587-A/5567: Abtibody libraries
VNCTACTACTHT
>LY756665.1 KR 1020190109587-A/5566: Abtibody libraries
VBCTGGTTCGGT
>LY756664.1 KR 1020190109587-A/5565: Abtibody libraries
BHCVGCTACAGT
>LY756663.1 KR 1020190109587-A/5564: Abtibody libraries
NHCTACTACTHT
>LY756662.1 KR 1020190109587-A/5563: Abtibody libraries
NHCTACGGAKCT
>LY756661.1 KR 1020190109587-A/5562: Abtibody libraries
VBCGVCTACAGT
>LY756660.1 KR 1020190109587-A/5561: Abtibody libraries
GACAGCAGCDBG
>LY756659.1 KR 1020190109587-A/5560: Abtibody libraries
VBTCDAGGAGTT
>LY756658.1 KR 1020190109587-A/5559: Abtibody libraries
VHAGTASSAGCT
>LY756466.1 KR 1020190109587-A/5267: Abtibody libraries
TGGTTCGATCCA
>LY756657.1 KR 1020190109587-A/5558: Abtibody libraries
BHCTACAGCKMT
>LY756656.1 KR 1020190109587-A/5557: Abtibody libraries
VBTBTCGGAGAG
>LY756655.1 KR 1020190109587-A/5556: Abtibody libraries
VHGGGARKCGCT
>LY756654.1 KR 1020190109587-A/5555: Abtibody libraries
VHACAACTAKKG
>LY756653.1 KR 1020190109587-A/5554: Abtibody libraries
VBCKMCGGATAT
>LY756652.1 KR 1020190109587-A/5553: Abtibody libraries
NHCTACTACGVT
>LY756651.1 KR 1020190109587-A/5552: Abtibody libraries
GTAGCAGCAVHA
>LY756650.1 KR 1020190109587-A/5551: Abtibody libraries
VBCAYATTCGGT
>LY756649.1 KR 1020190109587-A/5550: Abtibody libraries
GCAGCAGCAVBT
>LY756648.1 KR 1020190109587-A/5549: Abtibody libraries
VHAGTAACARMG
>LY756647.1 KR 1020190109587-A/5548: Abtibody libraries
BHCGGATACKMT
>LY756646.1 KR 1020190109587-A/5547: Abtibody libraries
NHCAGCGGABGG
>LY756645.1 KR 1020190109587-A/5546: Abtibody libraries
BHCGGATSGTAT
>LY756644.1 KR 1020190109587-A/5545: Abtibody libraries
BHCGGAAGCKMT
>LY756643.1 KR 1020190109587-A/5544: Abtibody libraries
VHACAACTAGNT
>LY756642.1 KR 1020190109587-A/5543: Abtibody libraries
BHCAGCTGGTHT
>LY756641.1 KR 1020190109587-A/5542: Abtibody libraries
NHCTMCTACGGT
>LY756640.1 KR 1020190109587-A/5541: Abtibody libraries
AGCAGCAGCDBG
>LY756639.1 KR 1020190109587-A/5540: Abtibody libraries
VBCACAGTARMG
>LY756638.1 KR 1020190109587-A/5539: Abtibody libraries
VHAGTAGCAGNT
>LY756637.1 KR 1020190109587-A/5538: Abtibody libraries
CAGTGGCTABHT
>LY756636.1 KR 1020190109587-A/5537: Abtibody libraries
VHATACAGCRST
>LY756635.1 KR 1020190109587-A/5536: Abtibody libraries
VHGRYGGCAACT
>LY756634.1 KR 1020190109587-A/5535: Abtibody libraries
NHCTACGGAGVT
>LY756633.1 KR 1020190109587-A/5534: Abtibody libraries
VBCGACGGATHT
>LY756632.1 KR 1020190109587-A/5533: Abtibody libraries
VHGGTARSAGGT
>LY756631.1 KR 1020190109587-A/5532: Abtibody libraries
TACAGCAGCVBT
>LY756630.1 KR 1020190109587-A/5531: Abtibody libraries
BHCGGAKMCTAT
>LY756629.1 KR 1020190109587-A/5530: Abtibody libraries
DBGTTCGGAGNG
>LY756628.1 KR 1020190109587-A/5529: Abtibody libraries
VHGGBAGCAACT
>LY756627.1 KR 1020190109587-A/5528: Abtibody libraries
BHCACAGCCAKS
>LY756596.1 KR 1020190109587-A/5497: Abtibody libraries
GCCAAGCCAGTG
>LY756595.1 KR 1020190109587-A/5496: Abtibody libraries
GCCAGACCGGTG
>LY756590.1 KR 1020190109587-A/5491: Abtibody libraries
GCCAAGCCTACT
>LY756589.1 KR 1020190109587-A/5490: Abtibody libraries
GCCAGACCTACT
>LY756586.1 KR 1020190109587-A/5487: Abtibody libraries
GCCAAGCCGGCT
>LY756585.1 KR 1020190109587-A/5486: Abtibody libraries
GCCAGACCAGCT
>LY756582.1 KR 1020190109587-A/5483: Abtibody libraries
GCCAAGCCACCT
>LY756581.1 KR 1020190109587-A/5482: Abtibody libraries
GCCAGACCACCT
>LY756572.1 KR 1020190109587-A/5473: Abtibody libraries
GCCAAGACCGGA
>LY756571.1 KR 1020190109587-A/5472: Abtibody libraries
GCCAGAACTGGA
>LY756560.1 KR 1020190109587-A/5461: Abtibody libraries
GCCAAGCCCGGA
>LY756559.1 KR 1020190109587-A/5460: Abtibody libraries
GCCAGACCAGGA
>LY756530.1 KR 1020190109587-A/5431: Abtibody libraries
GCCAAGGAATTG
>LY756529.1 KR 1020190109587-A/5430: Abtibody libraries
GCCAGAGAGTTG
>LY756528.1 KR 1020190109587-A/5429: Abtibody libraries
GCCAAGGAGCCT
>LY756527.1 KR 1020190109587-A/5428: Abtibody libraries
GCCAGAGAGCCT
>LY756470.1 KR 1020190109587-A/5271: Abtibody libraries
TATATGGATGTC
>LY756469.1 KR 1020190109587-A/5270: Abtibody libraries
TATTTCCAGCAC
>LY756468.1 KR 1020190109587-A/5269: Abtibody libraries
TACTTCGATTAC
>LY756467.1 KR 1020190109587-A/5268: Abtibody libraries
TATTTCGACTTA
>LY756267.1 KR 1020190109587-A/5068: Abtibody libraries
GCCAAGGAAGTG
>LY756465.1 KR 1020190109587-A/5266: Abtibody libraries
GTTTTCGATTAT
>LY756464.1 KR 1020190109587-A/5265: Abtibody libraries
ACATTTGACTAC
>LY756463.1 KR 1020190109587-A/5264: Abtibody libraries
AGTTTCGATTAC
>LY756462.1 KR 1020190109587-A/5263: Abtibody libraries
AGGTTTGACTAT
>LY756461.1 KR 1020190109587-A/5262: Abtibody libraries
CCCTTCGACTAT
>LY756460.1 KR 1020190109587-A/5261: Abtibody libraries
AACTTTGATTAC
>LY756459.1 KR 1020190109587-A/5260: Abtibody libraries
TTATTTGATTAT
>LY756458.1 KR 1020190109587-A/5259: Abtibody libraries
ATATTCGATTAC
>LY756457.1 KR 1020190109587-A/5258: Abtibody libraries
CACTTTGACTAT
>LY756456.1 KR 1020190109587-A/5257: Abtibody libraries
GGCATGGATGTA
>LY756455.1 KR 1020190109587-A/5256: Abtibody libraries
GGGTTCGACTAC
>LY756454.1 KR 1020190109587-A/5255: Abtibody libraries
GGGTTTGACCCA
>LY756453.1 KR 1020190109587-A/5254: Abtibody libraries
TTCTTCGATTAC
>LY756452.1 KR 1020190109587-A/5253: Abtibody libraries
GATTTCGACTAT
>LY756451.1 KR 1020190109587-A/5252: Abtibody libraries
GCCTTCGATTAC
>LY756450.1 KR 1020190109587-A/5251: Abtibody libraries
GCCTTCGATATC
>LY756449.1 KR 1020190109587-A/5250: Abtibody libraries
GCCGCAAGACCT
>LY756446.1 KR 1020190109587-A/5247: Abtibody libraries
GAGTACTCATCC
>LY756445.1 KR 1020190109587-A/5246: Abtibody libraries
CAGTGGTTAGTT
>LY756444.1 KR 1020190109587-A/5245: Abtibody libraries
TACTCAAGTGGT
>LY756443.1 KR 1020190109587-A/5244: Abtibody libraries
AGTTCCGGTTGG
>LY756442.1 KR 1020190109587-A/5243: Abtibody libraries
AGTGGTTGGTAT
>LY756437.1 KR 1020190109587-A/5238: Abtibody libraries
CAGCAATTGGTT
>LY756435.1 KR 1020190109587-A/5236: Abtibody libraries
TACAGCAGCTCC
>LY756434.1 KR 1020190109587-A/5235: Abtibody libraries
AGTAGCTCTTGG
>LY756430.1 KR 1020190109587-A/5231: Abtibody libraries
TATTCATATGGT
>LY756429.1 KR 1020190109587-A/5230: Abtibody libraries
GATACTGCTATG
>LY756428.1 KR 1020190109587-A/5229: Abtibody libraries
AGAGATGGTTAC
>LY756425.1 KR 1020190109587-A/5226: Abtibody libraries
ACAGTAACTACT
>LY756424.1 KR 1020190109587-A/5225: Abtibody libraries
ACAACTGTGACT
>LY756421.1 KR 1020190109587-A/5222: Abtibody libraries
TACGGCGATTAT
>LY756420.1 KR 1020190109587-A/5221: Abtibody libraries
GATTACGGCGAT
>LY756411.1 KR 1020190109587-A/5212: Abtibody libraries
AGATACTTTGAT
>LY756410.1 KR 1020190109587-A/5211: Abtibody libraries
TTGAGATATTTC
>LY756409.1 KR 1020190109587-A/5210: Abtibody libraries
GTGTTGAGGTAT
>LY756394.1 KR 1020190109587-A/5195: Abtibody libraries
AGCGGCTACTAT
>LY756393.1 KR 1020190109587-A/5194: Abtibody libraries
GGTTACTATTAC
>LY756392.1 KR 1020190109587-A/5193: Abtibody libraries
GACTCATCCGGT
>LY756374.1 KR 1020190109587-A/5175: Abtibody libraries
TATTATTATGAC
>LY756373.1 KR 1020190109587-A/5174: Abtibody libraries
TACTACGATTCC
>LY756365.1 KR 1020190109587-A/5166: Abtibody libraries
ATGGTAAGAGGT
>LY756359.1 KR 1020190109587-A/5160: Abtibody libraries
TACTACTATGGC
>LY756358.1 KR 1020190109587-A/5159: Abtibody libraries
TATTATGGCAGT
>LY756357.1 KR 1020190109587-A/5158: Abtibody libraries
AGTGGATCTTAT
>LY756356.1 KR 1020190109587-A/5157: Abtibody libraries
TGGTTTGGGGAG
>LY756334.1 KR 1020190109587-A/5135: Abtibody libraries
GTTGGCGCAACT
>LY756333.1 KR 1020190109587-A/5134: Abtibody libraries
GCCAAGCAAGGA
>LY756330.1 KR 1020190109587-A/5131: Abtibody libraries
GCAAAGGGCAAG
>LY756329.1 KR 1020190109587-A/5130: Abtibody libraries
GCAAAGGCAAAG
>LY756328.1 KR 1020190109587-A/5129: Abtibody libraries
GCAAAAGTCAGA
>LY756327.1 KR 1020190109587-A/5128: Abtibody libraries
GCCAAAGGACAG
>LY756325.1 KR 1020190109587-A/5126: Abtibody libraries
GCCAAAGTATCT
>LY756324.1 KR 1020190109587-A/5125: Abtibody libraries
GCAAAAGACAAG
>LY756323.1 KR 1020190109587-A/5124: Abtibody libraries
GCAAAAAGGAGA
>LY756322.1 KR 1020190109587-A/5123: Abtibody libraries
GCAAAAGGGGAC
>LY756320.1 KR 1020190109587-A/5121: Abtibody libraries
GCTAAAGCAGAG
>LY756318.1 KR 1020190109587-A/5119: Abtibody libraries
GCTAAATTGCAC
>LY756317.1 KR 1020190109587-A/5118: Abtibody libraries
GCAAAGAGCTTG
>LY756315.1 KR 1020190109587-A/5116: Abtibody libraries
GCCAAGAGTAGA
>LY756313.1 KR 1020190109587-A/5114: Abtibody libraries
GCCAAGGCATCT
>LY756312.1 KR 1020190109587-A/5113: Abtibody libraries
GCCAAGGCAAGA
>LY756311.1 KR 1020190109587-A/5112: Abtibody libraries
GCTAAAGACCAC
>LY756310.1 KR 1020190109587-A/5111: Abtibody libraries
GCCAAGGATCAG
>LY756308.1 KR 1020190109587-A/5109: Abtibody libraries
GCCAAGGTACCT
>LY756307.1 KR 1020190109587-A/5108: Abtibody libraries
GCCAAGACGCCT
>LY756306.1 KR 1020190109587-A/5107: Abtibody libraries
GCCAAGGCTCCT
>LY756305.1 KR 1020190109587-A/5106: Abtibody libraries
GCCAAGCTACCT
>LY756304.1 KR 1020190109587-A/5105: Abtibody libraries
GCCAAGAGTCCT
>LY756302.1 KR 1020190109587-A/5103: Abtibody libraries
GCCAAGAGGCCT
>LY756300.1 KR 1020190109587-A/5101: Abtibody libraries
GCCAAGCCGTTG
>LY756295.1 KR 1020190109587-A/5096: Abtibody libraries
GCCAAGCCTTCT
>LY756293.1 KR 1020190109587-A/5094: Abtibody libraries
GCCAAGCCTAGA
>LY756291.1 KR 1020190109587-A/5092: Abtibody libraries
GCCAAGGTAGGA
>LY756290.1 KR 1020190109587-A/5091: Abtibody libraries
GCCAAGGCTGGA
>LY756288.1 KR 1020190109587-A/5089: Abtibody libraries
GCCAAGTTAGGA
>LY756285.1 KR 1020190109587-A/5086: Abtibody libraries
GCCAAGTCTGGA
>LY756281.1 KR 1020190109587-A/5082: Abtibody libraries
GCCAAGAGAGGA
>LY756269.1 KR 1020190109587-A/5070: Abtibody libraries
GCCAAGGGCGTG
>LY756268.1 KR 1020190109587-A/5069: Abtibody libraries
GCCAAGGACGTG
>LY756266.1 KR 1020190109587-A/5067: Abtibody libraries
GCCAAGGGAACT
>LY756265.1 KR 1020190109587-A/5066: Abtibody libraries
GCCAAGGATACT
>LY756264.1 KR 1020190109587-A/5065: Abtibody libraries
GCCAAGGAAACT
>LY756263.1 KR 1020190109587-A/5064: Abtibody libraries
GCCAAGGGCGCT
>LY756262.1 KR 1020190109587-A/5063: Abtibody libraries
GCCAAGGACGCT
>LY756261.1 KR 1020190109587-A/5062: Abtibody libraries
GCCAAGGAAGCT
>LY756260.1 KR 1020190109587-A/5061: Abtibody libraries
GCCAAGGGGTTG
>LY756259.1 KR 1020190109587-A/5060: Abtibody libraries
GCCAAGGACTTG
>LY756258.1 KR 1020190109587-A/5059: Abtibody libraries
GCCAAGGGTCCT
>LY756257.1 KR 1020190109587-A/5058: Abtibody libraries
GCCAAGGATCCT
>LY756256.1 KR 1020190109587-A/5057: Abtibody libraries
GCCAAGGGATCT
>LY756255.1 KR 1020190109587-A/5056: Abtibody libraries
GCCAAGGATTCT
>LY756254.1 KR 1020190109587-A/5055: Abtibody libraries
GCCAAGGAATCT
>LY756253.1 KR 1020190109587-A/5054: Abtibody libraries
GCCAAGGGCAGA
>LY756252.1 KR 1020190109587-A/5053: Abtibody libraries
GCCAAGGACAGA
>LY756251.1 KR 1020190109587-A/5052: Abtibody libraries
GCCAAGGAAAGA
>LY756250.1 KR 1020190109587-A/5051: Abtibody libraries
GCCAAGGGCGGA
>LY756249.1 KR 1020190109587-A/5050: Abtibody libraries
GCCAAGGACGGA
>LY756248.1 KR 1020190109587-A/5049: Abtibody libraries
GCCAAGGAAGGA
>LY756247.1 KR 1020190109587-A/5048: Abtibody libraries
GCCAGGCAGGGA
>LY756244.1 KR 1020190109587-A/5045: Abtibody libraries
GCCAGGGGTAAG
>LY756243.1 KR 1020190109587-A/5044: Abtibody libraries
GCTAGGGCTAAG
>LY756242.1 KR 1020190109587-A/5043: Abtibody libraries
GCCAGGGTCAGA
>LY756241.1 KR 1020190109587-A/5042: Abtibody libraries
GCTAGGGGCCAG
>LY756239.1 KR 1020190109587-A/5040: Abtibody libraries
GCTAGAGTATCT
>LY756238.1 KR 1020190109587-A/5039: Abtibody libraries
GCTAGAGATAAG
>LY756237.1 KR 1020190109587-A/5038: Abtibody libraries
GCTAGGAGGAGA
>LY756236.1 KR 1020190109587-A/5037: Abtibody libraries
GCTAGAGGGGAC
>LY756234.1 KR 1020190109587-A/5035: Abtibody libraries
GCAAGAGCCGAG
>LY756232.1 KR 1020190109587-A/5033: Abtibody libraries
GCTAGGTTGCAC
>LY756231.1 KR 1020190109587-A/5032: Abtibody libraries
GCTAGATCTTTG
>LY756229.1 KR 1020190109587-A/5030: Abtibody libraries
GCTAGATCAAGA
>LY756227.1 KR 1020190109587-A/5028: Abtibody libraries
GCTAGGGCATCT
>LY756226.1 KR 1020190109587-A/5027: Abtibody libraries
GCAAGGGCTAGA
>LY756225.1 KR 1020190109587-A/5026: Abtibody libraries
GCAAGAGACCAC
>LY756224.1 KR 1020190109587-A/5025: Abtibody libraries
GCCAGGGACCAG
>LY756222.1 KR 1020190109587-A/5023: Abtibody libraries
GCCAGAGTCCCT
>LY756221.1 KR 1020190109587-A/5022: Abtibody libraries
GCCAGAACTCCT
>LY756220.1 KR 1020190109587-A/5021: Abtibody libraries
GCCAGAGCCCCT
>LY756219.1 KR 1020190109587-A/5020: Abtibody libraries
GCCAGACTTCCT
>LY756218.1 KR 1020190109587-A/5019: Abtibody libraries
GCCAGATCACCT
>LY756216.1 KR 1020190109587-A/5017: Abtibody libraries
GCCAGAAGGCCT
>LY756214.1 KR 1020190109587-A/5015: Abtibody libraries
GCCAGACCGTTG
>LY756209.1 KR 1020190109587-A/5010: Abtibody libraries
GCCAGACCATCT
>LY756207.1 KR 1020190109587-A/5008: Abtibody libraries
GCCAGACCCAGA
>LY756205.1 KR 1020190109587-A/5006: Abtibody libraries
GCCAGAGTGGGA
>LY756204.1 KR 1020190109587-A/5005: Abtibody libraries
GCCAGAGCTGGA
>LY756202.1 KR 1020190109587-A/5003: Abtibody libraries
GCCAGATTGGGA
>LY756199.1 KR 1020190109587-A/5000: Abtibody libraries
GCCAGATCAGGA
>LY756195.1 KR 1020190109587-A/4996: Abtibody libraries
GCCAGAAGAGGA
>LY756183.1 KR 1020190109587-A/4984: Abtibody libraries
GCCAGAGGGGTG
>LY756182.1 KR 1020190109587-A/4983: Abtibody libraries
GCCAGAGATGTG
>LY756181.1 KR 1020190109587-A/4982: Abtibody libraries
GCCAGAGAGGTG
>LY756180.1 KR 1020190109587-A/4981: Abtibody libraries
GCCAGAGGCACT
>LY756179.1 KR 1020190109587-A/4980: Abtibody libraries
GCCAGAGATACT
>LY756178.1 KR 1020190109587-A/4979: Abtibody libraries
GCCAGAGAGACT
>LY756177.1 KR 1020190109587-A/4978: Abtibody libraries
GCCAGAGGTGCT
>LY756176.1 KR 1020190109587-A/4977: Abtibody libraries
GCCAGAGATGCT
>LY756175.1 KR 1020190109587-A/4976: Abtibody libraries
GCCAGAGAGGCT
>LY756174.1 KR 1020190109587-A/4975: Abtibody libraries
GCCAGAGGGTTG
>LY756173.1 KR 1020190109587-A/4974: Abtibody libraries
GCCAGAGACTTG
>LY756172.1 KR 1020190109587-A/4973: Abtibody libraries
GCCAGAGGGCCT
>LY756171.1 KR 1020190109587-A/4972: Abtibody libraries
GCCAGAGACCCT
>LY756170.1 KR 1020190109587-A/4971: Abtibody libraries
GCCAGAGGTTCT
>LY756169.1 KR 1020190109587-A/4970: Abtibody libraries
GCCAGAGACTCT
>LY756168.1 KR 1020190109587-A/4969: Abtibody libraries
GCCAGAGAATCT
>LY756167.1 KR 1020190109587-A/4968: Abtibody libraries
GCCAGAGGCAGA
>LY756166.1 KR 1020190109587-A/4967: Abtibody libraries
GCCAGAGACAGA
>LY756165.1 KR 1020190109587-A/4966: Abtibody libraries
GCCAGAGAGAGA
>LY756164.1 KR 1020190109587-A/4965: Abtibody libraries
GCCAGAGGTGGA
>LY756163.1 KR 1020190109587-A/4964: Abtibody libraries
GCCAGAGACGGA
>LY756162.1 KR 1020190109587-A/4963: Abtibody libraries
GCCAGAGAGGGA
>LY719571.1 KR 1020190114911-A/67: Brain-targeted long-acting therapeutic enzyme conjugates
CCACCATGCCCA
>LY719520.1 KR 1020190114907-A/99: Long-acting protein conjugates for brain targeting, a preparation method thereof, and a composition comprising the same
CCACCATGCCCA
>LY716632.1 KR 1020190143249-A/19: New Di-valent antibody fragment platform
GGTGGCGGATCC
>LY787813.1 KR 1020190130608-A/10554: COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
GGAGGCAGTGGT
>LY787800.1 KR 1020190130608-A/10541: COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
AGGTGTCAGGTA
>LY787785.1 KR 1020190130608-A/10526: COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
GCAGTGGTGAGG
>LY716034.1 KR 1020190135797-A/1: Genetic maker for parentage and thereod in Turbot
GTGTGTGTGTGT
>LY751428.1 KR 1020190121319-A/183: COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
GTTTAAGAGCTA
>LY751427.1 KR 1020190121319-A/182: COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
GTTTTAGAGCTA
>LY714254.1 KR 1020190105785-A/6: Pepetide nucleicacid probe for detecting foot-and-mouth disease virus and Uses thereof
CAGGAGAAGTTG
>LY750692.1 KR 1020190110133-A/85: MULTIPLE MALARIA PRE-ERYTHROCYTIC ANTIGENS AND THEIR USE IN THE ELICITATION OF A PROTECTIVE IMMUNE RESPONSE IN A HOST
GCCACCATGGCC
>LY750691.1 KR 1020190110133-A/84: MULTIPLE MALARIA PRE-ERYTHROCYTIC ANTIGENS AND THEIR USE IN THE ELICITATION OF A PROTECTIVE IMMUNE RESPONSE IN A HOST
GCCACCATGGCT
>LY750515.1 KR 1020190110612-A/177: IMMUNOMODULATORY THERAPEUTIC MRNA COMPOSITIONS ENCODING ACTIVATING ONCOGENE MUTATION PEPTIDES
CCGCCGCCGCCG
>LY749433.1 KR 1020190113879-A/4: METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES
GACCGAAGGTTG
>LY749432.1 KR 1020190113879-A/3: METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES
ACCTTCGGTCGG
>LY748916.1 KR 1020190115019-A/232: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CYTANNNNNRTC
>LY748915.1 KR 1020190115019-A/231: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
TAAGNNNNCTAY
>LY748912.1 KR 1020190115019-A/228: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
YACNNNNNGTAG
>LY748910.1 KR 1020190115019-A/226: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GYAYNNNNGRTG
>LY748903.1 KR 1020190115019-A/219: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GGCANNNNNCTC
>LY748902.1 KR 1020190115019-A/218: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GCCNNNNNNTCG
>LY748898.1 KR 1020190115019-A/214: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GANNNNNNNTAY
>LY748892.1 KR 1020190115019-A/208: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CCAYNNNNNGCT
>LY748882.1 KR 1020190115019-A/198: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CGCANNNNNCTG
>LY748879.1 KR 1020190115019-A/195: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GAGNNNNNNTGG
>LY748878.1 KR 1020190115019-A/194: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GAGNNNNNNTTA
>LY748875.1 KR 1020190115019-A/191: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CGAANNNNNTGA
>LY748873.1 KR 1020190115019-A/189: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CAACNNNNNCTT
>LY748869.1 KR 1020190115019-A/185: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CAYNNNNNNTCA
>LY748868.1 KR 1020190115019-A/184: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
AAGNNNNNGTTC
>LY748867.1 KR 1020190115019-A/183: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
ACGNNNNNGTTG
>LY748850.1 KR 1020190115019-A/166: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
AAGNNNNNCTCC
>LY748848.1 KR 1020190115019-A/164: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CCANNNNNNTTT
>LY748835.1 KR 1020190115019-A/151: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
AYGNNNNNNCTG
>LY748822.1 KR 1020190115019-A/138: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GCCNNNNNGTTG
>LY748816.1 KR 1020190115019-A/132: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GAAGNNNNNTAC
>LY748815.1 KR 1020190115019-A/131: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
AGGNNNNNTTCA
>LY748811.1 KR 1020190115019-A/127: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
ACGNNNNNRTGT
>LY748809.1 KR 1020190115019-A/125: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CCCANNNNNCTG
>LY748808.1 KR 1020190115019-A/124: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GAYNNNNNNGTT
>LY748807.1 KR 1020190115019-A/123: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CTANNNNNGTTY
>LY748794.1 KR 1020190115019-A/110: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GANNNNNNTGCG
>LY748793.1 KR 1020190115019-A/109: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GAAYNNNNNGTC
>LY748789.1 KR 1020190115019-A/105: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GCANNNNNRTTA
>LY748780.1 KR 1020190115019-A/96: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
ACGNNNNNGTTG
>LY748777.1 KR 1020190115019-A/93: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CAGNNNNNNCGT
>LY748770.1 KR 1020190115019-A/86: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CCCNNNNNRTAG
>LY748717.1 KR 1020190115019-A/33: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GATGNNNNNGGC
>LY748716.1 KR 1020190115019-A/32: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
CAGNNNNNNCGT
>LY748710.1 KR 1020190115019-A/26: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GACNNNNNNGTC
>LY748705.1 KR 1020190115019-A/21: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GATGNNNNNCTG
>LY748695.1 KR 1020190115019-A/11: OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
GAGNNNNNGTTY
>LY747625.1 KR 1020190115447-A/14: GENETICALLY OPTIMISED MICROORGANISM FOR PRODUCING MOLECULES OF INTEREST
CACCATACACTG
>LY747620.1 KR 1020190115447-A/9: GENETICALLY OPTIMISED MICROORGANISM FOR PRODUCING MOLECULES OF INTEREST
AGGAGGTTTGGA
>LY746467.1 KR 1020190095965-A/2466: PLASMA KALLIKREIN BINDING PROTEINS
CCANNNNNNTGG
>LY746463.1 KR 1020190095965-A/2462: PLASMA KALLIKREIN BINDING PROTEINS
NNNNNNGAGACG
>LY746458.1 KR 1020190095965-A/2457: PLASMA KALLIKREIN BINDING PROTEINS
GACNNNNNNGTC
>LY746452.1 KR 1020190095965-A/2451: PLASMA KALLIKREIN BINDING PROTEINS
GCANNNNNNTCG
>LY746451.1 KR 1020190095965-A/2450: PLASMA KALLIKREIN BINDING PROTEINS
GTATCCNNNNNN
>LY746450.1 KR 1020190095965-A/2449: PLASMA KALLIKREIN BINDING PROTEINS
NNNNNNNGCGGG
>LY745160.1 KR 1020190102259-A/6: MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS
CGTGCAAAGCGT
>LY745158.1 KR 1020190102259-A/4: MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS
AGTGGCAGCGGC
>LY743738.1 KR 1020190114982-A/10: GENETICALLY OPTIMISED MICROORGANISM FOR PRODUCING MOLECULES OF INTEREST
CACCATACACTG
>LY743733.1 KR 1020190114982-A/5: GENETICALLY OPTIMISED MICROORGANISM FOR PRODUCING MOLECULES OF INTEREST
AGGAGGTTTGGA
>LY778141.1 KR 1020190130608-A/51: COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
GTTTAAGAGCTA
>LY778140.1 KR 1020190130608-A/50: COMPOSITIONS AND METHODS FOR IMMUNOONCOLOGY
GTTTTAGAGCTA
>LY743034.1 KR 1020190110554-A/89: SYNTHETIC GUIDE MOLECULES, COMPOSITIONS AND METHODS RELATING THERETO
TAATTTTAGGTA
>MD244277.1 JP 2020515525-A/21: STERILE FORMULATION COMPRISING A STABLE PHOSPHOROTHIOATE OLIGONUCLEOTIDE
CGCCATGCTGCT
>MD244239.1 JP 2020515522-A/2: VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS TO INDUCE IMMUNE RESPONSE
TCATAACGTTCC
>MD243501.1 JP 2020513777-A/6: MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS
CGTGCAAAGCGT
>MD243499.1 JP 2020513777-A/4: MODULATING EXPRESSION OF POLYPEPTIDES VIA NEW GENE SWITCH EXPRESSION SYSTEMS
AGTGGCAGCGGC
>MD243113.1 JP 2020514258-A/3: PEPTIDE NUCLEIC ACID CONJUGATES
CATTCAAATCCC
>MD240946.1 JP 2020513737-A/190: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGAGGAGGA
>MD240945.1 JP 2020513737-A/189: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGTGGAGGAGGA
>MD240944.1 JP 2020513737-A/188: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGTGGAGGA
>MD240943.1 JP 2020513737-A/187: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGAGGTGGA
>MD240942.1 JP 2020513737-A/186: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGAGGAGGT
>MD240941.1 JP 2020513737-A/185: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGTGGAGGT
>MD240940.1 JP 2020513737-A/184: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGAGGTGGT
>MD240939.1 JP 2020513737-A/183: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGAGGTGGTGGA
>MD240938.1 JP 2020513737-A/182: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGTGGAGGAGGT
>MD240937.1 JP 2020513737-A/181: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGTGGAGGTGGA
>MD240936.1 JP 2020513737-A/180: IMMUNOGENIC COMPOSITIONS TARGETING RECURRENT CANCER MUTATIONS AND METHODS OF USE THEREOF
GGTGGTGGAGGA
>MD240728.1 JP 2020513732-A/1: System for DNA editing and application thereof
GTTTTAGAGCTA
>MD240721.1 JP 2020513741-A/4: LINKED LIGATION
TGCAGGATGGTG
>MD240720.1 JP 2020513741-A/3: LINKED LIGATION
GCACCTCATCCA
>MD240719.1 JP 2020513741-A/2: LINKED LIGATION
ATGCGAGCCTCT
>MD240718.1 JP 2020513741-A/1: LINKED LIGATION
CCTACTCGCTAC
>MD235224.1 JP 2020096564-A/3: Method for detecting RNA, nucleic acid for detecting RNA, and kit for detecting RNA
GTTTTAGAGCTA
>MD233856.1 JP 2020512286-A/99: METHODS OF TREATING CANCERS CONTAINING FUSION GENES
CCAGAGCAAGAG
>MD232784.1 JP 2020510612-A/141: Substances for targeting various selected organs or tissues
ACAGATCTGTCA
>MD232789.1 JP 2020510612-A/146: Substances for targeting various selected organs or tissues
AGGAAGATGGCA
>MD232805.1 JP 2020510612-A/162: Substances for targeting various selected organs or tissues
AGGACATTGGCA
>MD232725.1 JP 2020510612-A/82: Substances for targeting various selected organs or tissues
NGGNNNNNGGNN
>MD232709.1 JP 2020510612-A/66: Substances for targeting various selected organs or tissues
NGGNNGNNGGNN
>MD232704.1 JP 2020510612-A/61: Substances for targeting various selected organs or tissues
NNNGNNNNGNNN
>MD231804.1 JP 2020510403-A/4: METHOD FOR SYNTHESIS OF ENCODED LIBRARIES
GACCGAAGGTTG
>MD231803.1 JP 2020510403-A/3: METHOD FOR SYNTHESIS OF ENCODED LIBRARIES
ACCTTCGGTCGG
>MD230033.1 JP 2020074683-A/20: MicroRNA detection system using novel sPCR primers
CTACCTGCACTA
>MD230032.1 JP 2020074683-A/19: MicroRNA detection system using novel sPCR primers
CTATCTGCACTA
>MD230031.1 JP 2020074683-A/18: MicroRNA detection system using novel sPCR primers
CTACCTGCACTG
>MV296268.1 Sequence 308 from patent US 10666592
TTATAAGTCCAG
>MV294229.1 Sequence 19 from patent US 10662485
CCGCCTGGGGAG
>MV292622.1 Sequence 130 from patent US 10662434
ATGGCCCCACAG
>MV292615.1 Sequence 8 from patent US 10662434
CTGTGGGGCCAT
>MV292374.1 Sequence 118 from patent US 10662432
TTAGTTAGTTAG
>MV292365.1 Sequence 109 from patent US 10662432
TTAGTTAGTTAG
>MV292306.1 Sequence 50 from patent US 10662432
TTAGTTAGTTAG
>MV292297.1 Sequence 41 from patent US 10662432
TTAGTTAGTTAG
>MV283998.1 Sequence 2 from patent US 10662421
CGTGGAGGCGTG
>MV283252.1 Sequence 25 from patent US 10662410
ACCGGTGCTCGC
>MV283250.1 Sequence 21 from patent US 10662410
CATTGCGAATTC
>MV283249.1 Sequence 20 from patent US 10662410
ACCGGTGCTCGC
>MV283247.1 Sequence 16 from patent US 10662410
CATTGCGAATTC
>MV283246.1 Sequence 15 from patent US 10662410
ACCGGTGCTCGC
>MV153550.1 Sequence 4 from patent US 10658069
ATTGACTACTGT
>MV151574.1 Sequence 17 from patent US 10655113
TGTGTGGGATCC
>MV151573.1 Sequence 16 from patent US 10655113
TGTGTGACTAGT
>MV151076.1 Sequence 427 from patent US 10654924
AAGGGGSGGGGS
>MV150704.1 Sequence 67 from patent US 10654907
TCTGGATCTGGC
>MV150703.1 Sequence 65 from patent US 10654907
AGGGCCAAGAGA
>MV150519.1 Sequence 125 from patent US 10654898
AAGTAAGAAAAA
>MV150508.1 Sequence 86 from patent US 10654898
AAATATAAAAAA
>MV150506.1 Sequence 84 from patent US 10654898
AATTATAAAAAA
>MV150502.1 Sequence 80 from patent US 10654898
AAATAAGAAAAA
>MV150500.1 Sequence 78 from patent US 10654898
AAATAAGAAAAA
>MV150499.1 Sequence 77 from patent US 10654898
AGGATTAAAGAC
>MV150496.1 Sequence 73 from patent US 10654898
AAGCACGAACCC
>MV150494.1 Sequence 71 from patent US 10654898
AGGCCAAATTAT
>MV150492.1 Sequence 69 from patent US 10654898
AGGTCCGAAAGC
>MV150487.1 Sequence 64 from patent US 10654898
TAGTAAGAAAAA
>MV150485.1 Sequence 62 from patent US 10654898
GAATAAGAAAAA
>MV150482.1 Sequence 59 from patent US 10654898
AAATAAGAAAAA
>MV150480.1 Sequence 57 from patent US 10654898
AATTAAGAAAAA
>MV150478.1 Sequence 55 from patent US 10654898
AAGTAAGAAAAA
>MV150454.1 Sequence 4 from patent US 10654894
TTTTTTTTTTTT
>MV150359.1 Sequence 17 from patent US 10653800
CTCGTTCGTTCT
>MV150355.1 Sequence 13 from patent US 10653800
TCTCGTACGTTC
>MV150354.1 Sequence 12 from patent US 10653800
TCTCGTACGTTC
>MV150353.1 Sequence 11 from patent US 10653800
TCTCGTACGTTC
>MV150352.1 Sequence 10 from patent US 10653800
TCTCGTACGTTC
>MV150349.1 Sequence 7 from patent US 10653800
TCTCGTACGTTC
>MV150345.1 Sequence 3 from patent US 10653800
TCTCGTACGTTC
>MV150344.1 Sequence 2 from patent US 10653800
TCTCGTACGTTC
>MV149941.1 Sequence 8 from patent US 10653712
CTCTTATTTCCC
>MV149940.1 Sequence 7 from patent US 10653712
GGGAAATAAGAG
>MV149934.1 Sequence 1 from patent US 10653712
CTCTTATTTCCC
>MV119810.1 Sequence 3 from patent US 10633663
GGTGTGTCGTCT
>MV119809.1 Sequence 2 from patent US 10633663
GGACGATGCGGC
>MV119759.1 Sequence 64 from patent US 10633662
AAAAAAAAAAAA
>MV119758.1 Sequence 63 from patent US 10633662
AAAAAAAAAAAA
>MV119741.1 Sequence 46 from patent US 10633662
CACCGCTACCTG
>MV119721.1 Sequence 26 from patent US 10633662
AAAAAAAAAAAA
>MV119720.1 Sequence 25 from patent US 10633662
AAAAAAAAAAAA
>MV119719.1 Sequence 24 from patent US 10633662
AAAAAAAAAAAA
>MV119718.1 Sequence 23 from patent US 10633662
AAAAAAAAAAAA
>MV119717.1 Sequence 22 from patent US 10633662
AAAAAAAAAAAA
>MV119713.1 Sequence 18 from patent US 10633662
GGCCTTCGAGTT
>MV119254.1 Sequence 8 from patent US 10633657
GTAAGCACTTTG
>MV116754.1 Sequence 3 from patent US 10633431
TAATCTAGAGCG
>MV099964.1 Sequence 40 from patent US 10630812
ATAAGAGACAGG
>MV099963.1 Sequence 39 from patent US 10630812
TATAAGAGACAG
>MV099962.1 Sequence 38 from patent US 10630812
GAATAAGAGACA
>MV099961.1 Sequence 37 from patent US 10630812
TGTATAAGAGAC
>MV099960.1 Sequence 36 from patent US 10630812
GTGTATAAGAGA
>MV099959.1 Sequence 35 from patent US 10630812
TGTGTATAAGAG
>MV099958.1 Sequence 34 from patent US 10630812
ATGTGTATAAGA
>MV099957.1 Sequence 33 from patent US 10630812
GATGTGTATAAG
>MV099956.1 Sequence 32 from patent US 10630812
AGATGTGTATAA
>MV099955.1 Sequence 31 from patent US 10630812
TAGATGTGTATA
>MV099954.1 Sequence 30 from patent US 10630812
CTAGATGTGTAT
>MV099953.1 Sequence 29 from patent US 10630812
TCTAGATGTGTA
>MV099952.1 Sequence 28 from patent US 10630812
ATCTAGATGTGT
>MV099951.1 Sequence 27 from patent US 10630812
CATCTAGATGTG
>MV099950.1 Sequence 26 from patent US 10630812
ACATCTAGATGT
>MV099949.1 Sequence 25 from patent US 10630812
CACATCTAGATG
>MV099948.1 Sequence 24 from patent US 10630812
ACACATCTAGAT
>MV099947.1 Sequence 23 from patent US 10630812
TACACATCTAGA
>MV099946.1 Sequence 22 from patent US 10630812
ATACACATCTAG
>MV099945.1 Sequence 21 from patent US 10630812
TATACACATCTA
>MV099944.1 Sequence 20 from patent US 10630812
TTATACACATCT
>MV099943.1 Sequence 19 from patent US 10630812
CTTATACACATC
>MV099942.1 Sequence 18 from patent US 10630812
TCTTATACACAT
>MV099941.1 Sequence 17 from patent US 10630812
CTCTTATACACA
>MV099940.1 Sequence 16 from patent US 10630812
TCTCTTATACAC
>MV099939.1 Sequence 15 from patent US 10630812
GTCTCTTATACA
>MV099938.1 Sequence 14 from patent US 10630812
TGTCTCTTATAC
>MV099937.1 Sequence 13 from patent US 10630812
CTGTCTCTTATA
>MV099936.1 Sequence 12 from patent US 10630812
AATAAGAGACAG
>MV099935.1 Sequence 11 from patent US 10630812
TAGAATAGACAG
>MV099934.1 Sequence 10 from patent US 10630812
CTTATACACATC
>MV099933.1 Sequence 9 from patent US 10630812
TTATACACATCT
>MV099932.1 Sequence 8 from patent US 10630812
AGATGTGTATAA
>MV099931.1 Sequence 7 from patent US 10630812
GATGTGTATAAG
>MV099930.1 Sequence 6 from patent US 10630812
ATGTGTATAAGA
>MV099929.1 Sequence 5 from patent US 10630812
TGTGTATAAGAG
>MV099928.1 Sequence 4 from patent US 10630812
GTGTATAAGAGA
>MV099927.1 Sequence 3 from patent US 10630812
TGTATAAGAGAC
>MV099926.1 Sequence 2 from patent US 10630812
GTATAAGAGACA
>MV099925.1 Sequence 1 from patent US 10630812
TATAAGAGACAG
>MV099231.1 Sequence 2 from patent US 10626455
ATGATGATGATG
>MV098725.1 Sequence 3 from patent US 10626443
GGATGNNNNNNN
>MV098239.1 Sequence 679 from patent US 10626419
GTTTTAGAGCTA
>MV097194.1 Sequence 6 from patent US 10626402
AAGGCTAGTCCG
>MV096699.1 Sequence 1 from patent US 10626209
CAAACACCATTG
>MV095292.1 Sequence 40 from patent US 10624349
GTTTTTGTACTC
>MV095286.1 Sequence 27 from patent US 10624349
AAATCATTTGAG
>MV095285.1 Sequence 26 from patent US 10624349
AATTCATTTGAG
>MV095184.1 Sequence 1 from patent US 10622096
ACGTCACATTTC
>MV094283.1 Sequence 50 from patent US 10619219
CTCGTTCGTTCT
>MV094279.1 Sequence 46 from patent US 10619219
TCTCGTACGTTC
>MV094278.1 Sequence 45 from patent US 10619219
TCTCGTACGTTC
>MV094277.1 Sequence 44 from patent US 10619219
TCTCGTACGTTC
>MV094276.1 Sequence 43 from patent US 10619219
TCTCGTACGTTC
>MV094272.1 Sequence 39 from patent US 10619219
TCTCGTACGTTC
>MV094271.1 Sequence 38 from patent US 10619219
TCTCGTACGTTC
>MV094266.1 Sequence 29 from patent US 10619219
GTACTTTTGAGA
>MV094265.1 Sequence 28 from patent US 10619219
TCTCAAAAGTAC
>MV094252.1 Sequence 6 from patent US 10619219
TCTCGTACGTTC
>MV092397.1 Sequence 8 from patent US 10619205
NNNACTNNNTGA
>MV090400.1 Sequence 22 from patent US 10619200
TTGTCGGATTGT
>MV090399.1 Sequence 21 from patent US 10619200
TTGTCGGATTGC
>MV090398.1 Sequence 20 from patent US 10619200
CCGTCGGACCGC
>MV084589.1 Sequence 45 from patent US 10618932
TGCTTCGGGATA
>MV146858.1 Sequence 28 from patent US 10648030
CGTACGTACGTG
>MV146857.1 Sequence 27 from patent US 10648030
CGTACGTACGTC
>MV146856.1 Sequence 26 from patent US 10648030
CGTACGTACGTT
>MV146855.1 Sequence 25 from patent US 10648030
CGTACGTACGTA
>MV146853.1 Sequence 23 from patent US 10648030
CGTACGTACGTA
>MV146851.1 Sequence 21 from patent US 10648030
CGTACGTACGTA
>MV146849.1 Sequence 19 from patent US 10648030
CGTACGTACGTC
>MV146848.1 Sequence 18 from patent US 10648030
CGTACGTACGTT
>MV146847.1 Sequence 17 from patent US 10648030
DGTACGTACGTA
>MV146844.1 Sequence 14 from patent US 10648030
CGTACGTACGTA
>MV146756.1 Sequence 101 from patent US 10648025
GACGAACGCACG
>MV146753.1 Sequence 98 from patent US 10648025
ATAGTGTTGTGG
>MV146750.1 Sequence 95 from patent US 10648025
GTTCGTTTATCG
>MV146747.1 Sequence 92 from patent US 10648025
CGGTTTTTTGCG
>MV146744.1 Sequence 89 from patent US 10648025
CGGCGTTCGCGA
>MV146740.1 Sequence 85 from patent US 10648025
ATCGGTTTCGTT
>MV146584.1 Sequence 1457 from patent US 10648020
AATGTTTCCTGA
>MV145972.1 Sequence 235 from patent US 10648009
CGGACGCGTGGG
>MV143257.1 Sequence 5 from patent US 10647740
GTGTGTGTGTGT
>MV143248.1 Sequence 1 from patent US 10647684
GAAACTGAAACT
>MV139920.1 Sequence 11 from patent US 10640826
ACTTCAGCTGCC
>MV139423.1 Sequence 9 from patent US 10640813
GGGAAAAAAGGG
>MV139422.1 Sequence 8 from patent US 10640813
CCCAAAAAACCC
>MV139421.1 Sequence 7 from patent US 10640813
CCCAAAAATCCC
>MV138764.1 Sequence 679 from patent US 10640791
GTTTTAGAGCTA
>MV136944.1 Sequence 38 from patent US 10640788
AAGGCTAGTCCG
>MV136694.1 Sequence 285 from patent US 10640780
GGTAAAATCAAC
>MV136680.1 Sequence 271 from patent US 10640780
CTTTGATCTACT
>MV131729.1 Sequence 249 from patent US 10640560
GCCTATGACTTG
>MV131276.1 Sequence 5 from patent US 10640529
GTGTGTGTGTGT
>MV130885.1 Sequence 10 from patent US 10639350
GGCGCGCACTCC
>MV087221.1 Sequence 28 from patent US 10619165
GCTCGTCGGCGT
>MV085669.1 Sequence 111 from patent US 10619153
AGACAAACCACA
>MV085668.1 Sequence 110 from patent US 10619153
CCGGATGCTCCT
>MV085667.1 Sequence 109 from patent US 10619153
CCCAGAAGTAAA
>MV085666.1 Sequence 108 from patent US 10619153
ATCAAGATTCTC
>MV085641.1 Sequence 23 from patent US 10619153
GCGCTCGAGTCC
>MV085640.1 Sequence 21 from patent US 10619153
GCGCTGGAGAGC
>MV085440.1 Sequence 44 from patent US 10619140
GGACGAAACACC
>MV085244.1 Sequence 88 from patent US 10618975
GGGGACGGCATC
>MV084797.1 Sequence 56 from patent US 10618941
CCANNNNNNTGG
>MV084647.1 Sequence 103 from patent US 10618932
TTCACAAGCGGA
>MV084646.1 Sequence 102 from patent US 10618932
ACTCGGCTTTCA
>MV084645.1 Sequence 101 from patent US 10618932
CTAGGTCAAGTC
>MV084644.1 Sequence 100 from patent US 10618932
GAGGTATGACTC
>MV084643.1 Sequence 99 from patent US 10618932
CCTATCATTCCC
>MV084642.1 Sequence 98 from patent US 10618932
CAGAGTCAATGG
>MV084641.1 Sequence 97 from patent US 10618932
TGGTGGCCATAA
>MV084640.1 Sequence 96 from patent US 10618932
CCAGACGTTGTT
>MV084639.1 Sequence 95 from patent US 10618932
CGATTGCAGAAG
>MV084638.1 Sequence 94 from patent US 10618932
TTGCAGTGCAAG
>MV084637.1 Sequence 93 from patent US 10618932
GGTGTATAGCCA
>MV084636.1 Sequence 92 from patent US 10618932
TCGAATCGTGTC
>MV084635.1 Sequence 91 from patent US 10618932
TCATGCGGAAAG
>MV084634.1 Sequence 90 from patent US 10618932
AACAGTAGTCGG
>MV084633.1 Sequence 89 from patent US 10618932
TGGCACTCTAGA
>MV084632.1 Sequence 88 from patent US 10618932
TGTAGATCCGCA
>MV084631.1 Sequence 87 from patent US 10618932
GACCTTCGGATT
>MV084630.1 Sequence 86 from patent US 10618932
TGAGCGAGTTCA
>MV084629.1 Sequence 85 from patent US 10618932
CGACATCCTCTA
>MV084628.1 Sequence 84 from patent US 10618932
TTGAGGGAGACA
>MV084627.1 Sequence 83 from patent US 10618932
GGACATGTCCAT
>MV084626.1 Sequence 82 from patent US 10618932
CGGTAGTTTGCT
>MV084625.1 Sequence 81 from patent US 10618932
ATTGTGTGACGG
>MV084624.1 Sequence 80 from patent US 10618932
GTGTGACAGAGT
>MV084622.1 Sequence 78 from patent US 10618932
CCATGGTCTTGT
>MV084621.1 Sequence 77 from patent US 10618932
CGTGAGATGAAC
>MV084620.1 Sequence 76 from patent US 10618932
ACCATCGACTCA
>MV084619.1 Sequence 75 from patent US 10618932
CAATTGGTAGCC
>MV084618.1 Sequence 74 from patent US 10618932
AACAAAGGGTCC
>MV084617.1 Sequence 73 from patent US 10618932
AGGCCGATTTGT
>MV084616.1 Sequence 72 from patent US 10618932
CTTGGCATCTTC
>MV084615.1 Sequence 71 from patent US 10618932
GGAAGGAACTGT
>MV084614.1 Sequence 70 from patent US 10618932
AGAATCGCAACC
>MV084613.1 Sequence 69 from patent US 10618932
TTCCCCGTTTAG
>MV084612.1 Sequence 68 from patent US 10618932
ACGCTAGAGCTT
>MV084611.1 Sequence 67 from patent US 10618932
CCTTTCTCGGAA
>MV084610.1 Sequence 66 from patent US 10618932
CTCGTGATCAGA
>MV084609.1 Sequence 65 from patent US 10618932
TCAGCCGAGTTA
>MV084608.1 Sequence 64 from patent US 10618932
TTTTCTCTGCGG
>MV084607.1 Sequence 63 from patent US 10618932
TCTTGCACACTC
>MV084606.1 Sequence 62 from patent US 10618932
GTTAGAGATGGG
>MV084605.1 Sequence 61 from patent US 10618932
GGTCTTCACTTC
>MV084604.1 Sequence 60 from patent US 10618932
TCACCACCCTAT
>MV084603.1 Sequence 59 from patent US 10618932
ACCCATTGCGAT
>MV084602.1 Sequence 58 from patent US 10618932
CCAGTTTCTACG
>MV084601.1 Sequence 57 from patent US 10618932
TCAACTGATCGG
>MV084600.1 Sequence 56 from patent US 10618932
GTCGCTGATCAA
>MV084599.1 Sequence 55 from patent US 10618932
TTCGTAGCGTGT
>MV084598.1 Sequence 54 from patent US 10618932
GAAGCCAAGCAT
>MV084597.1 Sequence 53 from patent US 10618932
TTAGCTTCCCTG
>MV084596.1 Sequence 52 from patent US 10618932
CGCAAGAGAACA
>MV084595.1 Sequence 51 from patent US 10618932
TCTCACGTCAAC
>MV084594.1 Sequence 50 from patent US 10618932
CGGACCTTCTAA
>MV084593.1 Sequence 49 from patent US 10618932
TGCCGCCAAAAT
>MV084592.1 Sequence 48 from patent US 10618932
CATACACACTCC
>MV084591.1 Sequence 47 from patent US 10618932
TAAGAAGCGCTC
>MV084590.1 Sequence 46 from patent US 10618932
GACAGCTCGTTA
>MV084588.1 Sequence 44 from patent US 10618932
TGTGGGATTGTG
>MV084587.1 Sequence 43 from patent US 10618932
TGTGGTTGATCG
>MV084586.1 Sequence 42 from patent US 10618932
GCGCAAAAGAAG
>MV084585.1 Sequence 41 from patent US 10618932
GGTAACAGTGAC
>MV084584.1 Sequence 40 from patent US 10618932
CGTCCAACTATG
>MV084583.1 Sequence 39 from patent US 10618932
GCTTGTTATCCG
>MV084582.1 Sequence 38 from patent US 10618932
GTATTCGCCATG
>MV084581.1 Sequence 37 from patent US 10618932
GATTCCACCGTA
>MV084580.1 Sequence 36 from patent US 10618932
GAGGACTTCACA
>MV084579.1 Sequence 35 from patent US 10618932
ACCCGAATTCAC
>MV084578.1 Sequence 34 from patent US 10618932
GTTCGAAGCAAC
>MV084577.1 Sequence 33 from patent US 10618932
CGTCAATCGTGT
>MV084576.1 Sequence 32 from patent US 10618932
TGACATAGAGGG
>MV084575.1 Sequence 31 from patent US 10618932
AAGTCCGTGAAC
>MV084574.1 Sequence 30 from patent US 10618932
ATGGGTCTTCTG
>MV084573.1 Sequence 29 from patent US 10618932
GGAGCATTTCAC
>MV084572.1 Sequence 28 from patent US 10618932
GTGCTCTATCAC
>MV084571.1 Sequence 27 from patent US 10618932
GGCATATACGAC
>MV084570.1 Sequence 26 from patent US 10618932
CGCTCATAACTC
>MV084569.1 Sequence 25 from patent US 10618932
GAAAAGCGTACC
>MV084568.1 Sequence 24 from patent US 10618932
TAGAAACCGAGG
>MV084567.1 Sequence 23 from patent US 10618932
CTTCCTACAGCA
>MV084566.1 Sequence 22 from patent US 10618932
CAGGAGGTACAT
>MV084565.1 Sequence 21 from patent US 10618932
TACTGTCACCCA
>MV084564.1 Sequence 20 from patent US 10618932
CTCTGAGGTTTG
>MV084563.1 Sequence 19 from patent US 10618932
CGGTGAGACATA
>MV084562.1 Sequence 18 from patent US 10618932
CAATTCCCACGT
>MV084561.1 Sequence 17 from patent US 10618932
GCCTAAGTTCCA
>MV084560.1 Sequence 16 from patent US 10618932
CGAAACGCTTAG
>MV084559.1 Sequence 15 from patent US 10618932
TTCATCCGAACG
>MV084558.1 Sequence 14 from patent US 10618932
ACTACGTCCAAC
>MV084557.1 Sequence 13 from patent US 10618932
CCGAGCTATGTA
>MV084556.1 Sequence 12 from patent US 10618932
CGGCTACTATTG
>MV084555.1 Sequence 11 from patent US 10618932
GGTGGAGTTACT
>MV084554.1 Sequence 10 from patent US 10618932
TATCGGAGTCCT
>MV084553.1 Sequence 9 from patent US 10618932
TACTGGACAAGG
>MV084552.1 Sequence 8 from patent US 10618932
CCTCTCCAAACA
>MV084551.1 Sequence 7 from patent US 10618932
AATGTGGTCTCG
>MV084550.1 Sequence 6 from patent US 10618932
ATCAGATCGCCT
>MV084549.1 Sequence 5 from patent US 10618932
TCTGTGAAGTCC
>MV084548.1 Sequence 4 from patent US 10618932
GTAGTGACAGGT
>MV084545.1 Sequence 1 from patent US 10618932
GCTGTACGGATT
>MV083439.1 Sequence 1010 from patent US 10614353
GTATGCAAAGGA
>MV083437.1 Sequence 1008 from patent US 10614353
CCCCCCCCCCCC
>MO965996.1 Sequence 5 from patent US 10597664
GATATACCATAT
>MO962341.1 Sequence 69 from patent US 10597642
TTCCTGTCACCC
>MO962340.1 Sequence 68 from patent US 10597642
TTCCTGTCACTC
>MO962144.1 Sequence 70 from patent US 10597463
GATCCTGCCCGG
>MO961248.1 Sequence 358 from patent US 10596252
GGGTTTTTTGGG
>MO961238.1 Sequence 347 from patent US 10596252
GGTTTTTTTTGG
>MO959464.1 Sequence 219 from patent US 10590489
CAGCTGCACAGG
>MO959462.1 Sequence 217 from patent US 10590489
CGGCTCATAGGG
>MO959460.1 Sequence 215 from patent US 10590489
GCGGCATGAAAT
>MO958076.1 Sequence 40 from patent US 10590473
AGGTCTTCATGC
>MO958075.1 Sequence 39 from patent US 10590473
AGGTAGTCATGC
>MO958074.1 Sequence 38 from patent US 10590473
AGGTGGTCATGC
>MO958073.1 Sequence 37 from patent US 10590473
AGGTTGTCATGC
>MO958072.1 Sequence 36 from patent US 10590473
AGGTCATCATGC
>MO958071.1 Sequence 35 from patent US 10590473
AGGTCTTCATGC
>MO958070.1 Sequence 34 from patent US 10590473
AGGTAGTCATGC
>MO958069.1 Sequence 33 from patent US 10590473
AGGTGGTCATGC
>MO958068.1 Sequence 32 from patent US 10590473
AGGTTGTCATGC
>MO958067.1 Sequence 31 from patent US 10590473
AGGTCATCATGC
>MO958064.1 Sequence 26 from patent US 10590473
AGGTAGTCATGC
>MO958063.1 Sequence 24 from patent US 10590473
AGGTGGTCATGC
>MO958062.1 Sequence 22 from patent US 10590473
AGGTTGTCATGC
>MO958061.1 Sequence 20 from patent US 10590473
AGGTCGTCATGC
>MO958060.1 Sequence 19 from patent US 10590473
AGGTCATCATGC
>MO957752.1 Sequence 15 from patent US 10590465
TGCCTACGCCAT
>MO957725.1 Sequence 261 from patent US 10590456
ATGGTGTTACTA
>MO957723.1 Sequence 259 from patent US 10590456
ATTCCTCCACTA
>MO950834.1 Sequence 250 from patent US 10590421
TAACAGCCCTTC
>MO950833.1 Sequence 249 from patent US 10590421
AGCCAGGTGTTA
>MO950113.1 Sequence 2300 from patent US 10590413
CCAGGTAAGTAT
>MO947941.1 Sequence 125 from patent US 10590413
CAGTCTGCTTCG
>MO947924.1 Sequence 108 from patent US 10590413
CAGTCTGCTTCG
>MO947887.1 Sequence 69 from patent US 10590413
TCAGCGTGCGCC
>MO946841.1 Sequence 11 from patent US 10590172
ATCGAGGGCAGG
>MO945876.1 Sequence 112 from patent US 10588935
GGTGGTTCTGGT
>MO945868.1 Sequence 104 from patent US 10588935
GGTGGTTCTGGT
>MV083409.1 Sequence 980 from patent US 10614353
AAAGGTGGTGAA
>MV083372.1 Sequence 940 from patent US 10614353
AAAGAGGAGAAA
>MV083349.1 Sequence 916 from patent US 10614353
TCACATCCCTCC
>MV083347.1 Sequence 913 from patent US 10614353
TCTCACGTGTGT
>MV081765.1 Sequence 6 from patent US 10612090
GAACNNNNNCTC
>MV081761.1 Sequence 2 from patent US 10612090
CAANNNNNGTGG
>MV080432.1 Sequence 679 from patent US 10612045
GTTTTAGAGCTA
>MV067140.1 Sequence 16 from patent US 10612018
GGGHHHNNNNNN
>MV067139.1 Sequence 15 from patent US 10612018
GGGHHHNNNNNN
>MV067132.1 Sequence 6 from patent US 10612018
GGGCACTGTACG
>MV067131.1 Sequence 5 from patent US 10612018
GGGCACTGTACG
>MV066818.1 Sequence 20 from patent US 10611846
AGCCATCAGCTG
>MV066817.1 Sequence 19 from patent US 10611846
TAGCTTGAGTCT
>MV066816.1 Sequence 18 from patent US 10611846
ATGGCTTAGCTT
>MV066575.1 Sequence 412 from patent US 10611827
ACCTGTCGACCC
>MV066088.1 Sequence 22 from patent US 10611801
GCTAGCGAATTC
>MV066087.1 Sequence 21 from patent US 10611801
GGATCCGGTACC
>MV065775.1 Sequence 6 from patent US 10610582
CGGCGCGCGCCG
>MV065366.1 Sequence 30 from patent US 10610521
GTGAAGATACTG
>MV065365.1 Sequence 29 from patent US 10610521
AAGGGGTAGAAG
>MV061522.1 Sequence 147 from patent US 10607716
GGCGGTGGCGGT
>MV061475.1 Sequence 95 from patent US 10607716
AGACTAGACAGA
>MV061474.1 Sequence 94 from patent US 10607716
GGCCAATGAGTA
>MV061473.1 Sequence 93 from patent US 10607716
GCNGAATAANAT
>MV061472.1 Sequence 92 from patent US 10607716
TNTAGACAGACC
>MV061471.1 Sequence 91 from patent US 10607716
ACGGCATGTATC
>MV061468.1 Sequence 88 from patent US 10607716
TGAGTACTGTAA
>MV061467.1 Sequence 87 from patent US 10607716
TCCACATGTAGC
>MV061465.1 Sequence 85 from patent US 10607716
TAGTGACGNTTA
>MV061422.1 Sequence 38 from patent US 10607716
GTGTCACTCAAA
>MV060516.1 Sequence 66 from patent US 10604805
CGGCCCGCTCGT
>MV060513.1 Sequence 63 from patent US 10604805
CGGCCCGCTTCT
>MV060510.1 Sequence 60 from patent US 10604805
CGGCCCGCCTCT
>MV060387.1 Sequence 335 from patent US 10604791
TTATTCCCAGGT
>MV058711.1 Sequence 279 from patent US 10604755
GTCTGATGGAGA
>MV058710.1 Sequence 278 from patent US 10604755
GCTAGTCTGTTG
>MV058694.1 Sequence 261 from patent US 10604755
GTCTGATGGAGA
>MV058693.1 Sequence 260 from patent US 10604755
GCTAGTCTGTTG
>MV058647.1 Sequence 214 from patent US 10604755
GCTAGTCTGTTG
>MV058631.1 Sequence 198 from patent US 10604755
TTTGCCATTTGG
>MV058630.1 Sequence 197 from patent US 10604755
TGCCATTTGGAT
>MV058629.1 Sequence 196 from patent US 10604755
TGCCATTTGGAT
>MV058628.1 Sequence 195 from patent US 10604755
GCCATTTGGATC
>MV058627.1 Sequence 194 from patent US 10604755
CCATTTGGATCT
>MV058625.1 Sequence 192 from patent US 10604755
CATTTGGATCTG
>MV058569.1 Sequence 136 from patent US 10604755
CAACAGACTAGC
>MV058553.1 Sequence 120 from patent US 10604755
CCAAATGGCAAA
>MV058552.1 Sequence 119 from patent US 10604755
TCCAAATGGCAA
>MV058551.1 Sequence 118 from patent US 10604755
ATCCAAATGGCA
>MV058550.1 Sequence 117 from patent US 10604755
GATCCAAATGGC
>MV058549.1 Sequence 116 from patent US 10604755
AGATCCAAATGG
>MV058547.1 Sequence 114 from patent US 10604755
CAGATCCAAATG
>MV044627.1 Sequence 5 from patent US 10603295
SNGSGGGCAMCC
>MO996675.1 Sequence 1 from patent US 10600217
AAGCTACTAGCT
>MO994689.1 Sequence 11 from patent US 10597713
TTTNTTNNTTTN
>MO994688.1 Sequence 10 from patent US 10597713
AAAAAAAAAAAA
>MO994681.1 Sequence 19 from patent US 10597711
TCGATGTACAGC
>MO994680.1 Sequence 18 from patent US 10597711
TCTAGACTCGAG
>MO994677.1 Sequence 15 from patent US 10597711
TACGTCTGAGCA
>MO994516.1 Sequence 1 from patent US 10597702
GAAAGTGAAAGT
>MO993946.1 Sequence 679 from patent US 10597680
GTTTTAGAGCTA
>MC403048.1 JP 2018157825-A/26: Compositions and Methods for Regulating Cell Osmolarity
TGGAAAATTCCA
>MC430653.1 JP 2019022512-A/22: CRISPR ENZYME MUTATIONS REDUCING OFF-TARGET EFFECTS
GTTTTAGAGCTA
>MC402698.1 JP 2019506889-A/1: CLOSED-ENDED LINEAR DUPLEX DNA FOR NON-VIRAL GENE TRANSFER
GCTCGCTCGCTC
>MC430260.1 JP 2018203779-A/12: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
GAATACCAATGC
>MC430257.1 JP 2018203779-A/9: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
GAATACCAATGC
>MC430252.1 JP 2018203779-A/4: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
GAATACCAATGC
>MC430251.1 JP 2018203779-A/3: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
GAATACCAATGC
>MC430250.1 JP 2018203779-A/2: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
GAATACCAATGC
>MC430249.1 JP 2018203779-A/1: CHIMERIC DOUBLE-STRANDED NUCLEIC ACID
GCATTGGTATTC
>MC402331.1 JP 2019508037-A/140: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
TCTTCCGAGCAG
>MC402321.1 JP 2019508037-A/130: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
TCTTCCGAGCAG
>MC402320.1 JP 2019508037-A/129: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
CTGCTCGGAAGA
>MC402201.1 JP 2019508037-A/10: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
TCTCTTTCTTTC
>MC402200.1 JP 2019508037-A/9: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
CTTTCTTTCTCT
>MC402194.1 JP 2019508037-A/3: COMPOSITIONS FOR ENHANCING TARGETED GENE EDITING AND METHODS OF USE THEREOF
GAAAGAAAGAGA
>MC429508.1 JP 2019013234-A/752: Stem Cell Microparticles
GTGCCCTTCTTC
>MC429503.1 JP 2019013234-A/747: Stem Cell Microparticles
GGGTCCGGTGCG
>MC427294.1 JP 2019004910-A/726: METHODS FOR TARGETED GENOMIC ANALYSIS
CTCCGAGTTCCG
>MC427292.1 JP 2019004910-A/724: METHODS FOR TARGETED GENOMIC ANALYSIS
GGGATCGGAGTC
>MC425273.1 JP 2019014717-A/17: Antibody to lipoarabinomannan and immunoassay of mycobacteriosis with the antibody
ACCTGCGGCCGC
>MC396885.1 JP 2019503186-A/33: PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
GGAGGAGGAGGA
>MC396884.1 JP 2019503186-A/32: PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
GGTGGAGGAGGA
>MC396883.1 JP 2019503186-A/31: PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
GGAGGTGGAGGA
>MC396882.1 JP 2019503186-A/30: PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
GGAGGAGGTGGA
>MC396881.1 JP 2019503186-A/29: PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
GGAGGAGGAGGT
>MC396880.1 JP 2019503186-A/28: PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
GGAGGTGGAGGT
>MC396879.1 JP 2019503186-A/27: PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
GGAGGAGGTGGT
>MC396878.1 JP 2019503186-A/26: PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
GGAGGTGGTGGA
>MC396877.1 JP 2019503186-A/25: PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
GGTGGAGGAGGT
>MC396876.1 JP 2019503186-A/24: PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
GGTGGAGGTGGA
>MC396875.1 JP 2019503186-A/23: PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF
GGTGGTGGAGGA
>MC422812.1 JP 2018171079-A/36: METHODS OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS
KKKKKKKKKKKK
>MC422810.1 JP 2018171079-A/34: METHODS OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS
KKKKKKKKKKKK
>MC422760.1 JP 2018171078-A/36: METHODS OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS
KKKKKKKKKKKK
>MC422758.1 JP 2018171078-A/34: METHODS OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS
KKKKKKKKKKKK
>MC422708.1 JP 2018174941-A/36: METHODS OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS
KKKKKKKKKKKK
>MC422706.1 JP 2018174941-A/34: METHODS OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS
KKKKKKKKKKKK
>MC421972.1 JP 2018183180-A/136: CHIMERIC POLYPEPTIDES HAVING TARGETED BINDING SPECIFICITY
GCGGGAGGCGTG
>MD224612.1 JP 2020058342-A/5501: OPTIMAL MAIZE LOCI
GAGGCGGAGGTG
>MD224611.1 JP 2020058342-A/5500: OPTIMAL MAIZE LOCI
CACGGACAGGAG
>MD224603.1 JP 2020058342-A/5492: OPTIMAL MAIZE LOCI
CAGCAGGACTCT
>MD224599.1 JP 2020058342-A/5488: OPTIMAL MAIZE LOCI
GGGTGGGGGGCA
>MD224587.1 JP 2020058342-A/5476: OPTIMAL MAIZE LOCI
GTGTCGAGAGCT
>MD224574.1 JP 2020058342-A/5463: OPTIMAL MAIZE LOCI
TATCAGCTCGAG
>MD224570.1 JP 2020058342-A/5459: OPTIMAL MAIZE LOCI
TATCCGATCCCG
>MD224555.1 JP 2020058342-A/5444: OPTIMAL MAIZE LOCI
TCGGCCATGGGA
>MD224545.1 JP 2020058342-A/5434: OPTIMAL MAIZE LOCI
GACGGATCGGAG
>MD224540.1 JP 2020058342-A/5429: OPTIMAL MAIZE LOCI
CGTGGGTACGAA
>MD224511.1 JP 2020058342-A/5400: OPTIMAL MAIZE LOCI
GGTGACTAAGCT
>MD224502.1 JP 2020058342-A/5391: OPTIMAL MAIZE LOCI
AGTCCGCTCGGG
>MD224499.1 JP 2020058342-A/5388: OPTIMAL MAIZE LOCI
CATGAGAGGGAT
>MD224497.1 JP 2020058342-A/5386: OPTIMAL MAIZE LOCI
GTCGATGCACCG
>MD224408.1 JP 2020058342-A/5297: OPTIMAL MAIZE LOCI
AGAGCAGGCGAG
>MD224404.1 JP 2020058342-A/5293: OPTIMAL MAIZE LOCI
AGAGGTGTAACC
>MC033760.1 JP 2018534939-A/2: PURIFICATION OF POLYMERASE COMPLEXES
TCTACTCTAACT
>MC415034.1 JP 2018183184-A/229: COMPOSITIONS AND METHODS FOR MODULATING APOLIPROTEIN C-III EXPRESSION
GCATTGGTATTC
>MC184869.1 JP 2018533375-A/16: CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS
AAGGCTAGTCCG
>MC032931.1 JP 2018530560-A/3391: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
ACAGATCTGTCA
>MC032952.1 JP 2018530560-A/3412: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
AGGACATTGGCA
>MC032936.1 JP 2018530560-A/3396: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
AGGAAGATGGCA
>MC032856.1 JP 2018530560-A/3316: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
NGGNNGNNGGNN
>MC032872.1 JP 2018530560-A/3332: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
NGGNNNNNGGNN
>MC032851.1 JP 2018530560-A/3311: COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCULAR DYSTROPHY AND RELATED DISORDERS
NNNGNNNNGNNN
>MC414381.1 JP 2018183178-A/35: Antisense Nucleic Acid
CCTGGAGTTCCT
>MC414380.1 JP 2018183178-A/34: Antisense Nucleic Acid
GTTTGCCGCTGC
>MC183486.1 JP 2018535695-A/60: ANTI-CANCER AND ANTI-INFLAMMATORY THERAPEUTICS AND METHODS THEREOF
CAGTTGTAACTG
>MC182883.1 JP 2019503179-A/26: HYBRID PROMOTER AND USES THEREOF
GTTCTACGTGGG
>MC182867.1 JP 2019503179-A/10: HYBRID PROMOTER AND USES THEREOF
GGCGCCGCCACC
>MC181687.1 JP 2019500043-A/2744: COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
GTTTAAGAGCTA
>MC181686.1 JP 2019500043-A/2743: COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
GTTTTAGAGCTA
>MC028878.1 JP 2018533975-A/14: Treatment of genetic diseases
GCAGCAGCAGCA
>MC028874.1 JP 2018533975-A/10: Treatment of genetic diseases
AGCAGCAGCAGC
>MC028870.1 JP 2018533975-A/6: Treatment of genetic diseases
CAGCAGCAGCAG
>MC028116.1 JP 2018533955-A/25: EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION
GGGGCCTCGAGA
>MC028115.1 JP 2018533955-A/24: EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION
CCGTCTCCCCCA
>MC028113.1 JP 2018533955-A/22: EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION
CCAACCCCCGCA
>MC028098.1 JP 2018533955-A/7: EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION
AAATAAACACAC
>MC028097.1 JP 2018533955-A/6: EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION
CACACAAATAAA
>MC028096.1 JP 2018533955-A/5: EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION
AATAAAAATAAA
>MC028094.1 JP 2018533955-A/3: EXOGENOUS CONTROL OF MAMMALIAN GENE EXPRESSION THROUGH APTAMER-MEDIATED MODULATION OF POLYADENYLATION
AATAAAAATAAA
>MC410179.1 JP 2018184423-A/23: COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
ATTCACTTTCAT
>MC410178.1 JP 2018184423-A/22: COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
TTCACTTTCATA
>MC410177.1 JP 2018184423-A/21: COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
TCACTTTCATAA
>MC410175.1 JP 2018184423-A/19: COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
CACTTTCATAAT
>MC410173.1 JP 2018184423-A/17: COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
ACTTTCATAATG
>MC410171.1 JP 2018184423-A/15: COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
CTTTCATAATGC
>MC410169.1 JP 2018184423-A/13: COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
TTTCATAATGCT
>MC410167.1 JP 2018184423-A/11: COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
TTCATAATGCTG
>MC410165.1 JP 2018184423-A/9: COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING
TCATAATGCTGG
>MC409981.1 JP 2018168186-A/130: REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES
GATCTTGACTTG
>MC409752.1 JP 2018171070-A/23: Aptamers for use against autoantibody-associated diseases
GGTTGGTGTGGT
>MC437500.1 JP 2019047787-A/120: ANTIBODIES TO IL-6 AND USE THEREOF
GCCTATGACTTG
>MC022536.1 JP 2018531245-A/4: OLIGONUCLEOTIDE CONJUGATION PROCESS
GTTGACACTGTC
>MC408280.1 JP 2018164458-A/4638: TERMINALLY MODIFIED RNA
AAGTCTTTGGGT
>MC408279.1 JP 2018164458-A/4637: TERMINALLY MODIFIED RNA
TTACTGGGTGTT
>MC408278.1 JP 2018164458-A/4636: TERMINALLY MODIFIED RNA
GGTGGGTGTGTC
>MC408277.1 JP 2018164458-A/4635: TERMINALLY MODIFIED RNA
GGTTTCNATAAC
>MC408276.1 JP 2018164458-A/4634: TERMINALLY MODIFIED RNA
CGGCTCACCAGT
>MC408275.1 JP 2018164458-A/4633: TERMINALLY MODIFIED RNA
TGGGCGAGTGGG
>MC408274.1 JP 2018164458-A/4632: TERMINALLY MODIFIED RNA
AGGAGGGTTTGT
>MC408273.1 JP 2018164458-A/4631: TERMINALLY MODIFIED RNA
CANGTGATATTC
>MC408272.1 JP 2018164458-A/4630: TERMINALLY MODIFIED RNA
GAATGGATGGGG
>MC408271.1 JP 2018164458-A/4629: TERMINALLY MODIFIED RNA
GGTGGGTGTGTC
>MC408270.1 JP 2018164458-A/4628: TERMINALLY MODIFIED RNA
TCCTTCTGGGTC
>MC408269.1 JP 2018164458-A/4627: TERMINALLY MODIFIED RNA
ATATGTGCCCTT
>MC408268.1 JP 2018164458-A/4626: TERMINALLY MODIFIED RNA
GATGGGGGCACA
>MC408267.1 JP 2018164458-A/4625: TERMINALLY MODIFIED RNA
AAGCTGTACATG
>MC408266.1 JP 2018164458-A/4624: TERMINALLY MODIFIED RNA
CACGGGGACAGC
>MC408265.1 JP 2018164458-A/4623: TERMINALLY MODIFIED RNA
TGTGTCTTTGCA
>MC408264.1 JP 2018164458-A/4622: TERMINALLY MODIFIED RNA
TGCTTCAATGCC
>MC408263.1 JP 2018164458-A/4621: TERMINALLY MODIFIED RNA
CGCTTCAATGCT
>MC408262.1 JP 2018164458-A/4620: TERMINALLY MODIFIED RNA
GGTGGGTGTGTC
>MC408261.1 JP 2018164458-A/4619: TERMINALLY MODIFIED RNA
AGGGTGAAGGTC
>MC408260.1 JP 2018164458-A/4618: TERMINALLY MODIFIED RNA
TTACTGGGTGTT
>MC408259.1 JP 2018164458-A/4617: TERMINALLY MODIFIED RNA
ATCTATTGGCCA
>MC408258.1 JP 2018164458-A/4616: TERMINALLY MODIFIED RNA
TCCAATTGGGAA
>MC408257.1 JP 2018164458-A/4615: TERMINALLY MODIFIED RNA
TCGGTTATTGTT
>MC408256.1 JP 2018164458-A/4614: TERMINALLY MODIFIED RNA
GCATTAGTATCT
>MC408255.1 JP 2018164458-A/4613: TERMINALLY MODIFIED RNA
GGCATTCATCGT
>MC019818.1 JP 2018528967-A/152: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019817.1 JP 2018528967-A/151: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019816.1 JP 2018528967-A/150: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019815.1 JP 2018528967-A/149: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019814.1 JP 2018528967-A/148: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019813.1 JP 2018528967-A/147: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019812.1 JP 2018528967-A/146: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019811.1 JP 2018528967-A/145: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019810.1 JP 2018528967-A/144: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019809.1 JP 2018528967-A/143: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019808.1 JP 2018528967-A/142: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019807.1 JP 2018528967-A/141: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019806.1 JP 2018528967-A/140: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019805.1 JP 2018528967-A/139: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019804.1 JP 2018528967-A/138: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019803.1 JP 2018528967-A/137: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019802.1 JP 2018528967-A/136: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019801.1 JP 2018528967-A/135: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019800.1 JP 2018528967-A/134: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019799.1 JP 2018528967-A/133: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019798.1 JP 2018528967-A/132: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019797.1 JP 2018528967-A/131: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019796.1 JP 2018528967-A/130: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC019795.1 JP 2018528967-A/129: MiR-19 MODULATORS AND USES THEREOF
GACAAGTGCAAT
>MC244218.1 JP 2018535651-A/15: Diagnostic Methods and Devices
CACAGATTTTGG
>MC244020.1 JP 2019504636-A/587: SLAM POLYNUCLEOTIDES AND POLYPEPTIDES AND USES THEREOF
TTGAGTGCTTGT
>MC019468.1 JP 2020500514-A/42: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GAGGGTTTTAAG
>MC019467.1 JP 2020500514-A/41: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
ATGTTGTGGGTA
>MC019466.1 JP 2020500514-A/40: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GAGTTGGATGAG
>MC019465.1 JP 2020500514-A/39: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
ATGGGAAAAAGT
>MC019464.1 JP 2020500514-A/38: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GTTAGTGGGAAA
>MC019463.1 JP 2020500514-A/37: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
TTTGGGTTTAGG
>MC019462.1 JP 2020500514-A/36: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GTTGTTATTGTG
>MC019461.1 JP 2020500514-A/35: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
TGAGAAGGGTAG
>MC019460.1 JP 2020500514-A/34: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGCGTGGAAAAG
>MC019459.1 JP 2020500514-A/33: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GAGGGCGAAAAG
>MC019458.1 JP 2020500514-A/32: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
CGAGAGGAAAAG
>MC019457.1 JP 2020500514-A/31: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGCCGAGAAAAG
>MC019456.1 JP 2020500514-A/30: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GTGAGGGAAAAG
>MC019455.1 JP 2020500514-A/29: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GGGGATGAAAAG
>MC019454.1 JP 2020500514-A/28: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GAAGGAGAAAAG
>MC019453.1 JP 2020500514-A/27: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
TGGATGGAAAAG
>MC019452.1 JP 2020500514-A/26: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGGGTGGATGAC
>MC019451.1 JP 2020500514-A/25: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGCCGAGATGAC
>MC019450.1 JP 2020500514-A/24: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGTGGGGAGGAG
>MC019449.1 JP 2020500514-A/23: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGAGGGGATGAC
>MC019448.1 JP 2020500514-A/22: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGGGGTGAGGAG
>MC019447.1 JP 2020500514-A/21: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGGAGTGATGAC
>MC019446.1 JP 2020500514-A/20: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
GTATCGGATGAC
>MC019445.1 JP 2020500514-A/19: CHEMICAL COMPOSITIONS AND METHODS OF USING SAME
AGGACAGATGAC
>MC016115.1 JP 2020042813-A/9: METHODS AND SYSTEMS FOR ALIGNING SEQUENCES
GGATCGAAATGG
>MC016029.1 JP 2020043794-A/87: Primer set, and amplification method of target nucleotide sequence using it
GCAGGAGCCTTC
>MC016025.1 JP 2020043794-A/83: Primer set, and amplification method of target nucleotide sequence using it
GCTGCCTACAAC
>MC016022.1 JP 2020043794-A/80: Primer set, and amplification method of target nucleotide sequence using it
ACAAGGCTCCCT
>MC016020.1 JP 2020043794-A/78: Primer set, and amplification method of target nucleotide sequence using it
ACCGACTCGCTC
>MC016017.1 JP 2020043794-A/75: Primer set, and amplification method of target nucleotide sequence using it
CTGCCCCCACTC
>MC016014.1 JP 2020043794-A/72: Primer set, and amplification method of target nucleotide sequence using it
TGCAAAACGGAA
>MC016011.1 JP 2020043794-A/69: Primer set, and amplification method of target nucleotide sequence using it
GCGCCGGTGTCC
>MC016009.1 JP 2020043794-A/67: Primer set, and amplification method of target nucleotide sequence using it
TGCTCGCGCTGC
>MC016005.1 JP 2020043794-A/63: Primer set, and amplification method of target nucleotide sequence using it
CTGCTCCGAAGC
>MC016002.1 JP 2020043794-A/60: Primer set, and amplification method of target nucleotide sequence using it
CTTGGTCTTTTC
>MC015999.1 JP 2020043794-A/57: Primer set, and amplification method of target nucleotide sequence using it
CCCAGAATGTGG
>MC015997.1 JP 2020043794-A/55: Primer set, and amplification method of target nucleotide sequence using it
GTCAGGGGCATA
>MC015993.1 JP 2020043794-A/51: Primer set, and amplification method of target nucleotide sequence using it
AGCGTTGCCAGC
>MC015990.1 JP 2020043794-A/48: Primer set, and amplification method of target nucleotide sequence using it
CCCCAAAACCCT
>MC015989.1 JP 2020043794-A/47: Primer set, and amplification method of target nucleotide sequence using it
CGACCAAGAGAC
>MC015986.1 JP 2020043794-A/44: Primer set, and amplification method of target nucleotide sequence using it
GAGGGCGCGACC
>MC015982.1 JP 2020043794-A/40: Primer set, and amplification method of target nucleotide sequence using it
CTCTTGGTCGCG
>MC015979.1 JP 2020043794-A/37: Primer set, and amplification method of target nucleotide sequence using it
GACACAAAAAGG
>MC015978.1 JP 2020043794-A/36: Primer set, and amplification method of target nucleotide sequence using it
GCCCATCTGCAA
>MC015975.1 JP 2020043794-A/33: Primer set, and amplification method of target nucleotide sequence using it
GATGGATCTGAT
>MC015971.1 JP 2020043794-A/29: Primer set, and amplification method of target nucleotide sequence using it
CAGCTTCGCCGC
>MC015969.1 JP 2020043794-A/27: Primer set, and amplification method of target nucleotide sequence using it
ATCAGATTGTCG
>MC015968.1 JP 2020043794-A/26: Primer set, and amplification method of target nucleotide sequence using it
AAGGCGGGAAAC
>MC015959.1 JP 2020043794-A/17: Primer set, and amplification method of target nucleotide sequence using it
GATCAGATTGTC
>MC015957.1 JP 2020043794-A/15: Primer set, and amplification method of target nucleotide sequence using it
GAAGGCGGGAAA
>MP567612.1 Sequence 211 from Patent WO2020056239
CCGCCGCCGCCG
>MP466877.1 Sequence 7 from Patent EP3598104
ACGGACGCGGAG
>MP375451.1 Sequence 26 from Patent EP3560502
TTATTCAACAAA
>MP565765.1 Sequence 115 from Patent WO2020053258
STCTATTCTAAA
>MP465324.1 Sequence 96 from Patent EP3595708
CACATCAGCAGA
>MP464887.1 Sequence 23 from Patent WO2020006067
TCTCGTACGTTC
>MP464443.1 Sequence 21 from Patent WO2019243888
AGAGCCAAGAGA
>MP464441.1 Sequence 19 from Patent WO2019243888
TCTGGAAGCGGC
>MP560602.1 Sequence 230 from Patent WO2020056147
CCGCCGCCGCCG
>MP462952.1 Sequence 144 from Patent EP3597744
GGTAAAATCAAC
>MP462938.1 Sequence 130 from Patent EP3597744
CTTTGATCTACT
>MP368945.1 Sequence 99 from Patent EP3555274
CCAGAGCAAGAG
>MP459891.1 Sequence 9 from Patent EP3597748
GTACTAGTACTA
>MP457672.1 Sequence 23 from Patent WO2020006036
TCTCGTACGTTC
>MP457052.1 Sequence 73 from Patent EP3594339
TTCACTTCCCGT
>MP457038.1 Sequence 59 from Patent EP3594339
TTATGCTGAGGA
>MP364141.1 Sequence 40 from Patent EP3556768
CGACGACGACGA
>MP620753.1 Sequence 36 from Patent WO2019226953
TCTGGCGGCTCA
>MP619986.1 Sequence 92 from Patent WO2019204743
CGATCGATCGAT
>MP619956.1 Sequence 62 from Patent WO2019204743
ATCGATCGATCG
>MP544733.1 Sequence 7 from Patent WO2020031142
ATTCAGTTCTCA
>MP544738.1 Sequence 12 from Patent WO2020031142
AACCCATGGAAT
>MP544735.1 Sequence 9 from Patent WO2020031142
ACTCTTGACTTA
>MP544740.1 Sequence 14 from Patent WO2020031142
AACCCATGGAAT
>MP543949.1 Sequence 20 from Patent WO2020033951
TCTCTTTCTTTC
>MP543990.1 Sequence 61 from Patent WO2020033951
CTGCTCGGAAGA
>MP543991.1 Sequence 62 from Patent WO2020033951
TCTTCCGAGCAG
>MP543948.1 Sequence 19 from Patent WO2020033951
CTTTCTTTCTCT
>MP543944.1 Sequence 15 from Patent WO2020033951
GAAAGAAAGAGA
>MP453951.1 Sequence 88 from Patent EP3593138
GGGGACGGCATC
>MP540260.1 Sequence 7 from Patent WO2020047007
AAAAAAAAACCC
>MP540259.1 Sequence 6 from Patent WO2020047007
AAAAAAAAAAAC
>MP452356.1 Sequence 150 from Patent EP3591036
GGTGACGTCACC
>MP452355.1 Sequence 149 from Patent EP3591036
GGTGACGTCAGC
>MP360138.1 Sequence 5 from Patent EP3556864
CCTATCCCCTGT
>MP360134.1 Sequence 1 from Patent EP3556864
CCATCTCATCCC
>MP359770.1 Sequence 188 from Patent EP3551767
AGCTAGTGGCGT
>MP359763.1 Sequence 181 from Patent EP3551767
GCTGATGGCGTA
>MP359762.1 Sequence 180 from Patent EP3551767
TGGAGCTGATGG
>MP615066.1 Sequence 154 from Patent WO2019195492
AAGGCTAGTCCG
>MP539720.1 Sequence 6 from Patent WO2020047184
CTTTCTCTCTGT
>MP539633.1 Sequence 278 from Patent WO2020047282
ACATCCTTCCGC
>MP452165.1 Sequence 148 from Patent EP3591074
AGCGGGGGGGCA
>MP452163.1 Sequence 146 from Patent EP3591074
AGTGGGGGGGCG
>MP452161.1 Sequence 144 from Patent EP3591074
AGTGGGGGGGCA
>MP359652.1 Sequence 70 from Patent EP3551767
GGAGACGGTCTG
>MP359599.1 Sequence 17 from Patent EP3551767
GGAGCTGTGATA
>MP359588.1 Sequence 6 from Patent EP3551767
TGGAGCTAGTGG
>MP538951.1 Sequence 13 from Patent WO2020038851
GGACCTATGGTG
>MP538950.1 Sequence 12 from Patent WO2020038851
TACGTCGGAAGC
>MP538548.1 Sequence 206 from Patent WO2020047201
CCGCCGCCGCCG
>MP537918.1 Sequence 207 from Patent WO2020043750
CCTTACCTTTCA
>MP449578.1 Sequence 10 from Patent WO2019238873
ATTTATTTATTT
>MP449556.1 Sequence 921 from Patent EP3589373
GCTAGCTTCGAA
>MP536330.1 Sequence 2 from Patent WO2020039201
GATCGAGCCTCA
>MP448781.1 Sequence 146 from Patent EP3589373
GGAGGATCTGGA
>MP447466.1 Sequence 823 from Patent EP3589646
GGAGGATCTGGA
>MP355177.1 Sequence 209 from Patent WO2019197583
ACCNNNNNNGGT
>MP355176.1 Sequence 208 from Patent WO2019197583
ACCGTTGCCGGT
>MP353035.1 Sequence 32 from Patent WO2019200171
CCCCCCTAAGCC
>MP353034.1 Sequence 31 from Patent WO2019200171
CCCCCCACCCCC
>MP353033.1 Sequence 30 from Patent WO2019200171
CCCCCCCCAACC
>MP353032.1 Sequence 29 from Patent WO2019200171
CCCCCCCAACCC
>MP351699.1 Sequence 59 from Patent EP3547825
CCAGGAACTGCG
>MP351696.1 Sequence 56 from Patent EP3547825
CCAGGAACTGCG
>MP351693.1 Sequence 53 from Patent EP3547825
CCAGGAACTGCG
>MP351171.1 Sequence 25 from Patent EP3550033
TTTTTTTTTTTT
>MP442769.1 Sequence 3 from Patent EP3587594
GTATCCACATGC
>MP527182.1 Sequence 5 from Patent EP3617321
CGTGGAGGCGTG
>MP527181.1 Sequence 4 from Patent EP3617321
GTGCGGAGGTGC
>MP527179.1 Sequence 2 from Patent EP3617321
CGTGGAGGCGTG
>MP441147.1 Sequence 85 from Patent EP3588091
GGTGGCGGTGGC
>MP441146.1 Sequence 83 from Patent EP3588091
CGCGCGCGCGCG
>MP609079.1 Sequence 307 from Patent WO2020086742
GGAGGATCTGGA
>MP608889.1 Sequence 117 from Patent WO2020086742
AGAACGAAGAGA
>MP608676.1 Sequence 9 from Patent WO2020086551
CTTCTTCTTCTT
>MP608672.1 Sequence 5 from Patent WO2020086551
GAAGAAGAAGAA
>MP608668.1 Sequence 1 from Patent WO2020086551
TTCTTCTTCTTC
>MP434828.1 Sequence 33 from Patent EP3583214
TATCACATCGGT
>MP434827.1 Sequence 32 from Patent EP3583214
ACTGTCTAACGG
>MP434826.1 Sequence 31 from Patent EP3583214
GTGTGACGTATT
>MP434825.1 Sequence 30 from Patent EP3583214
GAGGCTGAGCTA
>MP434824.1 Sequence 29 from Patent EP3583214
TCGATAATGCGA
>MP434823.1 Sequence 28 from Patent EP3583214
AGCTTACTATCC
>MP434822.1 Sequence 27 from Patent EP3583214
ACATGTTACCGT
>MP434821.1 Sequence 26 from Patent EP3583214
AGGACCATCCAA
>MP523230.1 Sequence 59 from Patent EP3600671
TCCGATAGTGAA
>MP343699.1 Sequence 156 from Patent WO2019195491
AAGGCTAGTCCG
>MP342859.1 Sequence 6 from Patent WO2019190590
TTTTATTGTTTT
>MP342856.1 Sequence 3 from Patent WO2019190590
TTTTATTGTTTG
>MP340305.1 Sequence 27 from Patent WO2019186274
TCAGCAGTGCCT
>MP340303.1 Sequence 25 from Patent WO2019186274
GGTGATAGCAAT
>MP518769.1 Sequence 90 from Patent WO2020041501
ATACGTGATGGC
>MP519085.1 Sequence 2 from Patent EP3601593
AATTGGCCGCTA
>MP333945.1 Sequence 39 from Patent EP3541424
GGGSGGGSGGGS
>MP333946.1 Sequence 40 from Patent EP3541424
GGGSGGGSGGGS
>MP333947.1 Sequence 41 from Patent EP3541424
GGGSGGGSGGGS
>MP333253.1 Sequence 149 from Patent EP3539980
GTTTTAGAGCTA
>MP333262.1 Sequence 158 from Patent EP3539980
AAGGCTAGTCCG
>MP604374.1 Sequence 99 from Patent WO2020086844
AGTGAAGCTCAG
>MP418232.1 Sequence 68 from Patent WO2019236673
ATTTATCAGATT
>MP418231.1 Sequence 67 from Patent WO2019236673
AATCTGATAAAT
>MP328240.1 Sequence 10 from Patent EP3543362
CTGGCGGCGTGC
>MP328239.1 Sequence 9 from Patent EP3543362
GCTGGCGGCGTG
>MP327809.1 Sequence 175 from Patent EP3536809
GGAAAATTAATC
>MP327807.1 Sequence 173 from Patent EP3536809
GAATWATGAAAG
>MP511991.1 Sequence 55 from Patent EP3612547
ATAAACCGCGCG
>MP511990.1 Sequence 54 from Patent EP3612547
CCGCACCGCGCG
>MP511986.1 Sequence 50 from Patent EP3612547
CCAAACTCCGGA
>MP511983.1 Sequence 47 from Patent EP3612547
CCAAACTAGCTA
>MP511981.1 Sequence 45 from Patent EP3612547
CCAAACCGCGCG
>MP326683.1 Sequence 20 from Patent EP3536779
AGCAAAAGCAGG
>MP326619.1 Sequence 175 from Patent EP3536810
GGAAAATTAATC
>MP326617.1 Sequence 173 from Patent EP3536810
GAATWATGAAAG
>MP326245.1 Sequence 394 from Patent EP3536804
ATGGTGACATGA
>MP510410.1 Sequence 2 from Patent EP3610034
CGACGCTCTTCC
>MP415760.1 Sequence 308 from Patent EP3576751
CCGCCGCCGCCG
>MP509919.1 Sequence 51 from Patent EP3609521
CTACGATCGGAG
>MP509918.1 Sequence 50 from Patent EP3609521
TGCTAGAACGTA
>MP509917.1 Sequence 49 from Patent EP3609521
TCTGCTACGTCG
>MP509916.1 Sequence 48 from Patent EP3609521
AGCCTAGAATCT
>MP509915.1 Sequence 47 from Patent EP3609521
TCGGAGACGCTG
>MP509914.1 Sequence 46 from Patent EP3609521
GCTCCTATAGAA
>MP509913.1 Sequence 45 from Patent EP3609521
CTACGATGCTAG
>MP509912.1 Sequence 44 from Patent EP3609521
AACGTAGCTTTC
>MP414228.1 Sequence 42 from Patent WO2019222178
GAGGGTTTTAAG
>MP414227.1 Sequence 41 from Patent WO2019222178
ATGTTGTGGGTA
>MP414226.1 Sequence 40 from Patent WO2019222178
GAGTTGGATGAG
>MP414225.1 Sequence 39 from Patent WO2019222178
ATGGGAAAAAGT
>MP414224.1 Sequence 38 from Patent WO2019222178
GTTAGTGGGAAA
>MP414223.1 Sequence 37 from Patent WO2019222178
TTTGGGTTTAGG
>MP414222.1 Sequence 36 from Patent WO2019222178
GTTGTTATTGTG
>MP414221.1 Sequence 35 from Patent WO2019222178
TGAGAAGGGTAG
>MP414220.1 Sequence 34 from Patent WO2019222178
AGCGTGGAAAAG
>MP414219.1 Sequence 33 from Patent WO2019222178
GAGGGCGAAAAG
>MP414218.1 Sequence 32 from Patent WO2019222178
CGAGAGGAAAAG
>MP414217.1 Sequence 31 from Patent WO2019222178
AGCCGAGAAAAG
>MP414216.1 Sequence 30 from Patent WO2019222178
GTGAGGGAAAAG
>MP414215.1 Sequence 29 from Patent WO2019222178
GGGGATGAAAAG
>MP414214.1 Sequence 28 from Patent WO2019222178
GAAGGAGAAAAG
>MP414213.1 Sequence 27 from Patent WO2019222178
TGGATGGAAAAG
>MP414212.1 Sequence 26 from Patent WO2019222178
AGGGTGGATGAC
>MP414211.1 Sequence 25 from Patent WO2019222178
AGCCGAGATGAC
>MP414210.1 Sequence 24 from Patent WO2019222178
AGTGGGGAGGAG
>MP414209.1 Sequence 23 from Patent WO2019222178
AGAGGGGATGAC
>MP414208.1 Sequence 22 from Patent WO2019222178
AGGGGTGAGGAG
>MP414207.1 Sequence 21 from Patent WO2019222178
AGGAGTGATGAC
>MP414206.1 Sequence 20 from Patent WO2019222178
GTATCGGATGAC
>MP414205.1 Sequence 19 from Patent WO2019222178
AGGACAGATGAC
>MP321714.1 Sequence 4 from Patent WO2019170709
AAAGAAGACCCT
>MP321713.1 Sequence 3 from Patent WO2019170709
AAAGAAGACCCT
>MP412217.1 Sequence 33 from Patent WO2019224548
CTGTCTCTTATA
>MP412184.1 Sequence 1 from Patent WO2019226650
GCTCGCTCGCTC
>MP318230.1 Sequence 94 from Patent WO2019173684
GGAGGAGGAGGA
>MP318229.1 Sequence 93 from Patent WO2019173684
GGTGGAGGAGGA
>MP318228.1 Sequence 92 from Patent WO2019173684
GGAGGTGGAGGA
>MP318227.1 Sequence 91 from Patent WO2019173684
GGAGGAGGTGGA
>MP318226.1 Sequence 90 from Patent WO2019173684
GGAGGAGGAGGT
>MP318225.1 Sequence 89 from Patent WO2019173684
GGAGGTGGAGGT
>MP318224.1 Sequence 88 from Patent WO2019173684
GGAGGAGGTGGT
>MP318223.1 Sequence 87 from Patent WO2019173684
GGAGGTGGTGGA
>MP318222.1 Sequence 86 from Patent WO2019173684
GGTGGAGGAGGT
>MP318221.1 Sequence 85 from Patent WO2019173684
GGTGGAGGTGGA
>MP318220.1 Sequence 84 from Patent WO2019173684
GGTGGTGGAGGA
>MP317699.1 Sequence 26 from Patent EP3535404
CAAAAGGAACAA
>MP317692.1 Sequence 19 from Patent EP3535404
TTAATTGATTAA
>MP317690.1 Sequence 17 from Patent EP3535404
TTGCGGACGCTG
>MP317687.1 Sequence 14 from Patent EP3535404
ACGATCAAAAGG
>MP316924.1 Sequence 36 from Patent EP3540059
CCCCCCTCGGCA
>MP316923.1 Sequence 35 from Patent EP3540059
ATGCGAGGGGGG
>MP316921.1 Sequence 33 from Patent EP3540059
CAAGTCACCAAG
>MP597271.1 Sequence 23 from Patent EP3643783
ATTCACTTTCAT
>MP597270.1 Sequence 22 from Patent EP3643783
TTCACTTTCATA
>MP597269.1 Sequence 21 from Patent EP3643783
TCACTTTCATAA
>MP597267.1 Sequence 19 from Patent EP3643783
CACTTTCATAAT
>MP597265.1 Sequence 17 from Patent EP3643783
ACTTTCATAATG
>MP597263.1 Sequence 15 from Patent EP3643783
CTTTCATAATGC
>MP597261.1 Sequence 13 from Patent EP3643783
TTTCATAATGCT
>MP597259.1 Sequence 11 from Patent EP3643783
TTCATAATGCTG
>MP597257.1 Sequence 9 from Patent EP3643783
TCATAATGCTGG
>MP316462.1 Sequence 16 from Patent EP3541952
GACGTCTCGAGT
>MP408140.1 Sequence 49 from Patent WO2019226836
GAAGAAGAAGAA
>MP407910.1 Sequence 11 from Patent WO2019219947
ATGCTGAGGAGA
>MP315205.1 Sequence 64 from Patent EP3536792
CCGGGGGGACAC
>MP595991.1 Sequence 6 from Patent EP3640375
TTATAGGTGTCT
>MP595990.1 Sequence 5 from Patent EP3640375
AGACACCTATAA
>MP406906.1 Sequence 85 from Patent WO2019224606
GCCACCATGGCC
>MP406905.1 Sequence 84 from Patent WO2019224606
GCCACCATGGCT
>MP593083.1 Sequence 990 from Patent EP3634496
DSTTTCDNTTYY
>MP313948.1 Sequence 9 from Patent EP3541940
GACGTCTCGAGT
>MP313900.1 Sequence 7 from Patent EP3541950
GCACTAGCTCAC
>MP313777.1 Sequence 29 from Patent EP3541168
GCTCAAGAACAT
>MP313776.1 Sequence 28 from Patent EP3541168
GCTCAAGAACAT
>MP404714.1 Sequence 17 from Patent EP3573646
CTCTTCCGATCT
>MP404113.1 Sequence 43 from Patent EP3545096
TGGGGGTGTGAA
>MP311095.1 Sequence 19 from Patent EP3534916
AAATCCAGTGAC
>MP590208.1 Sequence 232 from Patent EP3635132
CGTGCAAAGCGT
>MP590207.1 Sequence 231 from Patent EP3635132
AGAGCTAAGAGG
>MP589993.1 Sequence 17 from Patent EP3635132
AGTGGCAGCGGC
>MP587095.1 Sequence 8 from Patent WO2020069791
TTTCCCCCCCCC
>MP587055.1 Sequence 81 from Patent EP3636753
CAGGCCAATGGG
>MP400766.1 Sequence 13 from Patent EP3572525
TCTGGTGGTTCT
>MP400754.1 Sequence 1 from Patent EP3572525
GTTTTAGAGCTA
>MP585609.1 Sequence 9 from Patent WO2020081768
GGTCTCGCAGTG
>MP585607.1 Sequence 7 from Patent WO2020081768
GGTCTCGCACTC
>MP585167.1 Sequence 58 from Patent EP3635118
AAGGCCAGAGTG
>MP484969.1 Sequence 209 from Patent WO2020023390
CCGCCGCCGCCG
>MP397183.1 Sequence 14 from Patent EP3572072
CATGACGTTCCT
>MP396946.1 Sequence 45 from Patent EP3565891
GCCGCCATTTTG
>MP396908.1 Sequence 7 from Patent EP3565891
ACTGTGTTTTCA
>MP396906.1 Sequence 5 from Patent EP3565891
CGGGTGCTTGGA
>MP482905.1 Sequence 404 from Patent WO2020023864
TCAACACACAGA
>MP482895.1 Sequence 394 from Patent WO2020023864
CACAGAGAATGG
>MP482884.1 Sequence 383 from Patent WO2020023864
ATTCAACATACA
>MP395520.1 Sequence 35 from Patent EP3565595
GGGSGGGSGGGS
>MP580186.1 Sequence 47 from Patent WO2020065062
TCACAGGTCATA
>MP580177.1 Sequence 38 from Patent WO2020065062
ATGGACCATCAG
>MP579870.1 Sequence 47 from Patent WO2020058438
GGTCTCTATAAT
>MP579869.1 Sequence 46 from Patent WO2020058438
CGCCAGGAGACC
>MP579859.1 Sequence 36 from Patent WO2020058438
CTTTCATTCCAG
>MP579647.1 Sequence 210 from Patent WO2020069169
CCGCCGCCGCCG
>MP393837.1 Sequence 14 from Patent EP3561059
TCTGGTGGTTCT
>MP393824.1 Sequence 1 from Patent EP3561059
GTTTTAGAGCTA
>MP479996.1 Sequence 19 from Patent EP3604555
ACTTCAGCTGCC
>MP479986.1 Sequence 9 from Patent EP3604555
GCGTTATACCGT
>MP479017.1 Sequence 9 from Patent WO2020007953
CGANNNNNNTGC
>MP479016.1 Sequence 8 from Patent WO2020007953
CAANNNNNGTGG
>MP575355.1 Sequence 165 from Patent WO2020065096
TCAGGCAGATCT
>MP631162.1 Sequence 343 from Patent EP3573448
GTAAGCGCTTAC
>MP631072.1 Sequence 253 from Patent EP3573448
CCAATTTAATGG
>MP631044.1 Sequence 225 from Patent EP3573448
TCTAACCTACCA
>MP630990.1 Sequence 171 from Patent EP3573448
TTCCNNNNNNGG
>MP476102.1 Sequence 38 from Patent WO2020010158
CGGCGGCGGCGG
>MP390749.1 Sequence 49 from Patent WO2019217757
GGGGCCGGGGCC
>MP389390.1 Sequence 94 from Patent WO2019210034
GGAGGAGGAGGA
>MP389389.1 Sequence 93 from Patent WO2019210034
GGTGGAGGAGGA
>MP389388.1 Sequence 92 from Patent WO2019210034
GGAGGTGGAGGA
>MP389387.1 Sequence 91 from Patent WO2019210034
GGAGGAGGTGGA
>MP389386.1 Sequence 90 from Patent WO2019210034
GGAGGAGGAGGT
>MP389385.1 Sequence 89 from Patent WO2019210034
GGAGGTGGAGGT
>MP389384.1 Sequence 88 from Patent WO2019210034
GGAGGAGGTGGT
>MP389383.1 Sequence 87 from Patent WO2019210034
GGAGGTGGTGGA
>MP389382.1 Sequence 86 from Patent WO2019210034
GGTGGAGGAGGT
>MP389381.1 Sequence 85 from Patent WO2019210034
GGTGGAGGTGGA
>MP389380.1 Sequence 84 from Patent WO2019210034
GGTGGTGGAGGA
>MP572343.1 Sequence 211 from Patent WO2020068261
GGGGGGGGGGCG
>MP572342.1 Sequence 210 from Patent WO2020068261
GGGGGGGGTTCG
>MP572341.1 Sequence 209 from Patent WO2020068261
GGGGGGTTTTCG
>MP572340.1 Sequence 208 from Patent WO2020068261
GGGGTTTTTTCG
>MP572339.1 Sequence 207 from Patent WO2020068261
GGTTTTTTTTCG
>MP572338.1 Sequence 206 from Patent WO2020068261
TTTTTTTTTTCG
>MP388619.1 Sequence 66 from Patent EP3567104
CAACGCGAGTGA
>MP388618.1 Sequence 65 from Patent EP3567104
CAACGTGAGTGA
>MP388617.1 Sequence 64 from Patent EP3567104
CAACGCGAGTGA
>MP388616.1 Sequence 63 from Patent EP3567104
GGGCCCGGGACC
>MP388606.1 Sequence 53 from Patent EP3567104
GGGCCCGGGACC
>MP388602.1 Sequence 49 from Patent EP3567104
GGGCCCGGGACC
>MP572032.1 Sequence 9 from Patent EP3636758
GTACTAGTACTA
>MP386143.1 Sequence 25 from Patent WO2019211630
CCAGTTACTAAT
>MP385514.1 Sequence 7 from Patent EP3567122
GATCGGAAGAGC
>MP473185.1 Sequence 115 from Patent EP3536796
TAGGCATCGACC
>MP473165.1 Sequence 95 from Patent EP3536796
AGCGAGGAAGAA
>MP473161.1 Sequence 91 from Patent EP3536796
TCTGAGGACAAC
>MP471864.1 Sequence 88 from Patent EP3598980
GGGGACGGCATC
>MP569379.1 Sequence 104 from Patent EP3636766
AAAGCGGCTCCG
>MP569370.1 Sequence 95 from Patent EP3636766
ACTCTGTGGAAG
>MP469392.1 Sequence 16 from Patent WO2019243391
GTTGGTGTGTTG
>MP469391.1 Sequence 15 from Patent WO2019243391
CAACACACCAAC
>MP469384.1 Sequence 8 from Patent WO2019243391
CGTCAGGCAGTC
>MP469383.1 Sequence 7 from Patent WO2019243391
GACTGCCTGACG
>MP567836.1 Sequence 206 from Patent WO2020056155
CCGCCGCCGCCG
>MP322811.1 Sequence 18 from Patent WO2019166816
GTTCTCTCTCCC
>MP322810.1 Sequence 17 from Patent WO2019166816
ATCCTCTCTCCC
>MP322809.1 Sequence 16 from Patent WO2019166816
GCTCTCTCTCCC
>MP322808.1 Sequence 15 from Patent WO2019166816
ATCGTCAGTCCC
>MO940207.1 Sequence 15 from patent US 10584378
TTACAGATCTAC
>MO940193.1 Sequence 1 from patent US 10584378
ACGTACGTACGT
>MO940126.1 Sequence 2 from patent US 10584363
GGGCGGCGACCT
>MO940125.1 Sequence 1 from patent US 10584363
GGGCGGCGACCT
>MO935387.1 Sequence 53 from patent US 10584322
GTTTTAGAGCTA
>MO933639.1 Sequence 40 from patent US 10582712
GTTTTTGTACTC
>MO933633.1 Sequence 27 from patent US 10582712
AAATCATTTGAG
>MO933632.1 Sequence 26 from patent US 10582712
AATTCATTTGAG
>MO933303.1 Sequence 278 from patent US 10577666
CCCACCACGCTC
>MO932272.1 Sequence 679 from patent US 10577631
GTTTTAGAGCTA
>MO931733.1 Sequence 784 from patent US 10577630
GGNNNNNNNNCC
>MO931730.1 Sequence 781 from patent US 10577630
CCNNNNNNNNGG
>MO931705.1 Sequence 753 from patent US 10577630
GGTAATTTCGTG
>MO931704.1 Sequence 752 from patent US 10577630
AGTAAAGGCGCT
>MO931703.1 Sequence 751 from patent US 10577630
TAGCTAACCGTT
>MO931702.1 Sequence 750 from patent US 10577630
GTTAACAGCGTG
>MO931701.1 Sequence 749 from patent US 10577630
GGTCGTCATCAA
>MO931700.1 Sequence 748 from patent US 10577630
GTCGTGGACTAC
>MO931699.1 Sequence 747 from patent US 10577630
CTTCGCAAGGAG
>MO931698.1 Sequence 746 from patent US 10577630
AAGATCGGTAGC
>MO931697.1 Sequence 745 from patent US 10577630
CGCGTCAGATAT
>MO931696.1 Sequence 744 from patent US 10577630
CTATGCCGTGCA
>MO931695.1 Sequence 743 from patent US 10577630
CGTACGGCACAG
>MO931694.1 Sequence 742 from patent US 10577630
ACGCGTCAGATA
>MO931693.1 Sequence 741 from patent US 10577630
TCGACGACTCAC
>MO931692.1 Sequence 740 from patent US 10577630
CGACTTTTTGCA
>MO931691.1 Sequence 739 from patent US 10577630
TCGATGGTAAAC
>MO931690.1 Sequence 738 from patent US 10577630
GCGTTATCAGAA
>MO931689.1 Sequence 737 from patent US 10577630
CCCAAACGGTTA
>MO931688.1 Sequence 736 from patent US 10577630
CGTAGCCATGTT
>MO931687.1 Sequence 735 from patent US 10577630
TTTACCATCGAA
>MO931686.1 Sequence 734 from patent US 10577630
CGTGCCCTGAAC
>MO931685.1 Sequence 733 from patent US 10577630
CGAAAACGTGGC
>MO931684.1 Sequence 732 from patent US 10577630
CTTAGTCGGCCA
>MO931683.1 Sequence 731 from patent US 10577630
TAAAGCGACCCG
>MO931682.1 Sequence 730 from patent US 10577630
CACGAGGTATGC
>MO931681.1 Sequence 729 from patent US 10577630
CGGTGTATTGAG
>MO931680.1 Sequence 728 from patent US 10577630
ACACCGAAAACG
>MO931679.1 Sequence 727 from patent US 10577630
GCAGGACGTCCG
>MO931678.1 Sequence 726 from patent US 10577630
TCACCCAAAGCG
>MO931677.1 Sequence 725 from patent US 10577630
ACTATGCGTAGG
>MO931676.1 Sequence 724 from patent US 10577630
TTGACTGCGGCG
>MO931675.1 Sequence 723 from patent US 10577630
TGGGACACCGGT
>MO931674.1 Sequence 722 from patent US 10577630
GCCAACCCGCAC
>MO931673.1 Sequence 721 from patent US 10577630
CCCCTACGGCAC
>MO931672.1 Sequence 720 from patent US 10577630
AGTGGCGATGAC
>MO931671.1 Sequence 719 from patent US 10577630
CGTCATGAATAA
>MO931670.1 Sequence 718 from patent US 10577630
CGATTCCTTCGT
>MO931669.1 Sequence 717 from patent US 10577630
CCAAACGGTTAA
>MO931668.1 Sequence 716 from patent US 10577630
TTCATAACCGGC
>MO931667.1 Sequence 715 from patent US 10577630
CGCTACATAGCA
>MO931666.1 Sequence 714 from patent US 10577630
ACTCGATACCAT
>MO931665.1 Sequence 713 from patent US 10577630
AGGAAGTATCGC
>MO931664.1 Sequence 712 from patent US 10577630
TTTACGCAGAGG
>MO931663.1 Sequence 711 from patent US 10577630
TGAGTCGTCGAG
>MO931662.1 Sequence 710 from patent US 10577630
TTCGAGCGATTT
>MO931661.1 Sequence 709 from patent US 10577630
GTCGGGGACTAT
>MO931660.1 Sequence 708 from patent US 10577630
AAGGTCGCCCAT
>MO931659.1 Sequence 707 from patent US 10577630
TAACGTCGGAGC
>MO931658.1 Sequence 706 from patent US 10577630
TGCGCCTCCAGT
>MO931657.1 Sequence 705 from patent US 10577630
CCGATTCCTTCG
>MO931656.1 Sequence 704 from patent US 10577630
CTCCGTATCTCG
>MO931655.1 Sequence 703 from patent US 10577630
GCGTCAATGTTC
>MO931654.1 Sequence 702 from patent US 10577630
ATCGTGCCCTAA
>MO931653.1 Sequence 701 from patent US 10577630
ACACCGGTCTTC
>MO931652.1 Sequence 700 from patent US 10577630
GATTCATCAGCG
>MO931651.1 Sequence 699 from patent US 10577630
GAACCCGTCCTA
>MO931650.1 Sequence 698 from patent US 10577630
CGCCGGTGGAAT
>MO931649.1 Sequence 697 from patent US 10577630
TTTCAAGGCCGG
>MO931648.1 Sequence 696 from patent US 10577630
TCGTATCCCTAC
>MO931647.1 Sequence 695 from patent US 10577630
CAGGACGTCCGT
>MO931646.1 Sequence 694 from patent US 10577630
ACTCCGTAGTGA
>MO931645.1 Sequence 693 from patent US 10577630
TCGTCGGGTGCA
>MO931644.1 Sequence 692 from patent US 10577630
GTCTCACGATCG
>MO931643.1 Sequence 691 from patent US 10577630
GAGTCGATACGC
>MO931642.1 Sequence 690 from patent US 10577630
AACCAAGATACG
>MO931641.1 Sequence 689 from patent US 10577630
CACGAAATTACC
>MO931640.1 Sequence 688 from patent US 10577630
TACGGTAAGTCG
>MO931639.1 Sequence 687 from patent US 10577630
GCCTGTGCCGTA
>MO931638.1 Sequence 686 from patent US 10577630
CGGTACTCTTAC
>MO931637.1 Sequence 685 from patent US 10577630
GCATGGTACGGA
>MO931636.1 Sequence 684 from patent US 10577630
GCCGAATTCCTC
>MO931635.1 Sequence 683 from patent US 10577630
ATGGAAACGCAT
>MO931634.1 Sequence 682 from patent US 10577630
TGTCGCATGTTA
>MO931633.1 Sequence 681 from patent US 10577630
GGCGTTAATGAT
>MO931632.1 Sequence 680 from patent US 10577630
TAGGTCGACCAG
>MO931631.1 Sequence 679 from patent US 10577630
ACGTCGCCTGAT
>MO931630.1 Sequence 678 from patent US 10577630
ACTGCGTGTTAA
>MO931629.1 Sequence 677 from patent US 10577630
ACTCCCCGTAGG
>MO931628.1 Sequence 676 from patent US 10577630
TCGGTGACATGT
>MO931627.1 Sequence 675 from patent US 10577630
TAGCGGGTAAGC
>MO931089.1 Sequence 136 from patent US 10577630
CGACCCTGGAAA
>MO931049.1 Sequence 90 from patent US 10577630
GTTTTAGAGCTA
>MO931038.1 Sequence 63 from patent US 10577630
GTTTTAGAGCTA
>MO929453.1 Sequence 12 from patent US 10577610
GGGGTTGGCCCC
>MO929440.1 Sequence 166 from patent US 10577609
TGTGGTGGTCGG
>MO929405.1 Sequence 129 from patent US 10577609
TGTGAATTTATC
>MO929358.1 Sequence 76 from patent US 10577609
CGTTGACTTATC
>MO925231.1 Sequence 14803 from patent US 10577403
ATGTGGACATAG
>MO923592.1 Sequence 13164 from patent US 10577403
ATGTGGACATAG
>MO921952.1 Sequence 11524 from patent US 10577403
ATGTGGACATAG
>MO920281.1 Sequence 9853 from patent US 10577403
ATGTGGACCTAG
>MO918610.1 Sequence 8182 from patent US 10577403
ATGTGGACCTAG
>MO916939.1 Sequence 6511 from patent US 10577403
ATGTGGACCTAG
>MO915268.1 Sequence 4840 from patent US 10577403
ATGTGGACCTAG
>MO912114.1 Sequence 11 from patent US 10577396
CTCATAATCAAA
>MO912113.1 Sequence 10 from patent US 10577396
CTCATAATAAAA
>MO912112.1 Sequence 9 from patent US 10577396
CTCATAATCAAA
>MO912111.1 Sequence 8 from patent US 10577396
GAGTATTATTTT
>MO912110.1 Sequence 7 from patent US 10577396
CTCATAATAAAA
>MO912104.1 Sequence 1 from patent US 10577396
ATCTCCTCCCTT
>MO912103.1 Sequence 4 from patent US 10577388
GTTGACACTGTC
>MO911640.1 Sequence 2 from patent US 10572831
AGCTGGCTGGCG
>MO911639.1 Sequence 1 from patent US 10572831
AGCTTTTTGGGG
>MO911466.1 Sequence 11 from patent US 10570462
ACAGACCGCCGG
>MO911463.1 Sequence 8 from patent US 10570462
CAGCGGGTTGTT
>MO900772.1 Sequence 3 from patent US 10570197
GACAAGACCCAC
>MO900557.1 Sequence 106 from patent US 10570169
GCATTGGTATTC
>MO900270.1 Sequence 70 from patent US 10568958
GGGTTTTTTGGG
>MO900260.1 Sequence 59 from patent US 10568958
GGTTTTTTTTGG
>MO893076.1 Sequence 12 from patent US 10566077
TACTCCAACCTG
>MO893075.1 Sequence 11 from patent US 10566077
CTCCACTCATAG
>MO893074.1 Sequence 10 from patent US 10566077
ACTACTCTCACG
>MO893073.1 Sequence 9 from patent US 10566077
CATAGCGCCATA
>MO893072.1 Sequence 8 from patent US 10566077
GAGACCGTCATA
>MO893071.1 Sequence 7 from patent US 10566077
CATACCGTCTTG
>MO893070.1 Sequence 6 from patent US 10566077
TGCGCCTCCCGC
>MO893069.1 Sequence 5 from patent US 10566077
CCGCGCTGGCGA
>MO893068.1 Sequence 4 from patent US 10566077
GGATCGCCAGCG
>MO893067.1 Sequence 3 from patent US 10566077
ACGGCCTTCTTA
>MO893066.1 Sequence 2 from patent US 10566077
TCCCATGAGAGA
>MO893065.1 Sequence 1 from patent US 10566077
GTATTGCCAGAG
>MO892190.1 Sequence 679 from patent US 10563227
GTTTTAGAGCTA
>MO890630.1 Sequence 150 from patent US 10563215
GCCAACCCGGAG
>MO890624.1 Sequence 144 from patent US 10563215
CTCCGCCACATG
>MO890621.1 Sequence 141 from patent US 10563215
CGGTAAGATCGA
>MO890619.1 Sequence 139 from patent US 10563215
CAATAACAATGC
>MO890614.1 Sequence 134 from patent US 10563215
CACTTCAAGGGT
>MO890551.1 Sequence 71 from patent US 10563215
CAGCAAAGACGA
>MO890547.1 Sequence 67 from patent US 10563215
TAGTGTTGAAAT
>MO890145.1 Sequence 189 from patent US 10563211
TCTAAATTATAA
>MO889694.1 Sequence 4 from patent US 10563206
GTACAGACCAAT
>MO889693.1 Sequence 3 from patent US 10563206
CTCCAGGGCTGA
>MO889692.1 Sequence 2 from patent US 10563206
CTACAGACTGGA
>MO889691.1 Sequence 1 from patent US 10563206
ATACAGACCTTA
>MO889645.1 Sequence 99 from patent US 10563202
GCTAGTCTGTTG
>MO889583.1 Sequence 37 from patent US 10563202
GTCTGATGGAGA
>MO889582.1 Sequence 36 from patent US 10563202
GTCTGATGGAGA
>MO889581.1 Sequence 35 from patent US 10563202
GTCTGATGGAGA
>MO889580.1 Sequence 34 from patent US 10563202
GTCTGATGGAGA
>MO889579.1 Sequence 33 from patent US 10563202
GTCTGATGGAGA
>MO889449.1 Sequence 365 from patent US 10563199
GGCTCAAACAGC
>MO889171.1 Sequence 87 from patent US 10563199
TGTAGGAGTCTC
>MO888960.1 Sequence 10 from patent US 10563192
CATATGGGATCC
>MO888959.1 Sequence 9 from patent US 10563192
CTCGAGTAATGA
>MO888952.1 Sequence 2 from patent US 10563192
TAATGACTCGAG
>MO888903.1 Sequence 10 from patent US 10563191
CATATGGGATCC
>MO888902.1 Sequence 9 from patent US 10563191
CTCGAGTAATGA
>MO888895.1 Sequence 2 from patent US 10563191
TAATGACTCGAG
>MO887412.1 Sequence 18 from patent US 10561707
AGAAACAGGAGG
>MO887411.1 Sequence 17 from patent US 10561707
AGGAGCCGAAGA
>MO887410.1 Sequence 16 from patent US 10561707
AGAGGGAGGAGA
>MO887008.1 Sequence 40 from patent US 10561148
GTTTTTGTACTC
>MO887002.1 Sequence 27 from patent US 10561148
AAATCATTTGAG
>MO887001.1 Sequence 26 from patent US 10561148
AATTCATTTGAG
>MO693264.1 Sequence 51 from patent US 10538772
GGCTTTGGTGGA
>MO693262.1 Sequence 45 from patent US 10538772
GGGTTTGGCGGT
>MO693082.1 Sequence 334 from patent US 10538768
GTCGGCGACTCC
>MO693081.1 Sequence 333 from patent US 10538768
TCGGCGACTCCC
>MO692854.1 Sequence 106 from patent US 10538768
GAGCGGTTCGGT
>MO692853.1 Sequence 105 from patent US 10538768
CTTGCGACACCC
>MO692768.1 Sequence 20 from patent US 10538768
GCGGGATGGCAT
>MO692761.1 Sequence 13 from patent US 10538768
CCGCGGATCGCC
>MO692755.1 Sequence 7 from patent US 10538768
CTGCCCGCGGAT
>MO691327.1 Sequence 15 from patent US 10538591
TGGGTTGACTAC
>MO907983.1 Sequence 29 from patent US 10570441
NNNNNNNGACTC
>MO907982.1 Sequence 28 from patent US 10570441
GAGTNCNNNNNN
>MO907981.1 Sequence 27 from patent US 10570441
NNNNNNNGACTC
>MO907980.1 Sequence 26 from patent US 10570441
GAGTCNNNNNNN
>MO907949.1 Sequence 32 from patent US 10570440
TTTTTTTTTTTT
>MO906993.1 Sequence 679 from patent US 10570419
GTTTTAGAGCTA
>MO906588.1 Sequence 1418 from patent US 10570418
GGATCCAAGCTT
>MO906587.1 Sequence 1417 from patent US 10570418
AAGCTTGGATCC
>MO906586.1 Sequence 1416 from patent US 10570418
GGATCCAAGCTT
>MO906585.1 Sequence 1415 from patent US 10570418
AAGCTTGGATCC
>MO906584.1 Sequence 1414 from patent US 10570418
AAGCTTGGATCC
>MO906583.1 Sequence 1413 from patent US 10570418
GGATCCAAGCTT
>MO906582.1 Sequence 1412 from patent US 10570418
GGATCCAAGCTT
>MO906581.1 Sequence 1411 from patent US 10570418
GGATCCAAGCTT
>MO906429.1 Sequence 679 from patent US 10570418
GTTTTAGAGCTA
>MO901122.1 Sequence 1 from patent US 10570385
GTGGGCAAGAGT
>MO841712.1 Sequence 54 from patent US 10557151
GTTTTAGAGCTA
>MO841610.1 Sequence 178 from patent US 10557146
GACCCAATCTCC
>MO841593.1 Sequence 161 from patent US 10557146
TCGCTGCTGCTC
>MO841521.1 Sequence 89 from patent US 10557146
TCGCTGCTGCTC
>MO763696.1 Sequence 61 from patent US 10550429
TGATCCTAGCAA
>MO763112.1 Sequence 679 from patent US 10550407
GTTTTAGAGCTA
>MO757299.1 Sequence 428 from patent US 10550391
GTTGGTGTGGGC
>MO757298.1 Sequence 427 from patent US 10550391
GCCCACACCAAC
>MO757297.1 Sequence 426 from patent US 10550391
TTGGTGTGGGCC
>MO757296.1 Sequence 425 from patent US 10550391
GGCCCACACCAA
>MO757295.1 Sequence 424 from patent US 10550391
TGGTGTGGGCCT
>MO757294.1 Sequence 423 from patent US 10550391
AGGCCCACACCA
>MO757293.1 Sequence 422 from patent US 10550391
GGTGTGGGCCTC
>MO757292.1 Sequence 421 from patent US 10550391
GAGGCCCACACC
>MO757291.1 Sequence 420 from patent US 10550391
GTGTGGGCCTCC
>MO757290.1 Sequence 419 from patent US 10550391
GGAGGCCCACAC
>MO757289.1 Sequence 418 from patent US 10550391
TGTGGGCCTCCA
>MO757288.1 Sequence 417 from patent US 10550391
TGGAGGCCCACA
>MO757287.1 Sequence 416 from patent US 10550391
GTGGGCCTCCAC
>MO757286.1 Sequence 415 from patent US 10550391
GTGGAGGCCCAC
>MO757285.1 Sequence 414 from patent US 10550391
TGGGCCTCCACC
>MO757284.1 Sequence 413 from patent US 10550391
GGTGGAGGCCCA
>MO757283.1 Sequence 412 from patent US 10550391
GGGCCTCCACCA
>MO757282.1 Sequence 411 from patent US 10550391
TGGTGGAGGCCC
>MO757281.1 Sequence 410 from patent US 10550391
GGCCTCCACCAG
>MO757280.1 Sequence 409 from patent US 10550391
CTGGTGGAGGCC
>MO757279.1 Sequence 408 from patent US 10550391
GCCTCCACCAGC
>MO757278.1 Sequence 407 from patent US 10550391
GCTGGTGGAGGC
>MO757277.1 Sequence 406 from patent US 10550391
CCTCCACCAGCT
>MO757276.1 Sequence 405 from patent US 10550391
AGCTGGTGGAGG
>MO757275.1 Sequence 404 from patent US 10550391
CCATCCAGAAGC
>MO757274.1 Sequence 403 from patent US 10550391
GCTTCTGGATGG
>MO757273.1 Sequence 402 from patent US 10550391
CATCCAGAAGCC
>MO757272.1 Sequence 401 from patent US 10550391
GGCTTCTGGATG
>MO757271.1 Sequence 400 from patent US 10550391
ATCCAGAAGCCA
>MO757270.1 Sequence 399 from patent US 10550391
TGGCTTCTGGAT
>MO757269.1 Sequence 398 from patent US 10550391
TCCAGAAGCCAA
>MO757268.1 Sequence 397 from patent US 10550391
TTGGCTTCTGGA
>MO757267.1 Sequence 396 from patent US 10550391
CCAGAAGCCAAA
>MO757266.1 Sequence 395 from patent US 10550391
TTTGGCTTCTGG
>MO757265.1 Sequence 394 from patent US 10550391
CAGAAGCCAAAC
>MO757264.1 Sequence 393 from patent US 10550391
GTTTGGCTTCTG
>MO757263.1 Sequence 392 from patent US 10550391
AGAAGCCAAACT
>MO757262.1 Sequence 391 from patent US 10550391
AGTTTGGCTTCT
>MO757261.1 Sequence 390 from patent US 10550391
GAAGCCAAACTG
>MO757260.1 Sequence 389 from patent US 10550391
CAGTTTGGCTTC
>MO757259.1 Sequence 388 from patent US 10550391
AAGCCAAACTGG
>MO757258.1 Sequence 387 from patent US 10550391
CCAGTTTGGCTT
>MO757257.1 Sequence 386 from patent US 10550391
AGCCAAACTGGC
>MO757256.1 Sequence 385 from patent US 10550391
GCCAGTTTGGCT
>MO757255.1 Sequence 384 from patent US 10550391
GCCAAACTGGCC
>MO757254.1 Sequence 383 from patent US 10550391
GGCCAGTTTGGC
>MO757253.1 Sequence 382 from patent US 10550391
CCAAACTGGCCA
>MO757252.1 Sequence 381 from patent US 10550391
TGGCCAGTTTGG
>MO757251.1 Sequence 380 from patent US 10550391
CAAACTGGCCAC
>MO757250.1 Sequence 379 from patent US 10550391
GTGGCCAGTTTG
>MO757249.1 Sequence 378 from patent US 10550391
AAACTGGCCACC
>MO757248.1 Sequence 377 from patent US 10550391
GGTGGCCAGTTT
>MO757247.1 Sequence 376 from patent US 10550391
AACTGGCCACCC
>MO757246.1 Sequence 375 from patent US 10550391
GGGTGGCCAGTT
>MO757245.1 Sequence 374 from patent US 10550391
ACTGGCCACCCA
>MO757244.1 Sequence 373 from patent US 10550391
TGGGTGGCCAGT
>MO757243.1 Sequence 372 from patent US 10550391
CCTTCCTGCTCA
>MO757242.1 Sequence 371 from patent US 10550391
TGAGCAGGAAGG
>MO757241.1 Sequence 370 from patent US 10550391
CTTCCTGCTCAG
>MO757240.1 Sequence 369 from patent US 10550391
CTGAGCAGGAAG
>MO757239.1 Sequence 368 from patent US 10550391
TTCCTGCTCAGG
>MO757238.1 Sequence 367 from patent US 10550391
CCTGAGCAGGAA
>MO757237.1 Sequence 366 from patent US 10550391
TCCTGCTCAGGG
>MO757236.1 Sequence 365 from patent US 10550391
CCCTGAGCAGGA
>MO757235.1 Sequence 364 from patent US 10550391
CCTGCTCAGGGT
>MO757234.1 Sequence 363 from patent US 10550391
ACCCTGAGCAGG
>MO757233.1 Sequence 362 from patent US 10550391
CTGCTCAGGGTG
>MO757232.1 Sequence 361 from patent US 10550391
CACCCTGAGCAG
>MO757231.1 Sequence 360 from patent US 10550391
TGCTCAGGGTGA
>MO757230.1 Sequence 359 from patent US 10550391
TCACCCTGAGCA
>MO757229.1 Sequence 358 from patent US 10550391
GCTCAGGGTGAT
>MO757228.1 Sequence 357 from patent US 10550391
ATCACCCTGAGC
>MO757227.1 Sequence 356 from patent US 10550391
CTCAGGGTGATA
>MO757226.1 Sequence 355 from patent US 10550391
TATCACCCTGAG
>MO757225.1 Sequence 354 from patent US 10550391
TCAGGGTGATAT
>MO757224.1 Sequence 353 from patent US 10550391
ATATCACCCTGA
>MO757223.1 Sequence 352 from patent US 10550391
GCCAGTCAGCCA
>MO757222.1 Sequence 351 from patent US 10550391
TGGCTGACTGGC
>MO757221.1 Sequence 350 from patent US 10550391
CCAGTCAGCCAT
>MO757220.1 Sequence 349 from patent US 10550391
ATGGCTGACTGG
>MO757219.1 Sequence 348 from patent US 10550391
CAGTCAGCCATG
>MO757218.1 Sequence 347 from patent US 10550391
CATGGCTGACTG
>MO757217.1 Sequence 346 from patent US 10550391
AGTCAGCCATGG
>MO757216.1 Sequence 345 from patent US 10550391
CCATGGCTGACT
>MO757215.1 Sequence 344 from patent US 10550391
GTCAGCCATGGA
>MO757214.1 Sequence 343 from patent US 10550391
TCCATGGCTGAC
>MO757213.1 Sequence 342 from patent US 10550391
TCAGCCATGGAG
>MO757212.1 Sequence 341 from patent US 10550391
CTCCATGGCTGA
>MO757211.1 Sequence 340 from patent US 10550391
CAGCCATGGAGA
>MO757210.1 Sequence 339 from patent US 10550391
TCTCCATGGCTG
>MO757209.1 Sequence 338 from patent US 10550391
TTGTTGCAGTAT
>MO757208.1 Sequence 337 from patent US 10550391
ATACTGCAACAA
>MO757207.1 Sequence 336 from patent US 10550391
TGTTGCAGTATT
>MO757206.1 Sequence 335 from patent US 10550391
AATACTGCAACA
>MO757205.1 Sequence 334 from patent US 10550391
GTTGCAGTATTT
>MO757204.1 Sequence 333 from patent US 10550391
AAATACTGCAAC
>MO757203.1 Sequence 332 from patent US 10550391
TTGCAGTATTTC
>MO757202.1 Sequence 331 from patent US 10550391
GAAATACTGCAA
>MO757201.1 Sequence 330 from patent US 10550391
TGCAGTATTTCT
>MO757200.1 Sequence 329 from patent US 10550391
AGAAATACTGCA
>MO757199.1 Sequence 328 from patent US 10550391
GCAGTATTTCTC
>MO757198.1 Sequence 327 from patent US 10550391
GAGAAATACTGC
>MO757197.1 Sequence 326 from patent US 10550391
CAGTATTTCTCC
>MO757196.1 Sequence 325 from patent US 10550391
GGAGAAATACTG
>MO757195.1 Sequence 324 from patent US 10550391
AGGTCGTGTTGT
>MO757194.1 Sequence 323 from patent US 10550391
ACAACACGACCT
>MO757193.1 Sequence 322 from patent US 10550391
GGTCGTGTTGTA
>MO757192.1 Sequence 321 from patent US 10550391
TACAACACGACC
>MO757191.1 Sequence 320 from patent US 10550391
GTCGTGTTGTAG
>MO757190.1 Sequence 319 from patent US 10550391
CTACAACACGAC
>MO757189.1 Sequence 318 from patent US 10550391
TCGTGTTGTAGT
>MO757188.1 Sequence 317 from patent US 10550391
ACTACAACACGA
>MO757187.1 Sequence 316 from patent US 10550391
CGTGTTGTAGTC
>MO757186.1 Sequence 315 from patent US 10550391
GACTACAACACG
>MO757185.1 Sequence 314 from patent US 10550391
GTGTTGTAGTCA
>MO757184.1 Sequence 313 from patent US 10550391
TGACTACAACAC
>MO757183.1 Sequence 312 from patent US 10550391
TGTTGTAGTCAC
>MO757182.1 Sequence 311 from patent US 10550391
GTGACTACAACA
>MO757181.1 Sequence 310 from patent US 10550391
GTTGTAGTCACT
>MO757180.1 Sequence 309 from patent US 10550391
AGTGACTACAAC
>MO757179.1 Sequence 308 from patent US 10550391
TTGTAGTCACTG
>MO757178.1 Sequence 307 from patent US 10550391
CAGTGACTACAA
>MO757177.1 Sequence 306 from patent US 10550391
TGTAGTCACTGT
>MO757176.1 Sequence 305 from patent US 10550391
ACAGTGACTACA
>MO757175.1 Sequence 304 from patent US 10550391
GTAGTCACTGTA
>MO757174.1 Sequence 303 from patent US 10550391
TACAGTGACTAC
>MO757173.1 Sequence 302 from patent US 10550391
TAGTCACTGTAG
>MO757172.1 Sequence 301 from patent US 10550391
CTACAGTGACTA
>MO757171.1 Sequence 300 from patent US 10550391
AAGGAAGTGCCT
>MO757170.1 Sequence 299 from patent US 10550391
AGGCACTTCCTT
>MO757169.1 Sequence 298 from patent US 10550391
AGGAAGTGCCTT
>MO757168.1 Sequence 297 from patent US 10550391
AAGGCACTTCCT
>MO757167.1 Sequence 296 from patent US 10550391
GGAAGTGCCTTC
>MO757166.1 Sequence 295 from patent US 10550391
GAAGGCACTTCC
>MO757165.1 Sequence 294 from patent US 10550391
GAAGTGCCTTCT
>MO757164.1 Sequence 293 from patent US 10550391
AGAAGGCACTTC
>MO757163.1 Sequence 292 from patent US 10550391
AAGTGCCTTCTC
>MO757162.1 Sequence 291 from patent US 10550391
GAGAAGGCACTT
>MO757161.1 Sequence 290 from patent US 10550391
AGTGCCTTCTCT
>MO757160.1 Sequence 289 from patent US 10550391
AGAGAAGGCACT
>MO757159.1 Sequence 288 from patent US 10550391
GTGCCTTCTCTG
>MO757158.1 Sequence 287 from patent US 10550391
CAGAGAAGGCAC
>MO757157.1 Sequence 286 from patent US 10550391
TGCCTTCTCTGT
>MO757156.1 Sequence 285 from patent US 10550391
ACAGAGAAGGCA
>MO757155.1 Sequence 284 from patent US 10550391
GCCTTCTCTGTC
>MO757154.1 Sequence 283 from patent US 10550391
GACAGAGAAGGC
>MO757153.1 Sequence 282 from patent US 10550391
CCTTCTCTGTCA
>MO757152.1 Sequence 281 from patent US 10550391
TGACAGAGAAGG
>MO757151.1 Sequence 280 from patent US 10550391
CTTCTCTGTCAT
>MO757150.1 Sequence 279 from patent US 10550391
ATGACAGAGAAG
>MO757149.1 Sequence 278 from patent US 10550391
TTCTCTGTCATG
>MO757148.1 Sequence 277 from patent US 10550391
CATGACAGAGAA
>MO757147.1 Sequence 276 from patent US 10550391
TCTCTGTCATGC
>MO757146.1 Sequence 275 from patent US 10550391
GCATGACAGAGA
>MO757145.1 Sequence 274 from patent US 10550391
CTCTGTCATGCC
>MO757144.1 Sequence 273 from patent US 10550391
GGCATGACAGAG
>MO757143.1 Sequence 272 from patent US 10550391
AGATGTTGGTGG
>MO757142.1 Sequence 271 from patent US 10550391
CCACCAACATCT
>MO757141.1 Sequence 270 from patent US 10550391
GATGTTGGTGGC
>MO757140.1 Sequence 269 from patent US 10550391
GCCACCAACATC
>MO757139.1 Sequence 268 from patent US 10550391
ATGTTGGTGGCC
>MO757138.1 Sequence 267 from patent US 10550391
GGCCACCAACAT
>MO757137.1 Sequence 266 from patent US 10550391
TGTTGGTGGCCT
>MO757136.1 Sequence 265 from patent US 10550391
AGGCCACCAACA
>MO757135.1 Sequence 264 from patent US 10550391
GTTGGTGGCCTG
>MO757134.1 Sequence 263 from patent US 10550391
CAGGCCACCAAC
>MO757133.1 Sequence 262 from patent US 10550391
TTGGTGGCCTGC
>MO757132.1 Sequence 261 from patent US 10550391
GCAGGCCACCAA
>MO757131.1 Sequence 260 from patent US 10550391
TGGTGGCCTGCA
>MO757130.1 Sequence 259 from patent US 10550391
TGCAGGCCACCA
>MO757129.1 Sequence 258 from patent US 10550391
GGTGGCCTGCAG
>MO757128.1 Sequence 257 from patent US 10550391
CTGCAGGCCACC
>MO757127.1 Sequence 256 from patent US 10550391
AGACGCTGACCT
>MO757126.1 Sequence 255 from patent US 10550391
AGGTCAGCGTCT
>MO757125.1 Sequence 254 from patent US 10550391
GACGCTGACCTC
>MO757124.1 Sequence 253 from patent US 10550391
GAGGTCAGCGTC
>MO757123.1 Sequence 252 from patent US 10550391
ACGCTGACCTCC
>MO757122.1 Sequence 251 from patent US 10550391
GGAGGTCAGCGT
>MO757121.1 Sequence 250 from patent US 10550391
CGCTGACCTCCC
>MO757120.1 Sequence 249 from patent US 10550391
GGGAGGTCAGCG
>MO757119.1 Sequence 248 from patent US 10550391
GCTGACCTCCCA
>MO757118.1 Sequence 247 from patent US 10550391
TGGGAGGTCAGC
>MO757117.1 Sequence 246 from patent US 10550391
CTGACCTCCCAG
>MO757116.1 Sequence 245 from patent US 10550391
CTGGGAGGTCAG
>MO757115.1 Sequence 244 from patent US 10550391
TGACCTCCCAGC
>MO757114.1 Sequence 243 from patent US 10550391
GCTGGGAGGTCA
>MO757113.1 Sequence 242 from patent US 10550391
GACCTCCCAGCT
>MO757112.1 Sequence 241 from patent US 10550391
AGCTGGGAGGTC
>MO757111.1 Sequence 240 from patent US 10550391
ACCTCCCAGCTC
>MO757110.1 Sequence 239 from patent US 10550391
GAGCTGGGAGGT
>MO757109.1 Sequence 238 from patent US 10550391
TTCAGCAGGTAC
>MO757108.1 Sequence 237 from patent US 10550391
GTACCTGCTGAA
>MO757107.1 Sequence 236 from patent US 10550391
TCAGCAGGTACT
>MO757106.1 Sequence 235 from patent US 10550391
AGTACCTGCTGA
>MO757105.1 Sequence 234 from patent US 10550391
CAGCAGGTACTT
>MO757104.1 Sequence 233 from patent US 10550391
AAGTACCTGCTG
>MO757103.1 Sequence 232 from patent US 10550391
AGCAGGTACTTC
>MO757102.1 Sequence 231 from patent US 10550391
GAAGTACCTGCT
>MO757101.1 Sequence 230 from patent US 10550391
GCAGGTACTTCT
>MO757100.1 Sequence 229 from patent US 10550391
AGAAGTACCTGC
>MO757099.1 Sequence 228 from patent US 10550391
CAGGTACTTCTT
>MO757098.1 Sequence 227 from patent US 10550391
AAGAAGTACCTG
>MO757097.1 Sequence 226 from patent US 10550391
AGGTACTTCTTC
>MO757096.1 Sequence 225 from patent US 10550391
GAAGAAGTACCT
>MO757095.1 Sequence 224 from patent US 10550391
GGTACTTCTTCA
>MO757094.1 Sequence 223 from patent US 10550391
TGAAGAAGTACC
>MO754774.1 Sequence 371 from patent US 10550372
GGTAATTTCGTG
>MO754773.1 Sequence 370 from patent US 10550372
AGTAAAGGCGCT
>MO754772.1 Sequence 369 from patent US 10550372
TAGCTAACCGTT
>MO754771.1 Sequence 368 from patent US 10550372
GTTAACAGCGTG
>MO754770.1 Sequence 367 from patent US 10550372
GGTCGTCATCAA
>MO754769.1 Sequence 366 from patent US 10550372
GTCGTGGACTAC
>MO754768.1 Sequence 365 from patent US 10550372
CTTCGCAAGGAG
>MO754767.1 Sequence 364 from patent US 10550372
AAGATCGGTAGC
>MO754766.1 Sequence 363 from patent US 10550372
CGCGTCAGATAT
>MO754765.1 Sequence 362 from patent US 10550372
CTATGCCGTGCA
>MO754764.1 Sequence 361 from patent US 10550372
CGTACGGCACAG
>MO754763.1 Sequence 360 from patent US 10550372
ACGCGTCAGATA
>MO754762.1 Sequence 359 from patent US 10550372
TCGACGACTCAC
>MO754761.1 Sequence 358 from patent US 10550372
CGACTTTTTGCA
>MO754760.1 Sequence 357 from patent US 10550372
TCGATGGTAAAC
>MO754759.1 Sequence 356 from patent US 10550372
GCGTTATCAGAA
>MO754758.1 Sequence 355 from patent US 10550372
CCCAAACGGTTA
>MO754757.1 Sequence 354 from patent US 10550372
CGTAGCCATGTT
>MO754756.1 Sequence 353 from patent US 10550372
TTTACCATCGAA
>MO754755.1 Sequence 352 from patent US 10550372
CGTGCCCTGAAC
>MO754754.1 Sequence 351 from patent US 10550372
CGAAAACGTGGC
>MO754753.1 Sequence 350 from patent US 10550372
CTTAGTCGGCCA
>MO754752.1 Sequence 349 from patent US 10550372
TAAAGCGACCCG
>MO754751.1 Sequence 348 from patent US 10550372
CACGAGGTATGC
>MO754750.1 Sequence 347 from patent US 10550372
CGGTGTATTGAG
>MO754749.1 Sequence 346 from patent US 10550372
ACACCGAAAACG
>MO754748.1 Sequence 345 from patent US 10550372
GCAGGACGTCCG
>MO754747.1 Sequence 344 from patent US 10550372
TCACCCAAAGCG
>MO754746.1 Sequence 343 from patent US 10550372
ACTATGCGTAGG
>MO754745.1 Sequence 342 from patent US 10550372
TTGACTGCGGCG
>MO754744.1 Sequence 341 from patent US 10550372
TGGGACACCGGT
>MO754743.1 Sequence 340 from patent US 10550372
GCCAACCCGCAC
>MO754742.1 Sequence 339 from patent US 10550372
CCCCTACGGCAC
>MO754741.1 Sequence 338 from patent US 10550372
AGTGGCGATGAC
>MO754740.1 Sequence 337 from patent US 10550372
CGTCATGAATAA
>MO754739.1 Sequence 336 from patent US 10550372
CGATTCCTTCGT
>MO754738.1 Sequence 335 from patent US 10550372
CCAAACGGTTAA
>MO754737.1 Sequence 334 from patent US 10550372
TTCATAACCGGC
>MO754736.1 Sequence 333 from patent US 10550372
CGCTACATAGCA
>MO754735.1 Sequence 332 from patent US 10550372
ACTCGATACCAT
>MO754734.1 Sequence 331 from patent US 10550372
AGGAAGTATCGC
>MO754733.1 Sequence 330 from patent US 10550372
TTTACGCAGAGG
>MO754732.1 Sequence 329 from patent US 10550372
TGAGTCGTCGAG
>MO754731.1 Sequence 328 from patent US 10550372
TTCGAGCGATTT
>MO754730.1 Sequence 327 from patent US 10550372
GTCGGGGACTAT
>MO754729.1 Sequence 326 from patent US 10550372
AAGGTCGCCCAT
>MO754728.1 Sequence 325 from patent US 10550372
TAACGTCGGAGC
>MO754727.1 Sequence 324 from patent US 10550372
TGCGCCTCCAGT
>MO754726.1 Sequence 323 from patent US 10550372
CCGATTCCTTCG
>MO754725.1 Sequence 322 from patent US 10550372
CTCCGTATCTCG
>MO754724.1 Sequence 321 from patent US 10550372
GCGTCAATGTTC
>MO754723.1 Sequence 320 from patent US 10550372
ATCGTGCCCTAA
>MO754722.1 Sequence 319 from patent US 10550372
ACACCGGTCTTC
>MO754721.1 Sequence 318 from patent US 10550372
GATTCATCAGCG
>MO754720.1 Sequence 317 from patent US 10550372
GAACCCGTCCTA
>MO754719.1 Sequence 316 from patent US 10550372
CGCCGGTGGAAT
>MO754718.1 Sequence 315 from patent US 10550372
TTTCAAGGCCGG
>MO754717.1 Sequence 314 from patent US 10550372
TCGTATCCCTAC
>MO754716.1 Sequence 313 from patent US 10550372
CAGGACGTCCGT
>MO754715.1 Sequence 312 from patent US 10550372
ACTCCGTAGTGA
>MO754714.1 Sequence 311 from patent US 10550372
TCGTCGGGTGCA
>MO754713.1 Sequence 310 from patent US 10550372
GTCTCACGATCG
>MO754712.1 Sequence 309 from patent US 10550372
GAGTCGATACGC
>MO754711.1 Sequence 308 from patent US 10550372
AACCAAGATACG
>MO754710.1 Sequence 307 from patent US 10550372
CACGAAATTACC
>MO754709.1 Sequence 306 from patent US 10550372
TACGGTAAGTCG
>MO754708.1 Sequence 305 from patent US 10550372
GCCTGTGCCGTA
>MO754707.1 Sequence 304 from patent US 10550372
CGGTACTCTTAC
>MO754706.1 Sequence 303 from patent US 10550372
GCATGGTACGGA
>MO754705.1 Sequence 302 from patent US 10550372
GCCGAATTCCTC
>MO754704.1 Sequence 301 from patent US 10550372
ATGGAAACGCAT
>MO754703.1 Sequence 300 from patent US 10550372
TGTCGCATGTTA
>MO754702.1 Sequence 299 from patent US 10550372
GGCGTTAATGAT
>MO754701.1 Sequence 298 from patent US 10550372
TAGGTCGACCAG
>MO754700.1 Sequence 297 from patent US 10550372
ACGTCGCCTGAT
>MO754699.1 Sequence 296 from patent US 10550372
ACTGCGTGTTAA
>MO754698.1 Sequence 295 from patent US 10550372
ACTCCCCGTAGG
>MO754697.1 Sequence 294 from patent US 10550372
TCGGTGACATGT
>MO754696.1 Sequence 293 from patent US 10550372
TAGCGGGTAAGC
>MO754495.1 Sequence 41 from patent US 10550372
GTTTTAGAGCTA
>MO754493.1 Sequence 39 from patent US 10550372
GTTTTAGAGCTA
>MO754470.1 Sequence 15 from patent US 10550372
GCTAGAATAGCA
>MO750227.1 Sequence 30 from patent US 10545144
CGCGCGCGCGCG
>MO750226.1 Sequence 29 from patent US 10545144
CGCGCGCGCGCG
>MO746877.1 Sequence 76 from patent US 10544431
CAGCCCTACACT
>MO746874.1 Sequence 73 from patent US 10544431
GCTACCTGGACT
>MO746817.1 Sequence 14 from patent US 10544431
ACCAAACAAGAG
>MO746816.1 Sequence 13 from patent US 10544431
ACCAGACAAGAG
>MO746815.1 Sequence 12 from patent US 10544431
CTCTTGTTTGGT
>MO746814.1 Sequence 11 from patent US 10544431
CTCTTGTCTGGT
>MO746803.1 Sequence 18 from patent US 10544430
NNNNNNGAGACG
>MO746764.1 Sequence 16 from patent US 10544429
CAGCCACCATGG
>MO743642.1 Sequence 117 from patent US 10544410
GGAGGAAGCGGA
>MC007531.1 JP 2020500530-A/675: SYNTHETIC IMMUNE RECEPTORS AND METHODS OF USE THEREOF
CGCGCCAAGAGA
>MC007530.1 JP 2020500530-A/674: SYNTHETIC IMMUNE RECEPTORS AND METHODS OF USE THEREOF
AGGGCCAAGCGA
>MC007529.1 JP 2020500530-A/673: SYNTHETIC IMMUNE RECEPTORS AND METHODS OF USE THEREOF
CGGGCCAAGAGA
>MC007528.1 JP 2020500530-A/672: SYNTHETIC IMMUNE RECEPTORS AND METHODS OF USE THEREOF
AGCGGATCTGGC
>MC007527.1 JP 2020500530-A/671: SYNTHETIC IMMUNE RECEPTORS AND METHODS OF USE THEREOF
TCTGGATCTGGA
>MC006678.1 JP 2020501517-A/376: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
GCCACCCCACTC
>MC006676.1 JP 2020501517-A/374: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
CGGTGGCATTGG
>MC006674.1 JP 2020501517-A/372: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
GAGCCAAACGCC
>MC006662.1 JP 2020501517-A/360: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
CAGCGTTCCCGG
>MC006506.1 JP 2020501517-A/204: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
GCCACCCCACTC
>MC006476.1 JP 2020501517-A/174: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
GAGCCAAACGCC
>MC006326.1 JP 2020501517-A/24: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
CAGCGTTCCCGG
>MC006458.1 JP 2020501517-A/156: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
AGAACCAGCAGC
>MC006437.1 JP 2020501517-A/135: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
TCCAGCAGAGCT
>MC006392.1 JP 2020501517-A/90: DIGITAL ANALYSIS OF BLOOD SAMPLES TO DETERMINE EFFICACY OF CANCER THERAPIES FOR SPECIFIC CANCERS
TGCGGGTACTGG
>MC003959.1 JP 2020501507-A/1: METHOD FOR LABELING OLIGONUCLEOTIDE PROBES
CTAAATCCATTA
>MC003852.1 JP 2020501519-A/27: COMPOSITIONS AND METHODS FOR THE PRODUCTION OF COMPOUNDS
CTAGGGGGTTGC
>MC015303.1 JP 2020502256-A/1: NEW COMPOUNDS AND USES THEREOF FOR DETECTION OF TARGET MOLECULES IN A SAMPLE
CTTGGGATGAAC
>MB494674.1 JP 2020019718-A/31: agent and method for promoting cardiac differentiation
TGAGGGTGAGGG
>MB494673.1 JP 2020019718-A/30: agent and method for promoting cardiac differentiation
TGAGGGTTAGGG
>MB494672.1 JP 2020019718-A/29: agent and method for promoting cardiac differentiation
TTAGGGTGAGGG
>MB494671.1 JP 2020019718-A/28: agent and method for promoting cardiac differentiation
TTAGGGTTAGGG
>MB494663.1 JP 2020019718-A/20: agent and method for promoting cardiac differentiation
GGGTGAGGGTGA
>MB487864.1 JP 2020002136-A/14: NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
CATGACGTTCCT
>MB487160.1 JP 2020000051-A/56: Method of judging whether creation of aptamer is possible or not and method of creating aptamer using the same
GGAGGCGGCCGG
>MB487147.1 JP 2020000051-A/43: Method of judging whether creation of aptamer is possible or not and method of creating aptamer using the same
GGGGGATGGGGG
>MB488974.1 WO 2020017590-A/2: A lipid particle comprising A type CpG oligodeoxynucleotide
TGCATCGATGCA
>MB487074.1 JP 2019533476-A/8: HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF
CTCTTATTTCCC
>MB487073.1 JP 2019533476-A/7: HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF
GGGAAATAAGAG
>MB487067.1 JP 2019533476-A/1: HIGH PURITY RNA COMPOSITIONS AND METHODS FOR PREPARATION THEREOF
CTCTTATTTCCC
>MB487000.1 JP 2019533470-A/1: COMPOSITIONS AND METHODS FOR THE PRODUCTION OF COMPOUNDS
CTAGGGGGTTGC
>MB486021.1 WO 2019245060-A/25: A Composition for Preventing or Treating A Neurodegenerative Disease
AACAATACTACG
>MB486020.1 WO 2019245060-A/24: A Composition for Preventing or Treating A Neurodegenerative Disease
AACTACAATGCA
>MB484026.1 JP 2019205446-A/3: EXPRESSION AND PURIFICATION OF CRM197 AND RELATED PROTEINS
GATATACCATAT
>MB483363.1 JP 2019528312-A/24: MRNA-MEDIATED IMMUNIZATION METHODS
TAAAAAATGAAN
>MB483362.1 JP 2019528312-A/23: MRNA-MEDIATED IMMUNIZATION METHODS
NTAAAAATGRCT
>MB483361.1 JP 2019528312-A/22: MRNA-MEDIATED IMMUNIZATION METHODS
AAAAAAATGRNA
>MB482076.1 JP 2019528508-A/14: VIRAL POLYPEPTIDE FRAGMENTS THAT BIND CELLULAR POL II CTD AND THEIR USES
AGTAGTAACAAG
>MO689946.1 Sequence 32 from patent US 10533221
GAACNNNNNCTC
>MO689942.1 Sequence 28 from patent US 10533221
CAANNNNNGTGG
>MO689892.1 Sequence 5 from patent US 10533218
CCTATCCCCTGT
>MO689888.1 Sequence 1 from patent US 10533218
CCATCTCATCCC
>MO689104.1 Sequence 679 from patent US 10533190
GTTTTAGAGCTA
>MO684764.1 Sequence 14 from patent US 10533163
GGTGGGGNTCCC
>MO684760.1 Sequence 10 from patent US 10533163
ACTNTANANCTG
>MO684675.1 Sequence 15 from patent US 10533053
CAGTCTGGCCAG
>MO684304.1 Sequence 270 from patent US 10533048
GATCTTGACTTG
>MO639101.1 Sequence 1 from patent US 10527627
CGACAACCACAA
>MO638618.1 Sequence 5 from patent US 10526650
GTATTTTTTTCT
>MO638540.1 Sequence 28 from patent US 10526641
NNNNNNNTCTTC
>MO638224.1 Sequence 679 from patent US 10526619
GTTTTAGAGCTA
>MO637720.1 Sequence 35 from patent US 10526615
TGTGTCGTGCAG
>MO635430.1 Sequence 1146 from patent US 10526602
TTAAGGCACGCG
>MO635424.1 Sequence 1140 from patent US 10526602
TTAAGGCACGCG
>MO635421.1 Sequence 1137 from patent US 10526602
CGGTGAATGCCA
>MO635414.1 Sequence 1130 from patent US 10526602
TTAGCTCGTGGT
>MO635412.1 Sequence 1128 from patent US 10526602
TATAGGCACGCG
>MO635411.1 Sequence 1127 from patent US 10526602
TTAAGCGACGCG
>MO635407.1 Sequence 1123 from patent US 10526602
CGTGCCTATAAT
>MO635405.1 Sequence 1121 from patent US 10526602
CGTCGCTTAAAT
>MO635404.1 Sequence 1120 from patent US 10526602
CGGTAGATGCCA
>MO635397.1 Sequence 1113 from patent US 10526602
TTAAGGCACGCG
>MO635392.1 Sequence 1108 from patent US 10526602
CGTGCCTTAAAT
>MO635389.1 Sequence 1105 from patent US 10526602
GCATTCACCGCG
>MO635388.1 Sequence 1104 from patent US 10526602
CGGTGAATGCCA
>MO635381.1 Sequence 1097 from patent US 10526602
CGTGCCTTAAAT
>MO635378.1 Sequence 1094 from patent US 10526602
CGGTGAATGCCA
>MO631558.1 Sequence 40 from patent US 10524477
GTTTTTGTACTC
>MO631552.1 Sequence 27 from patent US 10524477
AAATCATTTGAG
>MO631551.1 Sequence 26 from patent US 10524477
AATTCATTTGAG
>MO631292.1 Sequence 1 from patent US 10520499
CTGATTGGCCAA
>MO630740.1 Sequence 16 from patent US 10519509
AGGAGGAAGATG
>MO630699.1 Sequence 51 from patent US 10519508
TACTACTACTAC
>MO630324.1 Sequence 22 from patent US 10519487
CGAGTGATCCGA
>MO629589.1 Sequence 679 from patent US 10519467
GTTTTAGAGCTA
>MO628212.1 Sequence 59 from patent US 10519456
CCAGGAACTGCG
>MO628209.1 Sequence 56 from patent US 10519456
CCAGGAACTGCG
>MO628206.1 Sequence 53 from patent US 10519456
CCAGGAACTGCG
>MO625870.1 Sequence 28 from patent US 10519436
CGGCTTCCTGAT
>MO625869.1 Sequence 27 from patent US 10519436
CCGGCTTTCCAA
>MO625868.1 Sequence 26 from patent US 10519436
CCTCCTTCGACC
>MO625866.1 Sequence 24 from patent US 10519436
GACACCGGGCCC
>MO625863.1 Sequence 21 from patent US 10519436
TTCCCGATCCGA
>MO625672.1 Sequence 5 from patent US 10519430
CGGGCAATCAAC
>MO619863.1 Sequence 21 from patent US 10517888
TGTAGTGCACTG
>MO619819.1 Sequence 10 from patent US 10517877
CTTCTTCTTCTT
>MO619815.1 Sequence 6 from patent US 10517877
GAAGAAGAAGAA
>MO619811.1 Sequence 2 from patent US 10517877
TTCTTCTTCTTC
